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Thesis Summary 
Tissue transglutaminase (TG2) has been reported as a wound response protein. 
Once over-expressed by cells under stress such as during wound healing or 
following tissue damage, TG2 can be secreted and deposited into extracellular 
matrix, where it forms a heterocomplex (TG-FN) with the abundant matrix 
protein fibronectin (FN). A further cellular response elicited after tissue damage 
is that of matrix remodelling leading to the release of the Arg-Gly-Asp (RGD) 
containing matrix fragments by matrix matelloproteinases (MMPs). These peptides 
are able to block the interaction between integrin cell surface receptors and ECM 
proteins, leading to the loss of cell adhesion and ultimately Anoikis. This study 
provides a mechanism for TG2, as a stress-induced matrix protein, in protecting 
the cells from the RGD-dependent loss of cell adhesion and rescuing the cells 
from Anoikis. Mouse fibroblasts were used as a major model for this study, 
including different types of cell surface receptor knockout mouse embryonic 
fibroblasts (MEFs) (such as syndecan-4, α5, β1 or β3 integrins). In addition  
specific syndecan-2 targetting siRNAs, β1 integrin and α4β1 integrin functional 
blocking antibodies, and a specific targeting peptide against α5β1 integrin A5-1 
were used to investigate the involvement of these receptors in the RGD-
independent cell adhesion on TG-FN. Crucial for TG-FN to compensate the 
RGD-independent cell adhesion and actin cytoskeleton formation is the  direct 
interaction between the heparan sulfate chains of syndecan-4 and TG2,  which 
elicits the inside-out signalling of α5β1 integrin and the intracellular activation of 
syndecan-2 by protein kinase C α (PKCα). By using specific inhibitors, a cell-
permeable inhibiting peptide and the detection of the phosphorylation sites for 
protein kinases and/or the translocation of PKCα via Western blotting, the 
activation of PKCα, focal adhesion kinase (FAK), ERK1/2 and Rho kinase 
(ROCK) were confirmed as downstream signalling molecules. Importantly, this 
study also investigated the influence of TG-FN on matrix turnover and 
demonstrated that TG-FN can restore the RGD-independent FN deposition 
process via an α5β1 integrin and syndecan-4/2 co-signalling pathway linked by 
PKCα in a transamidating-independent manner. These data provide a novel 
function for TG2 in wound healing and matrix turnover which is a key event in a 
number of both physiological and pathological processes.   
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Chapter 1: Introduction 
 
The communication between adhesion-dependent cells and their 
microenvironment triggers a signal transduction process, which is essential for 
cells to exert their functions including adhesion, migration, differentiation, 
proliferation and in some cells matrix remodelling (Hynes, et al., 1999). Among 
the matrix proteins, fibronectin (FN) is one of the most important matrices for 
various cell types e.g. fibroblasts and osteoblasts (Mosher, 1984). Via a direct 
interaction with matrix FN through their surface integrin receptors, cells can 
anchor themselves onto the matrix and further spread or migrate depending on 
the environment signals, such as the growth factors and signalling molecule 
produced by other cells. Cell surface heparan proteoglycans, including syndecans 
and glypicans (Moyano et al., 1999), can also regulate cell behaviour via 
mediating actin cytoskeleton organization. Under stress conditions, matrix 
metalloproteinases (MMPs) can digest matrix proteins leading to the release of 
the matrix fragments (Chau et al., 2005; Collighan and Griffin, 2009). RGD 
peptides are one of the most widely reported fragments since they can block the 
adhesion of cell on matrix proteins containing RGD motifs, resulting in the loss 
of cell adhesion and ultimately Anoikis (Buckley, et al., 1999; Hadden and 
Henke, 2000).  
Tissue transglutaminase (TG2) was previously known as an enzyme, which can 
crosslink matrix proteins including FN and collagen, via ε-(γ-glutamyl) lysine 
bridges (Griffin et al., 2002a), leading to protein stabilization and protection from 
protease degradation and thereby promoting cell adhesion (Verderio et al., 2004). 
Recent reports also demonstrate that TG2 can act as a co-receptor for integrins to 
regulate cell adhesion and migration in a transamidating-independent manner 
(Akimov et al., 2000a). As a stress-related protein (Ientile et al., 2007), TG2 can 
be released and deposited into extracellular matrix and function as a matrix 
protein via its binding to its high affinity binding partner with FN to form the 
TG-FN hetero-complex (Gaudry et al., 1999a). The function of TG-FN in 
rescuing the RGD-induced apoptosis was reported by Griffin and colleagues, 
which is regarded as a novel role for this multifunctional enzyme (Verderio et al., 
2003).  
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1.1 Transglutaminases 
 
The posttranslational modification of proteins plays an important role in 
regulating protein function. Transglutaminases were first reported in 1959 by 
Mycek and colleagues as an enzyme found in guinea pig liver, which could 
modify proteins by mediating an acyl-transfer reaction between the γ-
carboxamide group of peptide-bound glutamine and a primary amine, which can 
be either a polyamine or the ε-amino group of peptide-bound lysine, if the latter 
then protein crosslinking can occur through the formation of ε (γ-glutamyl) 
lysine bonds. Because of their ability to crosslink proteins together, TGs have 
been referred to as ‘‘Nature’s Glue’’. Transglutaminases are found widely in 
nature (Griffin et al., 2002), but in mammals their enzymatic activity is Ca2+-
dependent, and other factors including GTP/GDP can also affect the activity of 
some of the mammalian TGs.  
 
Even though the functions of TGs have been under investigation by scientists for 
more than 5 decades, not all members of the mammalian TGs have been fully 
characterised. Moreover further novel enzymatic activities of specific 
mammalian TGs have recently been reported, e.g. the protein disulfide isomerise 
and protein kinase activities of the tissue transglutaminase (TG2), thus extending 
the potential cell functions of this diverse group of enzymes.  
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1.2 Members of mammalian transglutaminase family 
 
It has been proved that TGs are widely expressed in the nature, including plants 
(Serafini-Fracassini et al. 1995), micro-organisms (Chung, 1972, Folk and 
Finlayson, 1977; Kanaji et al., 1993), invertebrates (Mehta et al., 1990 and 1992; 
Singh and Mehta, 1994) and mammals. It has been certified that even in the same 
tissue, the TGs might exert different functions (Griffin et al., 2002).  As shown in 
table 1.1, nine types of TGs have been identified in mammals, of which, apart 
from erythrocyte band 4.2, require Ca2+ for their transamidating activity. These 
are Factor XIII A, the keratinocyte transglutaminase (TG1), the ubiquitous tissue 
transglutaminase (TG2), the epidermal transglutaminase (TG3), the prostate 
transglutaminase (TG4), the non-catalytically active erythrocyte band 4.2, and 
the recently discovered transglutaminase X, Y, and Z (TG5, TG6 and TG7). 
They are distributed in various tissues (epithelium, endothelium, stratum 
corneum, dermis, liver, spleen, bone marrow, central nervous system (CNS), etc.) 
and physiological fluids (platelets and lymphatic system), and different parts of 
cells (cytosol, nuclear and membrane), as well as the extracellular matrix.  
 
All transglutaminase enzymes are encoded by a family of closely related genes 
with a high degree of sequence similarity. All members of the TG gene family 
share a similar gene organization with remarkable conservation of intron 
distribution and intron splice types. According to the structure of the individual 
genes, they can be divided into two subclasses, wherein the genes encoding TG2, 
TG4, band 4.2 protein and TG5 contain 13 exons, and the genes encoding factor 
XIII A subunit and TG1 contain 15 exons.   
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Table 1.1 Members of Transglutaminase Family
Protein Gene Gene location Synonyms Tissue Expression Activity Function 
Factor 
XIIIa 
subunit 
F13A1 
Chromosome 6 
Factor XIIIa, plasma Tg, fibrin-
stabilising factor, Laki-Lorand factor, 
fibrinoligase, plasma pro-TG 
Platelets, astrocytes, dermal 
dendritic cells, 
chondrocytes, placenta, 
synovial fluid  
Latent (thrombin 
activated) 
Blood coagulation, bone 
growth,  
ECM stabilisation 
TG1 TGM1 
Chromosome14 
TGK, keratinocyte-, particulate-, 
membrane-bound TG, Tg type1, TG 
B 
Keratinocytes, brain 
Latent (protease 
activated) 
Cornified envelope formation 
by terminally differentiating 
epidermal keratinocytes 
TG2 TGM2 
Chromosome 20 
TGC, tissue Tg, endothelial-, 
erythrocyte-, cytosolic-, liver-, tissue 
TG, Gh, Ghα, TG type 2 Ubiquitous Yes 
ECM stabilisation, formation 
of cross-linked envelop 
during cell death, cell 
signalling, cell adhesion 
protein and cell survival.  
TG3 TGM3 
Chromosome 20 
TGE, epidermal-, callus-, hair follicle-
, bovine snout TG, TG type 3 Squamous epithelium, brain 
Latent (protease 
activated) 
Cornified envelope 
formation, hair shaft 
formation 
TG4 TGM4 
Chromosome 3 
TGP, prostate TG, Vesiculase, dorsal 
prostate protein 1 (DP1), major 
androgen-regulated prostate secretory 
protein 
Prostate Yes 
Semen coagulation in rodents 
TG5 TGM5 Chromosome 15 TGX, TG type 5 Ubiquitous expression 
except for the CNS and 
lymphatic system  
Yes 
Unknown 
TG6 TGM6 Chromosome 20 TGY, TG type 6 Brain Yes Unkown 
TG7 TGM7 Chromosome 15 TGZ, TG type 7 Ubiquitous Yes Unkown 
Band 4.2 EPB42 Chromosome 15 ATP-binding erythrocyte membrane 
protein band 4.2, Erythrocyte protein 
band 4.2, B4.2 
Erythrocytes, bone marrow, 
fetal liver and spleen No 
Structural membrane skeletal 
component 
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1.3 Factor XIII 
 
Factor XIII (also known as FXIII, pXIII-A2B2, plasma coagulation factor XIII, 
or fibrin stabilizing factor) is a heterotetramer composed of a catalytic dimer of 
two A subunits (FXIII A) and two non-catalytic B subunits (FXIII B) that can 
protect A subunits in the blood circulation (Schwartz et al., 1973).  Plasma FXIII 
(pFXIII) is the last enzyme in the blood coagulation cascade and in contrast to all 
other enzymes involved, it is not a serine protease but a transglutaminase, 
catalyzing the formation of isopeptide bonds between the side chains of peptide 
bound glutamine and lysine residues. As a zymogen, FXIII requires the cleavage 
at Arg37-Gly38 by thrombin in the presence of Ca2+ (Schwartz et al., 1973). 
 
1.3.1 Factor XIII A subunit 
 
As one of the most widely studied members in the TG family, the structure, 
amino acid sequence of the catalytic FXIII A and the localization of its genes 
have been revealed. Localized on human chromosome 6 p24-25, the FXIIIA 
gene, F13A1, consists of 15 exons and is more than 160kb in size (Ichinose et al., 
1990). F13A1 encodes 83kDa FXIII A subunit composed of 731 amino acids 
(Ichinose et al., 1986a), which has been reported to be regulated by a myeloid-
enriched transcription factor (MZF-1-like protein) and two ubiquitous 
transcription factors NF-1 and SP-1 (Kida et al., 1999). According to the 
discovery by cDNA cloning (Grundmann et al., 1986) and protein sequencing 
(Ichinose et al., 1986a), the amino acid sequence of FXIII A was deduced, while 
the X-ray crystallographs demonstrated the crystal structure of FXIIIA, showing 
it is composed of 5 domains including an activation peptide, an N-terminal β-
sandwich domain, a core domain and two C-terminal β-barrels (Yee et al., 1994).  
Human FXIII A is expressed mainly in hepatocytes, megakaryocytes, platelets, 
monocytes and macrophages. At the organ level, FXIII A is mainly located in the 
uterus, the placenta and the liver (Iismaa et al., 2009). The localization of FXIII 
A has been identified intracellularly (cytoplasma and nuclei), on the cell surface 
and extracellularly (extracellular matrix or in serum, secreted through an 
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unknown non-classic secretion pathway) (Adany and Bardos, 2003). Its 
mechanism of secretion into the extracellular environment is still unknown.  
 
1.3.2 Factor XIII B subunit 
 
Localized at human chromosome 1q31-32.1, the 28kb FXIII B gene— F13B 
encodes the 80kDa protein containing 641 amino acids (Bohn, 1972; Bottenus et 
al., 1990). The gene F13B is composed of 12 exons separated by 11 introns, 
among which the first exons encodes the leader sequence and the 12th encodes 
the C-terminal portion (Bottenus et al., 1990).  Each of the remaining 10 exons is 
in charge of the expression one tandem repeat known as Sushi domains or GI-I 
structures (Ichinose et al., 1986b). Synthesized by the liver, even though known 
as the regulatory/carrier of FXIII A, 50% of FXIII B subunits remain FXIII A 
free in the plasma (Yorifuji et al., 1988). Unlike FXIII A, Kaetsu and colleagues 
(1996) reported that, in baby hamster kidney, FXIII B is secreted through a 
classical endoplasmic reticulum (ER)/Golgi secretory pathway. By using 
recombinant human FXIII B, recent research identified certain functions of the 
Sushi domains of FXIII B by Souri and colleagues (Souri et al., 2008). The first 
Sushi domain is involved in the interaction of FXIII B to the A subunits, while 
the fourth and ninth domains mediate the formation of the homodimers of FXIII 
B. Apart from the functions of the individual domains of FXIII B, they also 
suggested that only the full length or nearly full length FXIII B can protect FXIII 
A from degradation by covering its surface. 
 
1.3.3 Activation of FXIII 
 
Existing as a zymogen, the activation of pXIII-A2B2 is a multi-step process. 
Initiated by the disassociation from the B subunits in the presence of fibrin and 
Ca2+, the cleavage of pFXIII by thrombin exposes the catalytic Cys in the active 
centre. A thrombin-independent activation of FXIII has also been reported, when 
only a much higher concentration of Ca2+ is present in this process. Through 
Ca2+-regulated conformation changes, FXIII A exerts its transglutaminase 
activity in the final stages of coagulation (Iismaa et al., 2009). Apart from 
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protecting FXIII A from proteolytic degradation, the importance and the 
mechanism of FXIII B in regulating the activation of FXIII has been well 
reported including facilitating the interaction of the zymogen pXIII-A2B2 with 
fibrinogen. The FXIII B released from pXIII-A2B2 can also act as a negative 
feedback signal to terminate the cleavage of the zymogen by thrombin (Halkier 
and Magnusson, 1988). 
 
1.3.4 Factor XIII functions 
 
Also named as plasma coagulation factor XIII or fibrin stabilizing factor, the 
main role of FXIII is to stabilize the fibrin soft clots, and to render it less 
susceptible to fibrinolysis either by cross-linking of fibrin itself or by cross-
linking α-antiplasmin, a potent inhibitor of the protease plasmin, into the fibrin 
clot (Weiss et al., 1998). 
 
The intracellular functions of FXIII have been widely studied, even though there 
are still conflicting opinions. Like other transglutaminase family members, the 
cytoskeleton proteins actin (Cohen et al., 1980) and myosin (Cohen et al., 1979) 
and the focal adhesion protein vinculin (Asijee et al., 1988; Horvath et al., 1992) 
are substrates for FXIII A, which, if the enzyme is activated by Ca2+ (which 
seems unlikely in the intracellular environment), suggests its possible  function in 
regulating the cytoskeleton organization and remodelling. The impaired 
capability of phagocytosis in FXIII A deficient monocytes suggested its 
importance in this process, which could be linked to its function in the 
cytoskeleton system.  Extracellularly, FXIII A is well-defined in maintaining the 
hemostasis in connective tissues. In the extracellular matrix (ECM), its cross-
linking activity is thought crucial in the interaction of ECM proteins, including 
fibronectin/collagen (Akagi et al., 2002; Mosher, 1984a; Mosher and Schad, 
1979) and vitronectin (Sane et al., 1988), also in collagen synthesis (Paye et al., 
1989). The impaired wound healing ability in FXIII A deficient patients 
suggested its importance in this process, which could be due to its function in 
stabilizing the fibrin/fibronectin network (Corbett et al., 1997), as well as  its role 
in fibroblast cell proliferation and migration (Dardik et al., 2007). 
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Apart from in vitro studies, the functions of FXIII A have been widely 
investigated in animal models. In FXIII A deficient animal models, a relative 
mild bleeding with prolonged tail-tip bleeding times was discovered. Even 
though fertile, impaired reproduction is significantly observed in FXIII A 
knockout models, while frequent genital bleeding is found in female animals and 
leads to fetal abortion (Koseki-Kuno et al., 2003). In tumour metastasis studies, 
significant decreased lung and liver metastasis was discovered in FXIII A-/- 
animals, compared to wild type models, which could be due to its inhibiting 
effect on the functions of natural killer cells or its importance in the formation of 
tumour emboli (Palumbo et al., 2008). In agreement with in vitro studies and 
patient case reports, delayed wound healing was discovered in FXIII A-/- 
animals. Deficiency in extracellular reconstitution, including an attenuated 
inflammatory response and enhanced ECM degradation, was discovered 
(Nahrendorf et al., 2006). Recent studies also suggest the role of FXIII A in 
vascular disease, indicating the cross-linking reaction between β3 integrins and 
VEGFR-2 by FXIII A can in turn activate VEGFR-2 and its relevant signalling 
transduction in angiogenesis (Dardik et al., 2005).  It has also been reported that 
FXIII A can catalyse the dimerization of angiotensin II type 1 (AT1) receptor to 
mediate its signalling pathway (AbdAlla et al., 2004).  
 
The function of FXIII B is still under investigation. But it has been reported that 
FXIII B deficiency is always accompanied with FXIII A deficiency in patients 
(Saito et al., 1990). Even though no fetal difference, e.g. survival rates, was 
discovered in both genders of FXIII B-/- mice compared to the wild type controls, 
only the male knockout animals developed mild fibrosis with haemosiderin 
deposits in the heart tissues (Souri et al., 2008). A more recent case report 
revealed the existence of a specific autoantibody against FXIII B, which caused 
severe bleeding, while no effect of this antibody on FXIII activation and its 
activity was found (Ajzner et al., 2009). This finding highlights the importance 
of FXIII in the coagulation process.  
 
Nowadays, the FXIII A or FXIII B deficient animals have become a very 
sufficient tool in the study of the functions of these FXIII subunits and it is 
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promising that in the near future the functions of FXIII A and B will be revealed 
by using this technique. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 Introduction 
 
 28 
1.4 Keratinocyte transglutaminase 
 
Keratinocyte TG (TG1) is an 817-residue polypeptide (about 106kDa) and the 
largest member of the TG family (Kim et al., 1995b). Localized to chromosome 
14 q11.2-13, it has been reported that the gene encoding TG1 is composed of 15 
exons and 14 introns that have conserved position in comparison to the other 
TGs (Kim et al., 1992). At  the tissue level, the localization of TG1 has been 
identified in the granular layer at the later stages of differentiation by 
immunohistological and immunochemical methods (Steinert et al., 1996; 
Thacher and Rice, 1985), while a specific antibody against the N-terminal of the 
active fragments of TG1 revealed its existence in suprabasal and spinous layers 
(Iizuka et al., 2003). Although majorly anchored in the inner plasma membrane 
by acylated fatty acid, a small fraction of TG1 (5-35%) is normally found in a 
soluble state in the cytosol (Kim et al., 1995a).  
 
As a specific marker of epidermal differentiation, till now many aspects of the 
biochemical properties and substrate properties of TG1 have been well 
understood (Rice et al., 1992). The enzymatic activity of TG1 experiences 
different stages during keratinocytes differentiation. TG1 exists as a zymogen in 
the differentiating keratinocytes, while in the terminal differentiation, the 
proteolysis process results in the formation of a 10/33/67kDa complex of TG1 
with a dramatic increase of specific activity (Kim et al., 1995a). The cross-
linking function of TG1 plays an important role in the formation and stabilisation 
of the cellular and tissue structures. TG1 is responsible for the formation and 
structural stability of the 15nm highly cross-linked thick layer of insoluble 
protein on the intracellular surface of the plasma membrane. In the granular layer 
of the epidermis, TG1 catalyzes cross-links of proteins, such as keratins (Yaffe et 
al., 1992), involucrin (Simon and Green, 1988), cornifin (Marvin et al., 1992), 
loricrin (Hohl, 1993) and elafin (Simon et al., 1996), so that it can contribute to 
the formation and stabilisation of  the cell envelope. It has been reported that 
TG1 knockout animals presented defective cell envelope formation and loss of 
loricrin immunoreactivity in their stratum corneum, which also indicated the 
irreplaceable role of TG1 in the formation of the cell envelope, even though there 
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were other TGs, e.g. TG3, expressed in these animals (Matsuki et al., 1998). It 
has also been reported that intracellular TG1 is also present in the cytoplasm of 
spinous cells (Ta et al., 1990) and vascular endothelial cells (Baumgartner et al., 
2004), suggesting that TG1 might also function in maintaining the intracellular 
stabilization of cells via its cross-linking activity. As an important protein in the 
formation of cell envelope, the expression of TG1 can be regulated by different 
proteins, including ROCK (Kotake-Nara et al., 2007), tazarotene-induced gene 3 
(TIG3) (Eckert et al., 2009), βig-h3 and TGFβ1 (Oh et al., 2005), while other 
proteins, such as cathepsin D, are involved in regulating the enzymatic activity of 
this transglutaminase (Egberts et al., 2004).  
 
The abnormalities shown in TG1 knockout mice, including degradation of nuclei, 
definitive cell envelope assembly, and impaired skin barrier function, suggest the 
importance of TG1 in development. The early neonatal death of the null mice (4-
5 hours after birth) indicated that TG1 is also involved in the adaptation to the 
environment after birth (Matsuki et al., 1998). Yang and colleagues (2001) 
discovered 3 mutants of TG1 caused lamellar ichthyosis in two different families, 
which led to the misfolding of the catalytic core domain in TG1 and probably 
results in the reduced TG1 activity. Their work suggested that TG1 is crucial in 
the pathological progress in lamellar ichthyosis. In the vitamin A-deficient rats, 
TG1 activity and expression were significantly increased, leading to the 
existence of involucrin, loricrin and keratin 10 on the cornea epithelial cells. The 
above discovery suggests the role of TG1 in the abnormal keratinisation of the 
cornea (Toshino et al., 2005). A recent study also suggests that TG1 deficiency is 
the cause of bathing suit ichthyosis (Oji et al., 2006), while inappropriate TG1 
expression might be involved in Stevens-Johnson syndrome (Nishida et al., 
1999). 
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1.5 Epidermal transglutaminase 
Although characterised (Buxman and Wuepper, 1975) and purified (Buxman and 
Wuepper, 1976) in 1970s, the epidermal TG (TG3) is still the least understood 
member of TG family. The human gene for TG3 was localised to chromosome 
14 (Polakowska et al., 1991). TG3 is a latent, intact proenzyme (77kDa) with low 
specific activity. After cleavage to two fragments of 47 and 30kDa by certain 
enzyme/s, the enzyme becomes activated via the non-covalent interaction of the 
two fragments (Kim et al., 1993). A recent study indicated that cathepsin L can 
cleave TG3 in vitro (Cheng et al., 2006).  Like the other TGs, the binding of Ca2+ 
can increase the specific activity of TG3 around two fold (Kim et al., 1990; Kim 
et al., 1995a).  
Until  now the cellular and tissue distribution of TG3 has not been well-
investigated, but the utilization of polyclonal antibodies indicated that TG3 could 
be detected in the epidermis in the later stage of differentiation (Lee et al., 1996) 
and the presence of TG3 in brain, small intestine, the testis and forestomach has 
been identified (Hitomi et al., 1999). By using a monoclonal antibody raised 
against the enzyme, Hitomi and colleagues (Hitomi et al., 2003) showed the 
cytoplasmic distribution of TG3 in the granular and cornified layer, and proposed 
a role for TG3 in the early phase of cornified cell envelope formation. During 
epidermal terminal differentiation, activated TG3 can crosslink cornified 
envelope (CE) proteins, including loricrin, small proline-rich proteins (SPRs) 1, 
2, and 3, and trichohyalin, which are also known TG1 substrates (Candi et al., 
1995; Steinert et al., 1998; Tarcsa et al., 1997) (Steinert and Marekov, 1995). 
Unlike TG1, to date no relevance for TG3 mutants in  human diseases have  been 
reported (Zocchi et al., 2007). Although pathological roles of TG3 in human 
diseases have not been completely demonstrated, a recent study indicated that the 
co-localisation of IgA and TG3 in the healthy skin of coeliac patients, suggesting 
that TG3 may play a central role in the pathogenesis of Dermatitis herpetiformis 
(DH) (Cannistraci et al., 2007). By studying autoantibodies  against TG3 in 
serum samples from DH patients on a normal or gluten-free diet via ELISA, 
Rose and colleagues further confirmed the importance of TG3 in DH and 
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suggested that anti-TG3 antibodies can serve as a sensitive serological marker for 
this disease (Rose et al., 2009).    
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1.6 Prostate transglutaminase 
 
Previously named dorsal protein 1, prostate transglutaminase (TG4) has been 
shown to be a 150kDa dimeric protein (62kDa on SDS-polyacrylamide gels) 
(Wilson and French, 1980). Human TG4 gene (TGM4) is localized to 
chromosome 3 p21.33-p22, and the polymerase chain reaction (PCR) technique 
revealed that TGM4 (approximately 35kb of genomic DNA) consists of 13 exons 
and 12 introns to encode 684 amino acid TG4 protein (Dubbink et al., 1998; 
Gentile et al., 1995). Although still unknown at the molecular level, the 
expression of TG4 by the luminal prostatic epithelial cells in coagulating gland 
and dorsal prostate is strictly regulated by androgens (Dubbink et al., 1996; 
Steinhoff et al., 1994; Dubbink et al., 1999). A recent study indicated that the 
positions between -113 and -61 of TGM4 promoter might be essential in TG4 
expression (Dubbink et al., 1999).  
 
Like other TGs, TG4 demonstrates both transamidating and GTPase activities 
(Spina et al., 1999). By analysing different TG4 mutants, Mariniello and 
colleagues (2003) demonstrated that TG4 requires its N-terminal end for its 
catalytic activity, and this domain of TG4 is thought crucial for its interaction 
with GTP. The crosslinking activity of TG4 secreted into the seminal fluid has 
been shown to participate in the formation of the copulatory plug in the vagina 
after coitus (Williams-Ashman, 1984). It has been reported that the polymeric 
form of TG4 can bind to the epididymal sperm cells and mask their 
immunogenicity, so that the sperm cells can escape the immune response in the 
female genital tract (Mukherjee et al., 1983; Paonessa et al., 1984; Porta et al., 
1986). As a prostate-specific protein, the relevance between TG4 and prostatic 
tumours has been studied. Interestingly, there was found to be a down-regulation 
of human TG4 in most metastatic prostatic cancers, while in prostate tumours 
with low-metastatic potential TG4 was up-regulated, which indicated that TG4 
might be a marker for the invasive potential of prostate cancer cells (Davies et al., 
2007; Dubbink et al., 1996). The potential relationship between TG4 and prostate 
cancer still requires further investigation. However by using prostate cancer cells 
expressing different level of TG4, recent work suggested that over-expression of 
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TG4 increased the interaction between prostate cancer cells and endothelial cells, 
which was inhibited by knocking down TG4 via siRNA treatment (Jiang et al., 
2009). 
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1.7 Erythrocyte band 4.2 
 
Human erythrocyte band 4.2 (also known as protein 4.2 and pallidin) is a 
peripheral membrane protein, which is N-terminally myristoylated and 
palmitoylated. It has been reported that the erythrocyte protein 4.2 gene EPB42 is 
located in bands q15 to q21 of human chromosome 15 (Sung, et al., 1992), which 
contains 13 exons (20kb) (Cohen et al., 1991; Sung et al., 1992). There are two 
isoforms of protein 4.2: a protein of 721 amino acids with a molecular weight of 
74kDa encoded by the long isoform cDNA (P4.2L) and a protein of 691 amino 
acids with a molecule weight of 72kDa encoded by the short isoform cDNA 
(Sung, et al., 1992). Protein 4.2 is a major constituent of the red blood cells 
(RBCs) membrane skeletal network and comprises approximately 5% of the total 
membrane protein, which means it is present in about 200,000 copies per RBC 
(Cohen et al., 1993).  
 
As a member of transglutaminase family, protein 4.2 is the only catalytically 
inactive one (Aeschlimann and Paulsson, 1994). The exact role of protein 4.2 in 
RBC has not been elucidated yet, but the binding of protein 4.2 to the 
cytoplasmic domain of band 3 (Bhattacharyya et al., 1999) and its interacting 
with spectrin (Colan et al. 1996) and ankyrin (Korsgren et al., 1988) suggest its 
function in stabilizing linkages between the cytoskeleton and the overlying 
membrane. Meanwhile the presence of band 3 is also crucial for the stable of 
protein 4.2 incorporation of protein 4.2 into the RBC membrane. It has been 
shown that RBCs deficient in band 3 in human (Ribeiro et al., 2000), mouse 
(Peters et al., 1996) and cow (Inaba et al., 1996) are completely deficient in 
protein 4.2. Recently, protein 4.2 has been shown to interact with CD47, which 
probably contributes to the anchoring of the Rh complex to the RBC skeleton 
(Mouro-Chanteloup et al., 2003). The interaction of band 4.2 with other RBC 
proteins highlights the importance of protein 4.2 in maintaining the integrity, 
stability and flexibility of RBCs. Hereditary deficiency in protein 4.2 results in 
erythrocytes fragility (Cohen et al., 1993). To date, 9 kinds of protein 4.2 
mutations have been found associated with herediatary spherocytosis (HS).  
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1.8 Transglutaminases X, Y, and Z 
 
With the further research in TG family, three different types of transglutaminase 
were discovered, namely transglutaminase X (TG5), transglutaminase Y (TG6), 
and transglutaminase Z (TG7). Even though the physiological functions of above 
three TGs have not been well defined, genomic research has revealed the 
structure and location of their genes (Aeschlimann et al., 1998; Grenard et al., 
2001). 
 
The gene encoding human TG5 (TGM5) is localized in the q15.2 region of 
chromosome 15, composed of 13 exons and 12 introns (about 35 kb) (Grenard et. 
al., 2001). The enzyme consists of 720 amino acid residues with the molecular 
weight of approximately 81kDa. Now two isoforms of TG5 have been 
discovered: a long 720 amino acid form, which contains an insert in the N-
terminal region, and a short 638 amino acid form. TG5 is almost ubiquitously 
expressed (Grenard et al. 2001) and, in particular, is widely expressed in the 
epidermis (Candi et al. 2002). As a dual-functional enzyme, TG5 exerts both 
transamidating and GTPase activities.  Like TG2 and TG3, the activity of TG5 is 
inhibited by GTP, and Ca2+ is capable of completely reversing this inhibition 
(Candi, et. al. 2004). Other studies doing in situ measurement demonstrated that 
TG5 can be activated by phorbol acetate (Rufini et al., 2004). TG5 has been 
found in keratinocytes of early-staged differenciation and showed high 
crosslinking activity toward some epidermal proteins, including loricrin, 
involucrin, and SPR3 (Candi et al., 2001). Recent studies demonstrated that TG5 
might be involved in different pathological processes and relevant diseases. Two 
types of TG5 mutants, T109M and G113C, were discovered in unrelated peeling 
skin syndrome (PSS) patient families, respectively. Even though no pathological 
effect of T109M was discovered, G113C, in a position near the catalytic domain 
of TG5, showed no crosslinking activity.  The role of TG5 in mediating the 
structure of epidermis through its crosslinking activity was also suggested 
(Gassidy et al., 2005). In Darier’s disease, two extreme situations of TG5 
expression over-expression or absence, was discovered in different areas of the 
same lesion (Candi, et al., 2002).  
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A recent study introduced two types of TG members, TG6 and TG7, located at 
mouse chromosome 20 q11. By using PCR, Grenard and colleagues revealed 
TGZ is a protein of 710aa (80kDa) (Grenard et al. 2001). Even though the 
physiological functions of these TGs still remain unknown, interestingly one 
recent work by Stamnaes and colleagues (2010) demonstrated the role of TG6, as 
a target of gluten ataxia (GA) autoantibody, in mediating the autoimmune 
response in celiac disease (CD).   
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1.9 Tissue transglutaminase 
 
In contrast to the other members of the transglutaminase family, tissue 
transglutaminase (tTG, TG2, or type II transglutaminase) is a multifunctional 
enzyme involved in a number of disparate biological processes. Although mainly 
a cytosol protein, TG2 can also be localized in the plasma membrane, nucleus 
and nuclear membrane and the mitochondria. Unlike the majority of other 
secretory proteins, TG2 lacks the hydrophobic leader sequences and cannot be 
secreted by the classical ER/Golgi-dependent mechanism, but the presence of the 
enzyme has been detected in cell membrane fractions (Griffin et al., 1978b) and 
in the ECM (Verderio et al., 1998a). A novel function for TG2 present in the 
ECM forms the subject of this thesis. 
 
1.9.1 Structure of tissue transglutaminase 
 
The cDNA sequence study shows that the TG2 molecule is a monomeric protein 
of 685-691amino acids with a molecular weight of 75-85kDa. The three-
dimensional structure of TG2 has been modelled on that of factor XIIIa and has 
been predicted to consist of 4 main domains, namely the N- terminal β- sandwich 
(residues 1-138), α/β catalytic core (residues 139-471), and two C-terminal β-
barrel domains (residues 472-584 and 585-686, respectively) (Chen and Mehta, 
1999b) (modified in this work, Figure 1.1). Although with 17 cysteine residues 
and six potential N-linked glycosylation sites, TG2 molecule contains neither 
disulfide bonds nor glycosylated structures (Ikura et al., 1988a). It has been 
reported that the protein undergoes a series of post-translational processes, 
including the removal of its initiator methionine and N-acetylation of the 
adjacent alanine residue. Even though the transamidation activity of the enzyme 
is not affected by the acetylation at the N-terminal of guinea pig TG2, this 
modification may be involved in the protein’s secretion (Muesch et al., 1990).  
 
In the N-terminus  of the TG2 molecule, there is a fibronectin binding site 
mediating the interaction between TG2 and FN with high affinity, which has 
been reported to be involved in regulating cell adhesion (Akimov et al., 2000b), 
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Figure 1.1 Schematic structure and functional domains of TG2.  
A) Backbone structure of TG2 (the picture was produced with Rasmol). Domains 
I-IV are coloured respectively in magenta, orange, blue and green; the regulatory 
loop between domain II and III is coloured red. The colours yellow, black and 
light grey represent the amino acids involved in the active site (Cys277, His335 
and Asp358), in Ca2+ binding (Ser449, Pro446, Glu451 and Glu452) and in 
interaction with GTP (Ser171, Lys173, Arg478, Val479 and Arg580), 
respectively. (B) Space-filling presentation of TG2 structure in the absence of 
ligands. (C) The proposed structural and functional domains of TG2.  N-terminal 
amino acid residue 1-7 and the amino acids 88-106: required for TG2’s 
intereaction with FN; Try241: essential for TG2 cross-linking activity; Cys277 
(Cysteine), H335 (Histidine) & D358 (Aspartic Acid): conserved among all 
enzymatically active members of the TG family; Cys277: crucial for the 
formation of the thioester bond and secretion of TG2 into the ECM (Chen and 
Mehta, 1999). 
 
 
Figure 1.1 
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matrix assembly (Telci and Griffin, 2006) and TG2 externalization  (Balklava et 
al., 2002). The truncation of in the N-terminal of TG2 molecule led to the loss of 
almost all the ability for its binding to FN, which suggested the importance of the 
N-terminal sequence in the interaction between TG2 and FN (Gaudry et al., 
1999a). Another FN binding site, localized at amino acids 80-106 within the β-
sandwich domain of this enzyme, was suggested as the FN binding sites by 
Belkin and colleagues (Hang et al., 2005). By using a synthetic peptide sequence 
matching these residues, the interaction between TG2 and FN was significantly 
inhibited, and the peptide inhibited cell adhesion process on FN mediated by 
TG2, suggesting this domain is a novel FN binding site in TG2.  It has also been 
reported that the β-sandwich domain is crucial to the transamidating activity of 
TG2 (Iismaa et al., 1997).  The α/β catalytic domain is involved in the GTPase/ 
ATPase activity of TG2. As a Ca2+-dependent enzyme, the transamidating 
activity of TG2 is regulated by the binding of the enzyme molecule with Ca2+ 
through the Ca2+-binding site within the 430-453 amino acids of the core domain 
(Ikura et al., 1988b). By using mutagenesis of TG2, most recent report 
demonstrated that there are 5 other possible Ca2+ binding sites (around amino 
acids 228, 395, 305, 149 and 432), the mutations of which led to the decreased 
transglutaminase activity of TG2 (Kiraly et al., 2009). It has been demonstrated 
that the GTP-binding site is localised to a 15-residue segment spanning between 
amino acids 159-173 in the core domain of TG2 and Trp332 is also relevant in the 
regulation by GTP (Murthy et al., 2002). Recently it was reported that Arg580 in 
human TG2 and Arg579 in rat TG2 is important in the binding ability of TG2 with 
GTP. The mutants of these two sites also showed increased in situ TG activity 
compared to the wild type enzymes (Ruan et al., 2008). Within the catalytic 
domain of TG2, the Tyr241 is essential for activity of TG2, while the Cys277 forms 
the thioester bond involved in  transamidation (Chen and Mehta, 1999a). Close to 
the C-terminal of the TG2 molecule, eighteen- amino acid residues, Val655- 
Lys672, are crucial for the protein to recognize and activate phospholipase C 
(PLC), which is important in transmitting the α1B- adrenoceptor (AR) signal 
(Feng et al., 1999). 
 
1.9.2 Regulation of expression 
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The human TG2 gene (TGM2) has been mapped on chromosome 20q11-12 and 
is 32.5kb (Gentile et al., 1994). TGM2 is composed of 13 exons separated by 12 
introns. Evidence indicates that the expression of TGM2 can be regulated by 
cytokines and hormones.  
 
Retinoic acid (RA) treatment can induce TG2 expression both at the mRNA and 
at the protein level in vitro and in vivo (Defacque et al., 1995; Verma et al., 1992). 
It has been reported that the TGM2 gene contains regulatory elements for several 
transcriptional factors, including two tandem retinoid-responsive elements 
(RREs), which bind the retinoid receptors RAR and RXR. RA promotes the 
expression of TG2 via its interaction with its receptors to promote the formation 
of RAR/RXR heterodimers or RXR/RXR homodimers, which triggers the 
activation of the transcription of TGM2 (Glass, 1994; Mehta et al., 1996). It has 
been reported that TG2 expression can be regulated by some cytokines including 
transforming growth factor β1 (TGFβ1), interleukins (e.g., IL-1), and 
morphogenic protein 4. TGFβ1 can increase the expression of cell surface TG2, 
which results in the enhanced cell adhesion (Priglinger et al., 2004). On the other 
hand, TG2 can activate the matrix bound TGFβ via cross-linking of the Large 
Latent TGFβ-binding protein-1 (LTBP-1). The activation of macrophages, the 
main “producer” of TGFβ, is characterized by increased TG2 levels, which is 
related to its phagocytotic capacity and its ability to secrete and activate TGFβ1 
(Griffin et al., 2002b; Telci and Griffin, 2006). These results indicate there might 
be a positive feedback loop between TG2 and TGFβ1 production by cells. 
Another inflammatory cytokine TNFα can increase the TG2 expression by liver 
cells through the NF-κB (nuclear factor kappa-light-chain-enhancer of activated 
B cells)-dependent mechanism, which could be important  in the progress of liver 
fibrosis (Kuncio et al., 1998). Some results also suggest that DNA methylation, 
together with alterations in the chromatin structure, may play a role in regulating 
TG2 production (Lu and Davies, 1997; Grunstein, 1997). Blocking endogenous 
polyamine synthesis with α-difluoromethylornithine (DFMO) decreased TG2 in 
rat small intestinal crypt (IEC-6) cells, but led to the increase of TG2 in human 
colon carcinoma (Caco-2) cells, in both transamidating activity and mRNA level 
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(McCormack et al., 1994; Wang et al., 1998). These data indicated that as a 
widely-expressed protein, the expression of TG2 is also cell and tissue type- 
dependent.  
 
1.9.3 Regulation of activity 
 
Accumulating research focusing on the regulation of TG2 activity suggests that, 
as a multifunctional enzyme, TG2 can catalyse both Ca2+-dependent 
transglutaminase activity (transamidation) and Ca2+- independent Guanosine-5’-
triphosphate (GTP) and Adenosine-5’-triphosphate (ATP) hydrolysis regulated 
by magnesium (Lee et al., 1989), meanwhile it also can function as a protein 
disulphide isomerise (PDI) (Hasegawa et al., 2003) and a kinase (Mishra and 
Murphy, 2004).  
 
 
In the intracellular environment, recent reports demonstrate that the activity of 
TG2 can be modulated both by Ca2+ and GTP/GDP levels. A large increase in 
the intracellular Ca2+ can lead to an enhanced transglutaminase activity of TG2 
resulting in the crosslinking of a variety of proteins, including signalling 
molecules, enzymes and the cytoskeleton (Griffin et al., 2002b; Verderio et al., 
2004). Unlike other members of the transglutaminase family, TG2 is capable of 
both binding and hydrolyzing GTP (as a Gunoaine-5’-triphosphatase (GTPase)) 
(Lorand and Graham, 2003). Due to the presence of high concentrations of GTP 
and low levels of Ca2+ intracellularly, it is now generally believed that 
intracellular TG2 mainly functions as GTPase instead of a Tgase (Ruan et al., 
2008; Smethurst and Griffin, 1996b). The regulatory effect of GTP on TG2 
activity has been very well demonstrated from in vitro studies. The binding of 
GTP to TG2 leads to changes in the conformation of the TG2 molecule and 
results in its low affinity for Ca2+ (Kiraly et al., 2009; Ruan et al., 2008; 
Smethurst and Griffin, 1996a). Meanwhile the ability to bind and hydrolyze GTP 
links intracellular TG2 to a major signalling pathway, in which TG2 functions as 
a signal transduction GTP-binding protein, Gαh. In this pathway, TG2 transmits 
outside signals from the membrane (e.g. α1B and α1D adrenoceptor) to 
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downstream cytoplasmic targets such as phospholipase Cδ (PLCδ) to regulate 
cellular behaviour, e.g. cell migration (Murthy et al., 1999); (Feng et al., 1999; 
Kang et al., 2004)). It was demonstrated that, as a complex with TG2, PLC δ1 
remain inactive, while the binding of TG2 to GTP can release PLC from the 
complex and activate this protein (Murthy et al., 1999). Recent in vivo study 
further supports the regulatory effect of GTP on TG2 activity by demonstrating 
that in human SY5Y neuroblastoma cells, the depletion of intracellular GTP 
leads to increased in situ transamindating activity of TG2 (Zhang et al., 1998). 
Magnesium ions are also essential for the hydrolysis of both GTP and ATP (Lee 
et al., 1993). Mg2+-ATP induces a conformational change in TG2 that inhibits 
GTPase but does not interfere with the cross-linking activity, while Mg2+-GTP 
binding induces a different conformation that inhibits cross-linking activity 
without affecting the ATPase activity of TG2 (Lai et al., 1998). There are also 
some reports suggesting that nitric oxide (NO) is a potent inhibitor of TG2 
activity, through a Ca2+-sensitive nitrosylation of multiple cysteine residues (Lai 
et al., 2001; Telci et al., 2009).  
 
To sum up these findings the  binding of GTP or Ca2+ cause opposite 
conformational changes in the TG2 molecule and inhibit, respectively, the 
transamidation or GTPase functions of TG2. Meanwhile, other molecules, e.g. 
Mg2+ and NO, are also involved in regulating the TG2 activity. 
 
Recent studies proposed a novel function for TG2 as PDI, which can convert the 
completely reduced/ denatured inactive RNase, a molecule to the native active 
enzyme. Unlike the other enzymatic activities of TG2, the PDI activity depends 
neither on the Ca2+ nor on the binding of GTP (Hasegawa et al., 2003). A most 
recent reported demonstrated that the PDI activity of TG2 is important in 
maintaining the correct assembly of mitochondrial ADP/ATP transporter adenine 
nucleotide translocator 1 (ANT1) and its potential involvement in mitochondria- 
related apoptosis (Malorni et al., 2009). Mishra and Murphy also discovered an 
intrinsic kinase activity for TG2 (Mishra and Murphy, 2004). TG2 present in 
human breast cancer cell membranes can phosphorylate the insulin-like growth 
factor-binding protein-3 (IGFBP-3) and enhance its binding affinity to IGF-I to 
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modulate the pro-apoptotic anti-proliferation effect of IGFBP-3 in cancer cells. 
This IGFBP-3 kinase activity of TG2 can be inhibited by an increase in Ca2+ 
concentration. 
 
1.9.4 Localisation and cellular distribution of TG2 
 
Unlike the majority of other secretory proteins, TG2 lacks the hydrophobic 
leader sequences and it cannot be secreted by the classical endoplasmic 
reticulum/Golgi-dependent mechanism, but the presence of the enzyme has been 
detected in cell membrane fractions (Griffin et al., 1978c) and in the extracellular 
matrix (Verderio et al., 1998b); (Stephens et al., 2004). Although predominantly 
a cytosolic protein (80%), TG2 can translocate to the nucleus with the help of 
importin-α-3 protein or to the membranes in association with integrins (Akimov 
and Belkin, 2001a; Isobe et al., 1999; Mehta et al., 2006a; Takahashi et al., 2000). 
In addition, a current study showed TG2 is localised at the outer mitochondrial 
membrane, which has been suggested to be crucial in maintaining mitochondria 
function by regulating the ANT1 activity (Malorni et al., 2009). 
 
1.9.5 Physiological functions of TG2 
 
As a multi-functional protein and a widely -expressed member of the TG family, 
and despite attempts to demonstrate  a defined role for  TG2, the precise 
physiological functions of TG2 still remain a puzzle to researchers. 
Accumulating evidence demonstrates that TG2 is involved in various biological 
and physiological processes, including matrix stabilization (Aeschlimann et al., 
1995; Aeschlimann and Thomazy, 2000; Collighan and Griffin, 2009; Verderio 
et al., 1998b), cell growth and differentiation (Gentile et al., 1992), programmed 
cell death and necrosis (Fesus et al., 1987) (Nicholas et al., 2003), Ca2+ mediated 
stimulus secretion coupling (e.g. insulin secretion) (Bungay et al., 1986; Sener et 
al., 1985), receptor mediated endocytosis/ phogocytosis (Schroff et al., 1981), 
cell adhesion and migration (Akimov and Belkin, 2001b; Akimov et al., 2000a; 
Balklava et al., 2002; Verderio et al., 2004; Verderio et al., 2003; Zemskov et al., 
2006).     
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1.9.5.1 Importance of TG2 in cell growth and differentiation 
 
The involvement of TG2 in cell differentiation and proliferation was initially 
reported in the 1970s by Birckbichler and colleagues, based on the finding that 
cells with lower TG2 activity proliferated more rapidly than those with higher 
enzymatic activity (Birckbichler and Patterson, 1978). By using cystamine to 
inhibit the transglutaminase in WI-38 human lung fibroblasts, these authors 
demonstrated that with the decreased intracellular ε-(γ-glutamyl) lysine, some 
proliferation markers were enhanced, which could not be achieved by using other 
amines such as methylamine and histamine  (Birckbichler et al., 1981). More 
focused serious work from Griffin and co-worker demonstrated the role of TG2 
in regulating cell proliferation by using the highly metastatic hamster 
fibrosarcoma cell line MetB. Flow cytometry revealed an over-lap between the 
high TG2 activity and the high apoptotic cell cycle phase at mid-S-phase, while 
the quantity of the enzyme remained unchanged in the other phases of the cell 
cycle (el Alaoui et al., 1992). Further investigations were performed to study the 
activity of TG2 in the progression of the cell cycle. Both wild type and C277S 
mutant cDNA (in which the transamidation function was multigenized but the 
enzyme still showed GTPase activity) were transfected into the MetB cells, and a 
delayed progression from S phase to G2/M was discovered via flow cytometry, 
which indicated that the regulation of TG2 in cell progression is not dependent 
on its transamidating activity (Mian et al., 1995). Meanwhile the role of TG2 in 
modifying fibronectin (FN) was also suggested to be involved in cell progression 
control, since it was reported that FN with various 3-D structures affected the 
rate of G0/G1 to S phase progression (Sechler and Schwarzbauer, 1998).  
 
The role of TG2 in cell differentiation has been well documented. Via immuno-
fluorescence staining and transamidation assays, the presence of TG2 was 
studied in different immune cells with various differentiation stages. In induced 
macrophages more TG2 signal was detected compared to normal peritoneal 
washout macrophages, suggesting TG2 as a new marker for macrophages in 
certain differentiation stages (Schroff et al., 1981). In MC3T3-E1 osteoblasts, the 
role of active TG2 in cell differentiation was reported based on the fact that the 
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inhibition of TG2 activity resulted in the arrested stage of osteoblasts 
differentiation, while the transamidating activity of TG2 in moderating the FN-
collagen matrices network formation was also suggested to involve the above 
process and lead to matrix mineralization (Al-Jallad et al., 2006). By using 
tissue-engineered human skin, the inhibition of TG2 by site directed-
transglutaminase inhibitors, NTU283 and NTU285, was reported to block the 
differentiation of keratinocytes and led to the hyperproliferation in the epidermis 
(Harrison et al., 2007). Unlike its role in cell differentiation, the GTP-bound form 
of TG2, but not its transamidating activity, was suggested as a molecular switch 
in leading the maturation of chondrocytes to hypertrophy (Johnson and 
Terkeltaub, 2005).  The above function of TG2 in chondrocyte maturation was 
also reported in a study about guinea pig osteoarthritis (OA) by Huebner and 
colleagues (Huebner et al., 2009). In their work, the role of this protein in 
regulating the maturation of chondrocytes to hepertrophy suggested TG2 as a 
biomarker in evaluating the progression levels of OA.  
 
1.9.5.2 TG2 in Ca2+-mediated stimulus secretion coupling 
 
The involvement of TG2 in Ca2+ mediated insulin secretion was first raised in 
1984 by Griffin and colleagues, who discovered that incubation of rat islets with 
TG2 competitive substrates can inhibit the glucose-stimulated insulin release 
(Bungay et al., 1984). The role of TG2 in this process was further supported by 
the fact that monodansylcadaverine, a TG2 competitive amine substrate that can 
inhibit crosslinking, can decrease the glucose-stimulated insulin secretion 
significantly (Bungay et al., 1986; Sener et al., 1985). TG2 -/- mice showed 
decreased glucose tolerance after intraperitoneal glucose loading and a tendency 
of hypoglycemia induced by the increase of the phosphorylation of insulin 
receptor substrate 2 (IRS-2) (Bernassola et al., 2002). They also reported that the 
presence of one of TG2 mutants— N333S, in Italian subjects with the clinical 
features of maturity-onset diabetes of the young (MODY) (Bernassola et al., 
2002). A recent study reported the presence of TG2 mutants located close to the 
transamidation catalytic site of TG2, including M330, I331 and N333, which 
may be involved in early-onset type 2 diabetes (Porzio et al., 2007). 
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1.9.5.3 TG2 and receptor mediated endocytosis 
 
Based on the finding that receptor-mediated endocytosis of α2-macroglobulin 
can be inhibited by TG competitive primary amine substrates, the involvement of 
TG2 in endocytosis was first demonstrated. It was suggested that TG2 exerted its 
function by stabilising the membrane for the receptor aggregation or cross-
linking the ligand with its receptor (Davies et al., 1980). The role of TG2 in 
endocytosis was also studied in antigen presenting cells (APC) by using similar 
monoamines competitive substrates.  High TG2 activity was found in 
lymphocyte accessory cells, peritoneal exudate and spleen adherent cells, 
meanwhile the TG2 competitive primary amine substrate monodansylcadaverine 
inhibited the receptor-dependent endocytosis of immune complexes at 100μM, 
significantly less than the inhibiting effect of methylamine (over 20mM) 
(Teshigawara et al., 1985). Clear proof of increased TG2 activity and enhanced 
phagocytosis in macrophages was demonstrated (Murtaugh et al., 1983).  In vivo 
study in TG2 -/- mice indicated that the absence of TG2 led to the prevention of 
active TGFβ1 production by macrophages exposed to apoptotic cells, which in 
turn caused the inefficient phagocytosis of apoptotic cells (Szondy et al., 2003) 
(Boisvert et al., 2006).    
 
1.9.5.4 Tissue transglutaminase and cell death 
 
The involvement of TG2 in cell death, including apoptosis and necrosis, has been 
widely studied. Apoptosis means ‘dropping off’ in Greek, which was first 
proposed by Kerr and Searle after discovering a type of cell death that happened 
in individual liver cells after severe-weak portal vein branch ligation in 1970s 
(Kerr, 1965; Kerr and Searle, 1972) (Kohn et al., 1987). Apoptosis has been 
reported important in determining cell termination (removing of damaged cells), 
maintaining normal tissue homeostasis by balancing cell mitosis, tissue 
development and lymphocyte-mediated immune response (Gerschenson and 
Rotello, 1992; Thompson, 1995; Werlen et al., 2003). The role of TG2 in 
apoptosis varies depending on the activation of its enzymatic activity, GTP 
binding, or the presence of intracellular Ca2+, GTP or polyamines (Melino and 
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Piacentini, 1998). TG2 can prevent the occurrence of inflammation by promoting 
the irreversible formation of polymers of intracellular proteins, including actin, 
annexin, fibronectin, vinculin, retinoblastoma protein, and troponin (Ballestar et 
al., 1996; Gorza et al., 1997; Nemes et al., 1997; Oliverio et al., 1997), in the 
dying cells via its cross-linking activity. This effect limits the release of the 
intracellular proteins and protects the cells from autophagy until they are cleared 
by immune cells (Piredda et al., 1997). This enzymatic activity of TG2 suggests 
its role as a downstream effector in cell apoptosis, while recent research 
demonstrated an opposite effect of TG2 cross-linking activity. In thapsgargin-
treated HCT116 colon cancer cells, TG2 can promote the formation of two 
species of caspase 3, p40 and p64, via its cross-linking activity, thereby TG2 
blocked the activation of Bax-dependent pathway mediated by caspase to protect 
the cells from THG-induced apoptosis (Yamaguchi and Wang, 2006). Antonyak 
and collagues indicated that GTP-bound  TG2, as an intracellular signalling 
molecule, can protect cells from the synthetic retinoid N-(hydroxyphenyl) 
retinamide (HPR)-induced apoptosis via activating intracellular Ras-ERK 
pathway in fibroblasts (Antonyak et al., 2001) (Antonyak et al., 2003). In 
epithelial ovarian cancer cells, TG2 can protect the cells from cisplatin-induced 
apoptosis by activating the NF-κB survival pathway (Cao et al., 2008). It has also 
been shown that in fibroblasts and osteoblasts, matrix TG2 can rescue cells from 
RGD-induced apoptosis, named anoikis (Verderio et al., 2003).  
 
In contract to apoptosis, necrosis is a fatal process under external stimuli 
including infection, inflammation, injury, and cancer. Griffin and colleagues 
demonstrated that TG2 can stabilize intracellular proteins by mediating the 
formation of the cross-linked proteinaceous shells to block the release of the 
DNA and in turn preventing the cells from the classical apoptotic pathway 
mediated by Bcl2, Ca2+-activated and other cellular proteases and caspase 3. 
Their data indicated the protecting role of TG2 on necrosis after the loss of Ca2+ 
homeostasis (Johnson et al., 1998; Nicholas et al., 2003). By detecting TG2 in 
both hepatitis C virus (HCV)-infected patients and carbon tetrachloride (CCl4)-
induced liver injury mice, Nardacci et al. (Nardacci et al., 2003) discovered 
increased level of TG2 in the early stage of liver injury mostly localized in 
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hepatocytes facing periprotal infiltrate, while in the stage of prominent ECM 
deposition, TG2 was predominantly present in the ECM. This strict presence of 
TG2 during different stages of liver damage indicated the protective role of TG2 
in maintaining liver architecture against the inflammatory stimuli.  
 
The opposite effects of TG2 on determining cell fate, protecting or inducing, 
apoptosis or necrosis, may be cell type- and stimuli-dependent, and also can be 
regulated by the intracellular concentration of Ca2+ and GTP, as well as the 
localization of the protein (Fesus and Szondy, 2005). 
 
1.9.6 TG2 and human diseases 
 
During the recent decades, the potential role of TG2 in the development of 
human diseases has become the major interest of scientists. The contribution of 
its cross-linking activity, GTPase activity and its non-enzymatic function as a 
signalling protein has been reported in different pathological processes, such as 
celiac disease, neurodegenerative diseases, fibrosis and cancer in humans.  
  
1.9.6.1 TG2 in Celiac Disease 
 
Celiac disease (CD) is a chronic autoimmune disorder caused by a dysregulated 
T cell mucosal immune response to gluten from wheat or similar structural 
cereals such as rye and barley, which is relevant to the genes that encode HLA-II 
antigens, including  HLA-DQ2 and DQ8 (Sollid, 2000). The pathological study 
of CD suggested that the specific immunogenic peptides within the gluten 
protein can survive from the digestion of gastric and pancreative enzymes and 
can active specific CD4+ T-cell line to trigger the CD (Shan et al., 2002). Once 
activated by CD4+ T-cell, type I helper T cells can produce cytokines (e.g. 
intereferon-γ (IFN-γ)), leading to the subsequent immune and inflammatory 
responses and the intestinal lesion, meanwhile the clonal expansion of B cells 
results in the production of antibodies (Rodrigo, 2006). In serum sample of CD 
patients, specific antibodies against gliadin, endomysium, reticulin, jejwnum can 
be detected. The high level of specific anti-TG2 serum antibody found in celiac 
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patients exposed to gluten suggested the involvement of the enzyme in this 
disease (Sollid and Scott, 1998). Apart from the anti-TG2 antibody, other 
evidence suggests the potential role of TG2 in CD: (1) there is higher expression 
of TG2 in CD patients; (2) the increased TG2 in CD patients is localized to the 
small intestinal mucosa and in the extracellular matrix, while in normal subjects, 
TG2 can be found in all layers of the small intestinal wall; (3) the enzymatic 
activity of TG2 in intestinal mucosa is increased in CD patients compared to 
controls (Caputo et al., 2004).   
 
It has been well accepted that TG2 acts as a master regulator of CD. TG2 can 
regulate the progress of CD in several ways. It has been proven that the specific 
glutamine residues with gluten is an ideal substrate of TG2, and the deamination 
reaction mediated by TG2 is crucial for HLA-DQ2 binding and subsequent T cell 
activation (Schuppan and Hahn, 2002).  Meanwhile the formation of gliadin-TG2 
complexes supports the production of anti-TG2 antibody which can in turn 
modify the activity of the enzyme and some enzymatic-independent functions of 
protein on the cell surface (Caputo et al., 2004; Molberg et al., 2000). Other 
studies indicate that TG2 can activate TGFβ1 by promoting its maturation so that 
TGFβ1 can increase the activation of mucosal Th1 cells and the differentiation of 
intestinal epithelium (Hansson et al., 2002). Moreover, the role of TG2 in 
regulating the humoral response may also contribute to the T cell response in CD 
patients’ small intestine (Molberg et al., 1998). In addition to being a sensitive 
marker of CD in diagnosis, the potential application of TG2 in CD therapy has 
also been suggested, via the endocytosis of digestive-resistant oral vaccination 
with immunogenic peptide mediated by the protein. Meanwhile the T cell 
immune response to the gluten peptide could be inhibited by blocking the 
enzymatic activity of the enzyme (Reif and Lerner, 2004).    
 
1.9.6.2 TG2 in neurodegenerative diseases 
 
The physiological and pathological functions of TG2 in the neuronal system have 
been widely studied. It has been reported that TG2 is involved in the 
development, regeneration and functioning of neurons. Transient increases of 
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TG2 activity have been found in rat superior cervical ganglia after nerve injury 
and in the vagus nerve after crush injury (Ando et al., 1993; Tetzlaff et al., 1988). 
The increase of TG2 activity has been reported during development (Perry and 
Haynes, 1993). By introducing wild type TG2 into neuroblastoma cells, Lesort 
and colleagues (2000) discovered the formation of extensive neurites, but not in 
the cells transfected with inactive TG2. Midkine, an in vitro TG2 substrate, can 
be cross-linked by this enzyme to form a stable dimer, which is important in 
improving the neurite out-growth and neuronal survival (Iwasaki et al., 1997; 
Kojima et al., 1997; Mahoney et al., 1996). TG2 can also support regeneration of 
injured rat optic axons by stabilizing the dimers of interlukin-2 via its cross-
linking activity (Eitan et al., 1994). The direct interaction of core hisone 2B and 
TG2 was found in apoptotic SK-N-BE cells (Piredda et al., 1999). The above 
studies suggest the importance of TG2 in mediating neurite outgrowth and 
neuron survival and apoptosis.  
 
Based on its importance in neuronal development, regeneration, cell survival and 
apoptosis, the role of TG2 in different neurodegenerative diseases has been 
further demonstrated. Alzheimer’s disease is one of the most common age-
related neurodegenerative diseases, caused by selective damage of brain regions 
and neural circuits, which can lead to impaired memory, thinking and amygdala 
(Kim et al., 2002). Selkoe and colleague (Selkoe et al., 1982) first suggested the 
involvement of TG2 in the pathology of Alzheimer’s disease and accumulating 
evidence further proved its important role in the pathological progression of this 
disease due to its biochemical properties (Selkoe et al., 1982). Amyloid β- 
protein (Aβ), is an element of Alzheimer’s disease, can disrupt the calcium 
homeostasis in cultured neurons, which can activate the cross-linking activity of 
intracellular TG2 and might in turn promote the formation of Aβ dimers, trimers 
and tetramers and high-order oligomers. These oligomers of Aβ resemble those 
presented in Alzheimer’s disease brain samples (Mattson et al., 1992); (Dudek 
and Johnson, 1993; Ho et al., 1994). Oxidative stress and free radical production 
may also contribute the pathological damage of Alzheimer’s disease by 
promoting the oxidation of proteins, which are ideal substrates of TG2 (Groenen 
et al., 1993; Mattson, 1995). On the other hand, some regulators in TG2 
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expression, including NF-κB, TNF-α, interleukin-6, have been reported to be up-
regulated in Alzheimer’s disease brain (Mirza et al., 1997). Tau, a microtubule-
associated protein- a component of neurofibrillary tangles, has been shown to be 
an excellent substrate of TG2 (Dudek and Johnson, 1993), and the co-
localization of these two proteins was found in the neurofibrillary tangles of 
Alzheimer’s disease’s brain (Appelt et al., 1996). Apart from its cross-linking 
activity, the involvement of TG2 in apoptosis was also suggested to contribute to 
the pathological progression of Alzheimer’s disease (Lesort et al., 2000).  
 
Huntington’s disease is another neurodegenerative disease that has been reported 
to be relevant to TG2. Huntington’s disease is a progressive neurodegenerative 
motor and psychiatric disorders, with chorea, cognitive decline, incoordination, 
and behavioural difficulties. Huntington’s disease has been identified as an 
autosomal dominant disease and the presence of the mutated gene product, 
huntingtin, has been reported, although its function remains unknown (the 
Huntington’s Disease Collaborative Research Group, 1993). Expansion of CAG 
repeats in huntingtin mutations led to the stretches of polyglutamines of greater 
than 39 contiguous glutamine residues (Gusella et al., 1993). This increase of 
polyglutamines, compared to the normal range of 10-25 residues, cannot only 
serve as an excellent substrate for TG2, but also increases the binding affinity 
with this enzyme (Gentile et al., 1998; Kahlem et al., 1996; Karpuj et al., 1999). 
As a distinguishing characteristic of Huntington’s disease, aggregates has been 
found both in vitro and in vivo samples. Kim et al. (2002) also demonstrated that 
TG2 inhibitors treatment can inhibit the formation of the aggregate and improve 
the survival rates of the animals carrying the mutant gene (Kim et al., 2002). 
Other studies also suggested the potential mechanisms that can promote the 
activation of TG2, including the release of cytokines TNFα, IL-2 and IFN-γ 
induced by oxidative stress and the production free redicals caused by the 
damaged mitochondria (Kim et al., 2002). A recent report demonstrated that in 
striatal cells transfected with wild type huntingtin, as a response to thapsigargin-
induced, intracellular over-expressed TG2 showed more activity than in the cells 
with the mutant huntingtin, which led to the mitochondrial membrane 
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depolarization and the sensitivity of the cells to thasigargin-induced apoptosis 
(Ruan et al., 2008).  
 
Although a certain amount of in vitro and in vivo study has been devoted to 
discovering the role of TG2 in neurodegenerative diseases, there are still 
questions which remained unaddressed and await further investigation.   
 
1.9.6.3 TG2 in fibrosis 
 
Fibrosis and scarring is the result of chronic progressive wounding healing 
resulting from continuous insults, including that of diabetes, infections, 
hypertension, toxic chemicals, etc. Failure of the termination of the wound 
response, will eventually lead to the dysfunction and failure of organs. The cross-
linking activity of TG2 was a focus in the formation of fibrosis in a number of 
different organs, including lung (Griffin et al., 1978a), liver (Kuncio et al., 1998) 
(Piacentini et al., 1999), heart (Small et al., 1999), vasculature (Dolynchuk et al., 
1994), and kidney (Johnson et al., 2003; Johnson et al., 1997b; Skill et al., 2001). 
 
The hypothesis that TG2 is involved in the renal scarring is based on the facts: (1) 
tubular cells can release TG2 into the extracellular environment with high Ca2+, 
which can activate the transamidating activity of TG2 to promote matrix cross-
linking (Johnson et al., 1997a); (2) TG2 can cross-link the LTBP-1 to ECM 
proteins to regulate the matrix storage and activation of  TGFβ1 (Nunes et al., 
1997; Verderio et al., 1999). Griffin and colleagues (Johnson et al., 2003) 
confirmed the importance of the enzymatic activity of this enzyme and its 
expression in renal scarring by using biopsy samples from patients at different 
stages of renal scarring process (Johnson et al., 2003). The cross-linking of 
cytoplasmic proteins by intracellular TG2 has also been suggested to result in 
cell death in the tubular compartment (Johnson et al., 1997a). Recent studies by 
using TG2 null mice demonstrated that less fibrillar collagen was found in the 
KO animals and the decrease of collagen I at both the mRNA and protein levels 
was thought due to the decreased TG2 mediated TGFβ1 activation (Shweke et al., 
2008).  
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In mice liver injury and fibrosis models induced by CCl4 treatment, Mirza et al. 
reported the increase of TG2 at both the gene level and in enzymatic activity, 
which might be regulated by the increased binding to NF-κB to the TG2 
promoter (Mirza et al., 1997). Studies performed later investigated the role of 
TG2 in liver fibrosis in different liver fibrogenesis models. In the TG2 null 
animal treated with CCl4, a progressive accumulation of ECM and a derangement 
of the hepatic lobular architecture were discovered, which led to animals being 
more sensitive to the treatment resulting in an increased death rate in the KO 
animals compared to the wild type control animal. This study indicated that TG2 
can act in a protective role in liver fibrosis (Nardacci et al., 2003). Schnabel and 
colleagues discovered the upregulation of TG2 in both mRNA and protein levels 
during the transdiffrentiation of hepatic stellate cells to collagen producing 
myofibroblasts, a principle process of liver fibrogenesis (Schnabel et al., 2004). 
The similar increased level of TG2 was found in the liver samples from HCV 
infected patients (Nardacci et al., 2003). In ethanol-induced hepatic injury study, 
it was reported that inhibition of TG2 activity by pinocembrin can protect the 
liver from thioacetamide (TAA)-induced cirrhosis, which is regulated by NF-κB- 
dependent TG2 activation induced by ethanol treatment (Chen et al., 2008). 
Increased cross-linking activity of TG2 was also found in atherosclerotic plaques, 
hence it can stabilize collagen III in those areas (Bowness et al., 1989). Later 
studies by Small and colleagues demonstrated that enhanced cardiac TG2 in the 
transgenic mouse can induce cardiomyopathy (Small et al., 1999). Even though 
there are still conflicting ideas about the role of TG2 in the processes of fibrosis, 
the involvement of this enzyme has been widely proven and it could be a 
potential target for fibrosis treatment. 
 
1.9.6.4 TG2 in cancer 
 
Accumulating studies have focused on the relevance of TG2 in cancer 
progression. A huge amount of work based on human samples identified that that 
TG2 is one of the selectively amplified proteins in metastatic human lung 
carcinoma (Jiang et al., 2003), while the  TG2 gene was also revealed as one of 
the most differentially expressed genes in pancreatic tumours (Iacobuzio-
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Donahue et al., 2003). Further work on the locations of TG2 has suggested 
different roles for TG2 in tumour behaviour while more recent research has been 
devoted to discovering the intracellular molecules that are involved in TG2-
related tumour behaviour.  
 
Intracellular TG2 was reported as an anti-apoptotic effector in different cell types, 
including breast cancer, pancreatic cancer and melanoma cells (Mann et al., 
2006). In their work, Mann and colleagues discovered the activation of TG2 by 
the calcium ionophore A23187 can promote the activity of NF-κB, while 
inhibition of the enzymatic activity of TG2 by A23187 and siRNA treatment 
blocked the activation of this protein. The potential mechanism was suggested 
that TG2 modifies the IκBα (a good in vitro substrate to TG2) into high 
molecular weight polymers and modulates the affinity of IκBα for p65/p50, so 
that this enzyme can maintain the constitutive activation of NF-κB (Mann et al., 
2006). The similar anti-apoptotic effect of TG2 in regulating the activity of NF-
κB was also suggested in neuroblastoma cells (Condello et al., 2008). The 
opposite effect of TG2 was reported in highly metastatic malignant melanoma 
cells, suggesting that TG2 can inhibit tumour progression via its direct 
interaction with its binding partner GPR56 (Xu et al., 2006).  
 
High affinity of cell surface TG2 with β1 and β3 integrin receptors in fibroblasts 
and monocytes (Akimov and Belkin, 2001b), while in human breast cancer cell, 
the direct interaction of TG2 and β1, β4 and β5 integrins was observed, which 
was suggested to regulate the cancer adhesion, invasion and migration (Mangala 
et al., 2007). In glioma and fibrosarcoma cells, overexpression of membrane type 
1-metalloproteinase (MT1-MMP) can increase the degradation of cell surface 
TG2, which led to the inhibition of cell adhesion mediated by its interaction with 
integrin receptors and in turn promoted the cell migration process on FN (Belkin 
et al., 2001). A novel role of ECM TG2 in RGD-independent cell adhesion 
process has been reported, which can rescue the cell from anoikis caused by loss 
of integrin-mediated cell adhesion (Verderio et al., 2003). The involvement of 
matrix TG2 in regulating tumour cell behaviour was further studied by Griffin 
and colleagues (Jones et al., 2006). Reduced tumour growth and increased 
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survival rate was observed following intratumour injection of TG2 in animals 
and this effect of TG2 was relevant to its enzymatic activity, which can cross-
link matrix proteins and protect them from protease digestion and thereby 
produce an effective barrier to prevent the tumour growth and metastasis (Jones 
et al., 2006; Kotsakis and Griffin, 2007). In a different study, the similar 
increased deposition of stroma TG2 in human breast cancer samples was 
reported and it was suggested as a natural host defence mechanism (Grigoriev et 
al., 2001; Hettasch et al., 1996; Kotsakis and Griffin, 2007; Mangala et al., 2007).   
 
In order to investigate the mechanism of TG2 in regulating tumour cell behaviour, 
different intracellular signalling molecules were studied. The activation of focal 
adhesion kinase (FAK) and its downstream signal pathway phosphoinositide 3-
kinases (PI3K)/ Akt was reported to be involved in TG2-mediated cell-ECM 
interactions (Herman et al., 2006; Verma et al., 2006). In pancreatic cancer cells, 
PKCδ/ TG2 signalling was demonstrated in inhibiting autophagy in those cells 
(Ozpolat et al., 2007). Even though more and more studies have been trying to 
demonstrate the relationship between TG2 and cancer, the effect of this enzyme 
on tumour behaviours still remains unknown and conflicting. The role of TG2 in 
cancer biology might be due the types, locations and progressions of the cancers, 
as well as the presence of TG2 (Mehta, 2009). 
 
1.9.7 Fibronectin and its relevant signalling pathways in cell adhesion 
process  
 
1.9.7.1 Fibronectin  
 
The extracellular matrix (ECM) is crucial for adhesion-dependent cells to adhere, 
migrate, differentiate, proliferate and exert their physiological functions. As one 
of the most important extracellular matrix proteins, fibronectin (FN) and its 
relevant signal transduction pathways have been widely studied. FN is a high-
molecular-mass adhesive glycoprotein present in the pericellular matrix and body 
fluids. FN could exist as both soluble (in blood, amniotic fluid, joint fluid, and 
cerebrospinal fluid (Mosher, 1984b) or insoluble (in the ECM or basement 
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membranes) forms in body. There are two types of sources of FN: (1) 
hepatocytes, the source of plasma FN found mainly in blood; (2) fibroblasts and 
other cells are the source of cellular FN (Hynes, 1990).  The importance of FN in 
maintaining the cell morphology, adhesion, migration, proliferation, 
differentiation has been very-well studied (Kaspar et al., 2006). 
 
The molecular structure of FN has been well-documented, as shown in Figure-
1.2. The FN subunits, line into dimers and polymers joined by disulfide bonds in 
physiological conditions, consist of highly structural domains separated by 
flexible polypeptide segments. Each subunit of FN is composed of three different 
components, named type I, II and III modules. These modules compose various 
functional domains, and from the N-terminal, there are heparin and fibrin-
binding domain (30kDa), collagen-binding domain (40kDa), fibrin-binding 
domain (20kDa), cell-binding domain (57kDa), heparin-binding site (35kDa) and 
fibrin-binding site (30kDa). The domains are relatively resistant to proteases and 
contain the binding sites for macromolecules such as collagen, fibrinogen, fibrin, 
and proteoglycans, as well as cells (cell surface receptors, e. g. integrins and 
syndecans) (Fesus et al., 1986; Hynes, 1990). Among the domains within FN 
molecules, there are several sites that are closely relevant to cells and their 
surface receptors. The amino acid sequence Arg-Gly-Asp (Wollenberg et al., 
2002), a widely occurring cell adhesive motif originally discovered in fibronectin 
(Pierschbacher and Ruoslahti, 1984), is located in the domain of III9-10. The 
RGD motif in fibronectin and other cell adhesion proteins is the most important 
recognition site for about half of all known integrins, such as α3β1, α5β1, α8β1, 
αvβ1, αvβ3 and αvβ6 integrins (Johansson et al., 1997; Leiss et al., 2008). This 
cell adhesion process can be inhibited by a competitive synthetic peptide— RGD 
peptide leading to apoptosis (named anoikis) (Buckley, et al., 1999; Hadden and 
Henke, 2000). Another amino acid sequence PHSRN (Pro-His-Ser-Arg-Asn), 
which acts in synergy with the RGD site, has been located in III3 within the FN 
molecule. Studies using synthetic peptides containing the RGD motif, which 
induces apoptosis in  many cell types,  demonstrated  the  importance of the RGD  
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Figure 1.2. Domain model of fibronectin.  
The fibronectin protein is a dimer of two subunits which are identical except for 
the inclusion of the V-segment in one of the chains and are covalently connected 
close to the C-termini by two disulfide bridges. Three types of homologous 
structural units called I, II, and III make up most of the protein (represented by 
small ovals, triangles, and squares, respectively). Integrin binding sites are 
indicated in one of the subunits by arrows. The fibronectin found in blood plasma 
is a major form of the protein, but other splice variants are present at other 
locations and at specific developmental stages. The alternatively spliced exons 
(IIIA, IIIB, and V) are marked in green and may be present in one or both of the 
subunits. The known variants of the splicing reactions are illustrated (Johansson, 
et al., 1997).  
 
 
 
 
 
 
 
 
Figure 1.2 
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cell-binding domain in cell mediated adhesion, by acting as competitive 
inhibitors of FN-integrin interaction and activators of caspase 3 (Buckley et al., 
1999; Hadden and Henke, 2000). Of the integrins α5β1is probably the major cell 
surface integrin that interacts with the RGD cell binding site on FN, initiating the 
cell adhesion process by association with the PHSRN binding site (Ochsenhirt et 
al., 2006). The binding of αvβ3 integrin to the RGD domain can also support cell 
adhesion on FN (Danen and Sonnenberg, 2003). The domains located in III12-14 
of FN are the heparin-binding site, which bind the heparan sulfate chains of other 
cell surface receptors- heparan sulfate proteoglycans (HSPGs) (Woods et al., 
2000). Recently a novel cell binding site, which mediated RGD-independent cell 
adhesion via interacting with α4β1/α4β7 integrin, was located in the alternatively 
spliced V region of FN (Sechler et al., 2000).  
 
It is well-known that many cells produce, secrete and deposit FN into the ECM, 
known as cell-mediated FN deposition, which is dependent on the presence of 
cell surface α5β1 integrins and RGD cell binding domain within FN molecules 
(Fogerty et al., 1990). Initiated by the interaction between soluble FN and cell 
surface α5β1 integrin, the FN fibril formation process is composed of three steps, 
through which integrins play an important role in the initiating stage of FN fibril 
formation, which is acting as the link between the intracellular actin cytoskeleton 
network and the extracellular soluble FN dimers. The binding of FN dimers with 
integrins promotes the clustering of these receptors and their interaction with the 
actin cytoskeleton (Wu et al., 1995). The stretched FN molecules and further 
interaction between each other are mediated by the relocation of FN-bound α5β1 
integrin from focal adhesion to fibrillar adhesion along the actin stress fibres 
(Ohashi et al., 2002). Other cell surface receptors, including syndecan-2 and 
syndecan-4, and their downstream signalling molecules (RhoA and PKC) have 
also been suggested in participating in the above process (Lin et al., 2002; Xian 
et al., 2010; Zhong et al., 1998). In the extension stage, with the exposure of the 
binding sites within soluble FN molecules, soluble FN in a compact 
conformation further interacts with each other and forms the insoluble fibrils 
until the irreversible formation of a FN fibril network occurs. The further 
stretching and cell movements contribute to detach the FN fibrils from the cell 
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surface. Meanwhile other ECM components also participate in regulating FN 
deposition. It has been reported that in FN null fibroblasts, cells seeded on lamin 
can still lay down exogenous FN, while vitronectin inhibited the deposition of 
FN matrix, which could be caused by the relevant signaling pathways mediated 
by different ECM proteins (Mao and Schwarzbauer, 2005).  
 
1.9.7.2 Cell surface receptors in cell adhesion on FN 
 
Among the cell surface receptors interacting with FN, integrins and its co-
receptor syndecans deserve a special mention. Integrins are type I 
transmembrane glycoproteins that mediate the adhesion of cells to the ECM and 
to other cells (cell-cell adhesion) and play important roles in different aspects of 
various biological processes, including tissue remodelling, leukocyte migration, 
organogenesis (Howe et al., 1998). The integrins are non-covalent heterodimers 
composed of α (120-180kD) and β (90-110kD) subunits. To date, 18 α and 8 β 
subunits have been described and these combine to form over 20 different 
receptors (Wegener and Campbell, 2008). These receptors recognize their 
extracellular ligands, e.g. FN, vitronectin, collagen, with varied specificity 
(Jokinen et al., 2004). 
The syndecans are a four-member family (syndecan1-4) of transmembrane cell 
surface proteoglycans (PGs) that bear heparan sulfate glycosaminoglycan (GAG) 
chains. The syndecan family of transmembrane PGs is the major source of cell 
surface heparan sulfate (HS). It is divided into 2 subfamilies Syndecan-1 and -3, 
and Syndecan-2 and 4, according to their similarity in core protein size and 
sequence (Yamagata et al., 1993). Syndecans are characterized by highly 
conserved transmembrane and cytoplasmic domains. The intracellular part of the 
syndecans is composed of two constant regions (C1 and C2) separated by a 
variable region (V), which can be phosphorylated and bind a variety of 
intracellular ligands. The extracellular domains of the syndecans contain a site 
close to the plasma membrane (juxtamembrane domain, JMD) and a cell binding 
domain (CBD). At the distal end of the ectodomains are the GAG-attachment 
sites, to which the heparan sulfate chains are attached (Elenius et al., 2004). The 
syndecans are expressed on virtually all cell types throughout development and 
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adulthood, and their expression can be altered under certain pathophysiological 
conditions, including the process of tumour onset, progression and metastasis 
(Sanderson et al., 2004). The heparan sulphate chains bind to "heparin" – binding 
sites present in matrix ligands, as well as numerous "heparin"– binding growth 
factors and morphogens, including fibronectin, vitronectin, laminins and the 
fibrillar collagens (Bernfield et al., 1999). Among the syndecan family, 
syndecan-4 is widely expressed, in contrast to the other three syndecans, which 
are thought to exhibit a more tissue-specific distribution (Kim et al., 1994).   
 
1.9.7.3 FN-involved signalling pathway(s) 
 
There are two categories of integrin signalling that are widely recognized, 
namely “outside-in” and “inside-out” signalling pathways (Figure 1.3). The study 
of lymphocytes indicated the existence of integrin inside-out signalling pathway, 
which led to un-stimulated non-adherent lymphocytes adhering to other cells or 
the matrix within seconds in response to outside stimuli (Kinashi, 2005). The 
inside-out signalling pathway ultimately increases the affinity of the receptors for 
their matrix ligand, which leads to a change in conformation of the integrin 
extracellular domain (known as affinity regulation) or the extent to which 
integrins diffuse and cluster on the cell surface (Calderwood, 2004). Integrins are 
also subject to "outside-in" signalling in which the ligand-bound receptor 
initiates intracellular signalling through association of the β subunit cytoplasmic 
domain with a myriad of intracellular effectors including focal adhesion and Src 
family kinases (Datta, et al., 2001), and cytoskeletal components, such as α-actin 
(Brakebusch and Fassler, 2003). Talin has been reported as a crucial protein in 
integrin activation, especially to β1 and 3 integrins (Tadokoro et al., 2003). The 
integrin ligation to ECM components initiates the signal transduction from ECM 
to cells, which regulates many fundamental cellular processes, including cell 
migration, proliferation, and differentiation (Schwartz et al., 1995). 
Accumulating evidence indicates that the Ras/ERK1/2 pathway is one potential 
intracellular signalling pathway involved in the integrin-related cell adhesion 
processes. The activation of focal adhesion kinase (FAK) by interaction between 
integrins   and   ECM   proteins   triggers   the   ERK1/2   signal  transduction.  In  
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Figure 1.3 Integrin signalling mechanisms.  
The “inside-out” signalling is initiated by intracellular events, which might 
involve cytoskeleton reorganization mediated by Rho or the phosphorylation of 
integrin cytoplamic domain or its associated proteins. The “outside-in” signalling 
is triggered by the binding between integrin and its extracellular ligands and 
RhoA-mediated integrin clustering, followed by the activation of intracellular 
signalling pathways, in which FAK and MAP kinase are engaged (Jones and 
Walker, 1999).  
   
 
 
 
 
 
 
 
 
Figure 1.3 
 
 
 
Illustration removed for copyright restrictions 
 
Chapter 1 Introduction 
 
 62 
fibroblasts, the binding of integrin with its ligands enhances the activation and 
autophosphorylation of FAK at Tyr397, which activates the Ras and leads to the 
translocation of Raf-1 to the cell membrane. Raf-1 phosphorylates and activates 
MEK (MAP kinase), which subsequently phosphorylates ERK1/2 (Yee et al., 
2008). Recent evidence also supports the involvement of the Rho family of small 
GTPases. Ligation of integrins activates Rho, and the activation of Rho 
stimulates the phosphorylation of FAK and regulates the actin cytoskeleton 
dynamics and adhesive behaviour (Midwood et al., 2006).  
 
Although integrins are the main cell surface receptors responsible for cell-ECM 
interactions, in some cases, integrin engagement is not sufficient for a complete 
adhesion signalling process (Bloom et al., 1999; Woods and Couchman, 2001). 
Syndecan-4 can bind the HepII heparin-binding domain of FN with high affinity, 
which leads to the formation of focal adhesions necessary for cell adhesion 
(Woods et al., 2000). The binding of syndecan-4 to the heparin binding domain 
within FN provides a second signal that is required for formation of stress fibres 
and maturation of focal adhesions (Couchman and Woods, 1999). 
 
The studies from fibroblasts indicated that cells attach and spread on the central 
cell-binding domain of FN via integrin α5β1 but fail to form vinculin-containing 
focal adhesions unless co-stimulated with the heparin-binding fragment of FN 
(Bloom et al., 1999). The intracellular syndecan-4 signalling pathway is still 
under further investigation. But accumulating evidence indicates the involvement 
of phosphatidylinositol 4, 5-bisphosphate (PtdIns (4, 5) P2) and protein kinase C 
α (PKCα) in this signal transduction process in cell adhesion and spreading 
process (Oh, et al., 1997a, b, and 1998). Interaction with PtdIns (4, 5) P2 
promotes the oligomerization of syndecan-4 cytoplasmic domains (Oh et al., 
1997a; Oh et al., 1998) (Figure 1.4), while the oligomerized cytoplasmic 
domains of syndecan-4 can bind PKCa directly, through the PKCα catalytic 
domain (Oh et al., 1997b). This results in direct activation of PKCα in the 
absence  of  other  mediators  and  superactivation  in  their  presence,  which  is  
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Figure 1.4 A schematic structure of a syndecan molecule. 
The domains of syndecan core protein include the extracellular domain, 
transmembrane domain, conserved regions C1 and 2, and the variable region V, 
which are coloured in purple, blue, orange, green and pink, respectively. The 
extracellular heparan sulfate chains mediate the interaction between extracellular 
regulating factors, such as the ECM proteins and growth factors; the 
transmembrane domain is in charge of the self-association process of syndecans; 
C1 region interacts with the molecules related to actin skeleton organization; the 
C2 region can interact with the PDZ domain containing proteins such as syntenin 
and CASK; the structure of the V regions varies between different members of 
the syndecan family (from Couchman, 2003). 
 
 
 
 
 
 
 
 
 
Figure 1.4 
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Figure 1.5 The function of syndecan-4 on regulating α5β1-related signalling 
pathway.  
Syndecan-4 functions as a co-receptor for β1 integrin signalling pathway via its 
interaction with the heparin-binding sites of FN, which triggers the activation of 
PKCα, a intracellular signalling molecule. Meanwhile the intracellular domain of 
syndecan-4 core protein can also bind to other signalling molecules including 
CASK and FAK, as well as actin binding proteins, such as α-actinin to regulate 
the actin skeleton formation (from Beauvais and Rapraeger, 2004) 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 
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necessary for the cell spreading and focal adhesion formation (De Nichilo and 
Yamada, 1996; Woods and Couchman, 1992). The cytoplasmic tail also interacts 
with other structural and signalling proteins including CASK, FAK, paxillin and 
syndesmos (Beauvais and Rapraeger, 2004). It was also shown that focal 
adhesion assembly through syndecan-4 clustering is sensitive to inhibition of 
RhoA by C3 transferase (Saoncella et al., 1999), which indicated a requirement 
for RhoA signalling downstream of syndecan-4. A recent study demonstrated the 
existence of the linear pathway involving syndecan-4, PKCα and RhoA for the 
formation and maintenance of stress fibres in primary rat embryo fibroblasts 
(Dovas et al., 2006). Figure 1.5 shows the possible signalling transduction 
pathway mediated by syndecan-4. 
 
1.9.7.4 FN and TG2 
 
FN is a well-known substrate for TG2, and the cross-linking action of FN 
catalyzed by TG2 offers protection to FN from degradation (Kinsella and Wight, 
1990). It has also been reported that FN and TG2 secreted into the ECM can 
interact with each other independently from the enzyme’s cross-linking activity 
(Verderio, et al., 2003). It has been shown that TG2 secreted to the ECM, could 
bind to the N-terminal portion of FN interacting either with the Type I4-I5 motif 
(LeMosy et al., 1992) or with a sequence within the gelatin-binding domain of 
FN (I6-II1-II2-I7-I8-I9) (Lorand et al., 1993).  
 
The role of TG2 in FN-mediated cell adhesion  
 
Several studies of TG2, FN structure and the integrin signalling pathway have 
demonstrated a novel role for TG2 in the cell adhesion process. The structural 
study for FN showed that the TG2 binding site (42kD gelatin-binding domain) 
(Lorand et al., 1993) and the integrin binding site (RGD cell-binding site) are 
located in different parts of the FN molecule, which provides the possibility that 
TG2 and integrin collaborate rather than compete with each other in the cell 
adhesion process. Moreover, the binding of TG2 with FN activated FAK and 
increased  the  GTP  loading  of  the  small GTPase RhoA, which may trigger the  
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Figure 1.6 The role of TG2 as an integrin co-receptor for FN. 
Cell surface TG2 binds to the 42kD geletin binding sites of FN, which bridges 
the cell surface integrins with the matrix FN. This function of TG2 can enhance 
the cell adhesion via promoting the integrin clustering (from Akimov, et al., 
2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 
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intracellular signalling pathway and induce its relevant cell adhesion (Janiak et 
al., 2006). The studies from different groups indicated that TG2 associates with 
integrin receptors in a number of different cell types via binding to the 
extracellular domains of the β1, β3 and β5 integrin subunits (Akimov and Belkin, 
2001b; Akimov et al., 2000a; Gaudry et al., 1999b). Unlike FN, integrins do not 
appear to serve as enzymatic substrates of TG2 or other transglutaminases and 
the formation of stable non-covalent integrin-TG2 complexes is independent of 
the transamidating activity of TG2 (Akimov and Belkin, 2001b; Akimov et al., 
2000a) (Figure 1.6). Although the binding sites within integrins for TG2 are still 
unknown, it has been demonstrated that integrin-TG2 complexes have a 1:1 
stoichiometry and all the TG2 on the cell surface is bound to integrin receptors in 
a FN-independent way (Akimov and Belkin, 2001b; Akimov et al., 2000a). 
Besides the structural interaction evidence, a series of studies led by Mehta and 
colleagues for tumour cells demonstrated the connection between TG2 and the 
integrin-relevant downstream signalling molecule-FAK. The culture of TG2-
positive breast cancer cells and TG2-transfected fibroblasts on fibronectin-coated 
surfaces led to the activation of FAK, the downstream signalling molecule of 
integrins (Mehta et al., 2006b). Conversely, down-regulation of TG2 by small 
interfering RNA attenuated FN-mediated cell attachment (Herman et al., 2006) 
and cell survival and FAK phosphorylation (Verma et al., 2006).  
 
As introduced above, TG2 also exists in the ECM as a kind of structural protein 
(Verderio et al., 1998a). The importance of TG2, as an ECM protein, in RGD-
independent cell adhesion was first introduced by Griffin et al. (Verderio et al., 
2003). The TG2 bound FN matrix compensated the apoptosis (anoikis) induced 
by RGD synthetic peptides. This process was PKCα and FAK-dependent. A 
recent study showed that GTP-bound TG2, when present in the ECM, can induce 
hypertrophic differentiation of chondrocytes through a α5β1 integrin-dependent 
and FAK-associated cell adhesion processes (Tanaka et al., 2007). The 
importance and role of the TG-FN mediated and RGD-independent cell adhesion 
process forms the main topic of this report.  
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1.10 Project Aims 
 
Previous work suggested that TG2 and FN when present in  a hetero-complex— 
TG-FN can compensate the Arg-Gly-Asp (RGD) peptide induced loss of cell 
adhesion (which is due to the blocking effect of the peptide on the interaction 
between cell surface integrin receptors and FN). The actual mechanism behind 
this phenomenon and its physiological influence on cell behaviour remains 
unknown. The first aim of this project is to determine the involvement of the cell 
surface receptor(s), including syndecan-4, syndecan-2, α5 integrin, β1 integrin, 
α4β1 integrin and β3 integrin, in mediating the RGD-independent cell adhesion 
mediated by TG-FN. The second aim of this project is to further investigate the 
intracellular signalling pathway(s) that is required by TG-FN to compensate the 
loss of cell adhesion induced by the RGD peptides following binding of the TG-
FN complex to its receptor(s). A further part of this project was to study the role 
of TG-FN mediated cell adhesion in regulating FN fibril formation and the 
deposition of FN with emphasis on the role(s) of the different cell surface 
receptor(s) and their relevant intracellular signalling molecule(s) in the FN 
deposition process.    
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Chapter 2: Materials and Methods 
 
2.1 Materials 
 
2.2.1 List of Antibodies 
 
Primary Antibodies 
Company Antigen Name Host Species Clone 
Neomarks, Pierce, UK TG2 Mouse Monoclonal 
Santa Cruz, UK β1 integrin Rabbit Polyclonal 
Biolegend, UK β1 integrin Armenian hamster Monoclonal 
Biolegend, UK Isotype control 
IgG 
Armenian hamster Monoclonal 
Cell signalling, USA β3 integrin Rabbit Polyclonal 
Biolegend, UK  β4 integrin Armenian hamster Monoclonal 
Zymed Invitrogen, UK Syndecan-2 Rabbit Polyclonal 
Zymed Invitrogen, UK Syndecan-4 Rabbit Polyclonal 
Upstate Cell signalling p-Tyr397 FAK Rabbit Polyclonal 
Biosource UK p-Tyr861 FAK Rabbit Polyclonal 
Santa Cruz, UK FAK Mouse Monoclonal 
Santa Cruz, UK PKCα Mouse Monoclonal 
Sigma-Aldrich, UK α-Tubulin Mouse Monoclonal 
Sigma-Aldrich, UK Vinculin Mouse  Monoclonal 
Sigma-Aldrich, UK Fibronectin Rabbit Polyclonal 
Secondary Antibodies 
Sigma-Aldrich, UK Goat anti-mouse HRP conjugated 
Dako, Denmark Swine anti-rabbit HRP conjugated 
Dako, Denmark Rabbit anti-mouse FITC conjugated 
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2.2.2 Chemicals  
         
The deionised water (dH2O) used in experiments was obtained form an Eligastat 
system 2 water purifier or Milli Q water purifier (Millipore/Water, Watford, 
UK). 
The general chemical reagents and cell culture media were purchased from 
Sigma-Aldrich Company (Poole, Dorset, UK), unless otherwise stated. Other 
Chemicals and reagents were obtained from the following supplier. 
Zedira, Darmstadt, Germany 
Purified guinea pig liver transglutaminase (gplTG) and biotin-X-cadaverine 
Amersham Parmacia Biotech, UK 
The full range rainbow molecular markers and ECL Chemilunimescence 
development kit 
Bachem, Merseyside, UK 
The synthetic H-Gly-Arg-Gly-Asp-Thr-Pro-OH (GRGDTP) and H-Gly-Arg-Ala-
Asp-Ser-Pro-HO (GRADSP) peptides 
Bio-Rad, Hemel Hempstead, UK 
Bio-Rad protein assay kit 
Calbiochem, Nottingham, UK 
The synthetic The synthetic H-Gly-Arg-Gly-Asp-Thr-Pro-OH (GRGDTP) and 
H-Gly-Arg-Ala-Asp-Ser-Pro-HO (GRADSP) peptides, PKCα inhibitor Go6976, 
ERK inhibitor PD98059, Genecticin (G418 sulphate), ROCK inhibitor Y27632, 
human plasma fibronectin, γ-interferon.  
Vector Laboratories, UK 
Vectashield mounting medium  
Pierce, UK 
Sulfo-NHS-LC-Biotin and resin beads  
Peptide Protein Research, UK 
The GK21 peptide (GENPIYKSAVTTVVNPIYEGK) and the scrambled control 
peptide (GTAKINEPYSVTVPYGEKNKV) in tandem with the antennapedia 
third helix sequence (PQIKIWFQNRRMKWKK) and the A5-1 peptide 
(VILVLF)  
Jackson Immuno Research 
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CyTM5-conjugated streptavidin 
Roche, UK 
Sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium-bis (4-methoxy-6-nitor) 
benzeme sulfonic acid hydrate reagents (XTT reagents) 
Qiagen  
Syndecan-2 targetting siRNAs and HiPerfect Transfection Reagent 
InvivoGen  
Zeocin 
GE Healthcare 
A and G-Sepharose bead slurry 
 
2.1.3 Materials 
 
Amersham Pharmacia Biotech, UK Ltd, Little Calfont, UK 
Electrode paper (grade 1F) 
BDH laboratories suppliers, Milton Keynes, UK 
Coverslips, microscope slides 
Improved Neubauer, Calton, UK 
Haemocytometer 
Sarstedt Ltd., Leicester, UK 
0.5-,1.5- and 2- ml microcentrifuge tubes, 5ml scintillaion vial inserts and tops, 
15- and 50- ml sterile centrifuge tubes, 5-, 10- and 25- ml sterile pipettes, pipette 
tips, and disposable filters (0.2μm pore size) 
Lonza 
Mouse Embryonic Fibroblast nucleofector solution 
 
2.1.4 Equipments 
 
AMAXA Biosystem 
 AMAXA nucleofector and AMAXA certified cuvette and pipetts 
Beckman Instrument (UK) Ltd, High Wycombe, UK 
Spectrophotometer Model DU-7, centrifuges Avanti J-30 I, MSE Centaur 2 
Bio-Rad, Hemel Hempstead, UK 
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Protein III MInigel Vertical Electrophorisis Apparatus and Western Blot wet 
transfer system 
Corning, Staffs, UK 
pH meter 
Sanyo, UK 
CO2 incubator MoDel IG150 
Nikon Inc, Badhoevedorp, The Netherlands 
Inverted Phase Microscope model TM-100 and Nikon 500 digital camera 
Carl Zeiss MicroImaging GmbH, Germany 
Zeiss Meta 510 laser confocal microscope 
 
2.2 Methods 
 
2.2.1 Methods in cell culture 
 
2.2.1.1 Cells and culture conditions 
 
The cells used in this project included Swiss Albino mouse embryo 3T3 
fibroblast, primary human osteoblasts (HOB), β1 integrin knock out (ko), add-
back, vector control mouse embryo fibroblasts (MEF), syndecan-4 wild type (wt), 
ko, add-back and vector control MEF cells, wild type and heparan sulphate 
mutant Chinese hamster ovary cells (CHO), α5 integrin knockout (EA5) and add-
back MEF cells (EA5/α5), β3 ko and wt MEF cells. The Swiss-3T3 fibroblasts, 
HOB, CHO cells, EA5 and EA5/α5, β3 knockout and wt MEF cells were 
cultured in a humidified atmosphere at 37ºC 5% (v/v) CO2, 95% (v/v) air, while 
the β1 integrin and syndecan-4 serial MEF cells were kept in a humidified 
atmosphere at 32ºC 5% (v/v) CO2, 95% (v/v) air. 
 
Swiss 3T3 albino fibroblasts were obtained from American Type Culture 
Collection (ATCC, USA) and cultured in complete Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS), 2mM L-glutamine, 
1% (v/v) nonessential amino acids and penicillin/streptomycin (100U/ml and 
100μg/ml, respectively) and used for experiments between passages 10-30. 
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The β1 integrin and syndecan-4 serial MEF cells were a kind gift by Professor 
Martin Humphries (University of Manchester, UK) and maintained in complete 
DMEM medium supplemented with 20U/ml interferon-γ (IFN-γ). The cells 
above were used between the passages 15-30. 
 
The wild type and heparan sulphate mutant CHO cells were obtained from 
American Type Culture Collection (ATCC, USA) and cultured in Ham's F12 
medium containing 10% fetal bovine serum (FBS), 2mM L-glutamine, 1% (v/v) 
nonessential amino acids and penicillin/streptomycin (100U/ml and 100μg/ml, 
respectively) and used for experiments between passage 7-15.  
 
The EA5, EA5/α5, β3 ko and wt MEF cells were kind gift from Professor Eric 
Danen (Leiden University, Netherland) and cultured as Swiss 3T3 cells.  
 
2.2.1.2 Cell passaging 
 
When reaching approximately 90% confluency for immortalised cell lines and 
70% confluency for primary cell lines, cells were passaged. The cell monolayer 
was rinsed once with phophate buffered saline (PBS) pH 7.4 prior to treatment 
with 0.25% (w/v) trypsin, 5mM EDTA solution in PBS, pH 7.4 at 37 or 32ºC. 
The detached cells were collected in complete medium or medium with a trypsin 
inhibitor to inactivate the trypsin and centrifuged at 300×g for 5 min. Cells were 
resuspended in the growth medium and seeded in tissue culture flasks to the 
desired confluency. 
 
2.2.1.3 Determination of cell number 
 
Cells were trypsinised and centrifuged as described above (Section 2.2.1.2) and 
resuspended in relevant culture medium. 10μl aliquots of the cell suspension 
were applied to a haemocytometer. The cells were counted in 4 separate fields 
using phase contrast microscopy on an inverted microscope. The number 
obtained from the count was multiplied by 104 to determine the cell number per 
ml of cell suspension. 
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2.2.1.4 Cell freezing 
 
Cells were trypsinized and counted as described in Section 2.2.1.2 and 2.2.1.3, 
and resuspended in 10% (v/v) cell culture grade dimethyl sulfoxide (DMSO) in 
heat inactivated FBS. Cells were then pipetted in 1ml aliquots into cryogenic 
vials and slowly frozen at -80ºC in a specialised cryogenic container for at least 
24 h before transferring to a liquid nitrogen container for a long-term storage. 
 
2.2.1.5 Cell defrosting from storage 
 
Cryogenic vials of cells stored in liquid nitrogen were removed and quickly 
placed in a water bath at 37ºC. The cell suspension was carefully transferred into 
a sterile Falcon tube and 5ml of supplemented growth medium was added drop 
wise, with mixing after each addition to ensure slow dilution. The diluted cell 
suspension was then centrifuged at 300×g to eliminate the traces of DMSO 
present in the freezing mix. Cells were resuspended in the growth medium and 
transferred to a tissue culture flask. The media was changed the next 12-24 h and 
cells were passaged at least once before using them in an experiment. 
 
2.2.1.6 siRNA transfection 
 
In order to silence the expression of syndecan-2 in MEF cells, 2 different small 
interfering RNA (siRNA) sequences targeting mouse syndecan-2 were obtained 
from Qiagen. The sequences are listed below. 
 
Mm_Sdc2_1 SI01412250: TGGAATTTAATTTGTAGAATA 
Mm_Sdc2_2 SI01412264: CAAAGGCAAATTAATGTGTAA 
 
The scrambled negative control siRNAs (listed below) were kindly designed by 
Dr Russell Collighan, according to the syndecan-2 siRNA sequences, and 
synthesized by Sigma, UK.  
 
Scrambled siRNA1: GTAAATTATGTAAGTTAGTAT 
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Scrambled siRNAs: GATAATCAAAGCGAAATGTAT 
 
The universal negative control siRNA was purchased from Qiagen. Both 
scrambled and the universal negative siRNA were used as the control treatments. 
1nmol lyophilized siRNA was dissolved in 100µl of sterile, RNase-free water to 
obtain a 10µM solution and then stored at -20ºC. The transfection was performed 
according to the manufacture’s protocol. Before transfection, 3 ×105 cells were 
seeded into each well of a 6-well plate for 24 h to reach 50-80% confluency. 
Prior to transfection, cells were washed with PBS, pH 7.4 and the medium was 
replaced with 2.3ml pre-warmed fresh complete growth medium. 150ng of 
siRNAs were supplemented with DMEM serum free medium siRNAs to reach 
the final volume of 100µl of siRNA working solution. The siRNA and HiPerfect 
Transfection Reagent (Qiagen complex were prepared as directed by the 
manufacturer by incubating the mixture at room temperature for 5-10 min. The 
complex was added drop-wise onto the cells with gentle swirling the plate to 
ensure the uniform distribution of the transfection complex. Following an 
approximated 30 h siRNA transfection, cells were used in Western blotting or 
cell adhesion assay. 
 
2.2.1.7 Stable cell transfection 
 
2.2.1.7.1 Kill Curves 
 
3,000 cells/well of MEF cells were seeded into 96-well plates and treated with 
different concentrations of zeocin (0, 100, 200, 400, 600, 800, 1000, 1200 μg/ml, 
prepectively). After 24, 48 and 72 h incubation with the antibiotic, 30μl of 
sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitor) 
benzeme sulfonic acid hydrate (XTT) reagents mixture was added into each well 
and incubated with the cells for 4 h. The absorbance was read at 490nm and 
750nm using a Spectrafluor plate reader. Results were expressed as absorbance at 
(490nm-750nm). The inhibition of the antibiotic was calculated as below: 
                     
Inhibition rate % = (                                                                                       )×100% A in control group – A in experimental groups                             A in control group 
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2.2.1.7.2 Nucleofections using AMAXA’s proprietary technology 
 
Transfection of MEF cells with pSV40/Zeo2 vector containing wild type TG2 
cDNA was achieved by transfecting cells with 5µg of TG2 containing vector 
plasmid using the AMAXA nucleofector (Lonza Biosystems) according to the 
manufacturer’s protocol. Cells (106) were seeded in T150 tissue culture flasks 
and allowed to reach 90% confluence just prior to the DNA transfer. Cells were 
trypsinised, pelleted and resuspended in 100µl of Mouse Embryonic Fibroblast 
nucleofector solution at 106 cells/ transfection. The resulting cell suspension was 
then mixed with 5µg of relevant vectors, and transferred to an AMAXA certified 
cuvette. Nuclear transfer of DNA was achieved by placing the cuvette into the 
AMAXA nucleofector system and exposing the cells to short electric pulses of 
different voltage/duration under different pre-set programmes. Cells were then 
supplemented with 500µl of pre-warmed cell growth medium and transferred to 
100mm Petri dishes also containing 8ml pre-warmed medium. 
  
2.2.1.7.3 Selection of stably transfected cell lines 
 
Once transfected, cells were maintained in 800µg/ml zeocin until clones of cells 
became visible. After 1-2 weeks, when clones had reached 2-3mm in diameter, 
they were washed briefly to remove floating cell debris taking care not to 
dislodge and hence re-arrange the position of the clones on the tissue culture 
plate. The clones were then rapidly trypsinised individually by addition of 5µl of 
0.5% (w/v) trypsin in PBS, pH 7.4 directly onto the chosen colony for 30 sec, 
pipetting the trypsin dilution up and down several times. To avoid desiccation 
this process of washing and trypsinizing was carried out separately for each 
clone. The cell suspension was then transferred into T75 tissue culture flasks, 
where they were maintained in cell growth medium containing 800µg/ml zeocin. 
The clones were grown until sufficient numbers of cells were obtained for liquid 
nitrogen storage. Once clones were screened for the expression of the transfected 
DNA the selected clones were routinely cultured in standard growth medium 
supplemented with 400µg/ml zeocin.    
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2.2.2 Preparation of a physiological extracellular matrix 
 
2.2.2.1 Coating of plates with fibronectin 
 
The wells of a microtitre plate were coated with 5μg/ml FN diluted in 50mM 
Tris-HCl, pH 7.4 and 50μl/well used to coat the plate for 16 h at 4ºC. 
 
2.2.2.2 Immobilisation of tissue transglutaminase on FN matrix 
 
For immobilisation of guinea pig liver transglutaminase (gplTG) (Zedira, 
Germany) on FN, wells were washed once in 50mM Tris-HCl, pH 7.4. In some 
cases, the wells were blocked with 3% (w/v) bovine serum albumin (BSA) in 
PBS, pH 7.4 for 30 min at 37ºC prior to TG2 immobilisation. The 20μg/ml 
gplTG solution was prepared by dissolving the 1mg/ml of gplTG in PBS 
containing 2mM EDTA, pH 7.4 to inhibit Ca2+-dependent activity of the enzyme. 
The gplTG solution was then added to the tissue culture plastic (TCP) coated 
with FN for 1 h at 37ºC. 
 
2.2.2.3 Detection of relative levels of TG2 in matrices 
 
Detection of TG2 antigen by ELISA 
 
The presence of TG2 antigen on different substrates was detected by using a 
modified enzyme linked immunosorbent assay (ELISA) (Verderio et al., 1999). 
 
After coating the 96-well plate with 50μl of FN as described above (Section 
2.2.2.1), the wells were washed once in 50mM Tris-HCl, pH 7.4 and then 
blocked with 50μl of 3% BSA in PBS, pH 7.4 for 30 min at room temperature. 
To block the heparin-binding sites within FN, 50μl of 300μg/ml of heparin in 
50mM Tris-HCl, pH 7.4 was incubated with FN at room temperature for 30 min. 
Then the wells were washed three times in 50mM Tris-HCl, pH 7.4. The gplTG 
solutions at different concentrations (20μg/ml and 30μg/ml) were prepared by 
dissolving 1mg/ml of gplTG in PBS containing 2mM EDTA, pH 7.4 in order to 
 
Chapter 2 Materials and Methods 
 
79 
 
inhibit the TG2 activity. The gplTG solutions were then added to the FN matrix 
with or without heparin. After a 1 h incubation at 37ºC, the gplTG solutions were 
removed and wells were washed once with 100μl of Tris-HCl, pH 7.4. Prior to 
the incubation with anti-TG2 monoclonal antibody Cub 7402 (Neomarkers, UK), 
wells were blocked with 3% BSA in PBS, pH 7.4 (blocking buffer) for 30 min at 
room temperature. After a 2 h incubation with Cub7402 (diluted 1: 1000 in 
blocking buffer) at room temperature, the wells were washed 3 times (final wash 
for 20 min) with blocking buffer. To detect the antigen-antibody complex, the 
wells were incubated with peroxidase labelled anti-mouse IgG diluted 1:2000 in 
blocking buffer for 2 h at room temperature. At the end of incubation, the wells 
were washed three times with blocking buffer and once with PBS, pH 7.4. The 
wells were then pre-equilibrated with the developing buffer, phosphate-citrate 
buffer with urea and hydrogen peroxidise (HRP) (Sigma-Aldrich, UK). 
Development of the reaction was performed by addition of developing buffer 
containing the substrate 7.5% (w/v) 3,3’,5,5’-Tetramethyl benzidine in DMSO 
(TMB). The colour development was terminated by addition of 50μl of 2.5M 
H2SO4 and the absorbance read at 450nm using a Spectrafluor plate reader. 
Results were expressed as absorbance at 450nm.  
 
2.2.3 Cell adhesion assay 
 
2.2.3.1 Inhibition of the RGD-mediated cell adhesion 
 
Exponentially growing cells were trypsinised and collected into complete 
medium or serum free medium containing trypsin inhibitors. After a 5 min 
centrifugation at 300×g, the cell pellet was washed twice in serum free medium 
to remove the traces of serum proteins. In the experiments, cell suspensions of 
2.5×105 cell/ml were prepared in serum free medium, and incubated with 
GRGDTP and GRADSP synthetic peptides (Calbiochem or Bachem, UK) at 
concentration of 100μg/ml (~150μM) for 20 min at 37ºC in a 5% CO2, 95% (v/v) 
air atmosphere. Meanwhile coated wells were washed once with 50mM Tri-HCl, 
pH 7.4 and then pre-equilibrated with serum free medium for 10 min. Cell 
suspensions (100μl/well) were seeded on wells coated with FN, with and without 
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immobilised gplTG and allowed to attach in the presence of the synthetic 
peptides. The incubation time was limited 15-40 min to minimise the secretion of 
any endogenous proteins. 
 
2.2.3.2 Cell fixation and permeablisation 
 
Following cell adhesion and spreading, the medium was carefully removed and 
wells were gently washed once with PBS, pH 7.4. Cells were then fixed with 
100μl of 3.7% (w/v) paraformaldehyde dissolved in PBS, pH 7.4 for 15 min at 
room temperature and washed twice with PBS, pH 7.4. Following fixation, cells 
were permeabilized with 100μl of 0.1% (v/v) Triton-X in PBS, pH 7.4 for 15 min 
at room temperature. The wells were then washed twice with PBS, pH 7.4.  
 
2.2.3.3 May-Grunwald and Giemsa co-staining 
 
To visualise the attached cells, a two-step staining process was employed to stain 
both cytoplasm and nucleus. Following fixation and permeablisation (Section 
2.2.4.2), 100μl of May-Grunwald stain (Sigma-Aldrich, UK) was added to the 
wells to stain the cell cytoplasm for 15 min at room temperature. After the stain 
was removed, the wells were washed once with PBS, pH 7.4 and then incubated 
with 100μl of 5% (v/v) Giemsa stain (Sigma-Aldrich, UK) in dH2O to stain the 
nucleus for 20 min at room temperature. The plate was finally washed twice with 
dH2O and left to dry.   
 
2.2.3.4 Quantification of cell adhesion 
 
Digital images of three non-overlapping fields covering the centre of the well 
were acquired using a video digital camera (Olympus DP10) at 40× 
magnification. The cell attachment and spreading were quantified using the 
Scion image analysis programme (http://www.scioncorp.com), which is 
developed at the National Institute of Health (Washington DC, USA). The 
number of cells per image was assessed through threshold and particle analysis 
setting with a minimum particle size of 50 pixels. Spread cells were 
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discriminated from non-spread cells by their two-colour appearance (dark purple 
for nucleus and pink for cytoplasm). These were quantified by density slicing 
and particle analysis setting. The spreading cell particles were selectively 
highlighted through the adjustment of the Lut intensity. The number of attached 
cells per well was calculated by summing up the number of cells from the three 
images of non-overlapping fields. Cell attachment on FN without RGD peptide 
was considered as the control value for most of the experiments. The mean 
number of attached cells form three wells was calculated and that of the control 
was considered as 100%. The mean number of attached cells (cell attachment) 
for each sample was then expressed as the percentage of cell attachment on FN. 
The mean percentage of attached cells that are spread (cell spreading) for each 
sample was determined separately, and the mean percentage of spread cells on 
FN control was expressed as 100%. The mean percentage of spread cells for each 
sample was then normalised against that of FN control. Cell spreading was 
defined as the process whereby a rounded cell is flattened as a consequence of 
ECM-mediated signal transduction leading to the rearrangement in the actin 
cytoskeleton. 
 
2.2.4 Fluorescence staining of actin stress fibres 
 
Sub-confluent cells were serum-starved for 16 h and harvested. After different 
treatments, cells were seeded in 8-well glass chamber slides (8×104 cells/well) 
previously coated with FN and TG-FN and allowed to attach and spread for 40 
min. Cells were fixed and permeablized as described previously (Section 
2.2.3.2). For staining of actin stress fibres, cells were blocked in PBS buffer 
supplemented with 3% (w/v) BSA and then incubated with FITC-labelled 
phalloidin (20μg/ml) in blocking buffer. Coverslips were mounted with 
Vectashield mounting medium and using constant PMT and section depth 
settings 9 random fields/ sample were captured by using Zeiss LSM510 laser 
confocal microscope using Zeiss LSM Image Browser.  
 
2.2.5 Preparation of total cell lysates 
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A 6-well plate was coated with 1.5ml of 5μg/ml human plasma FN or heat-
inactivated 3% (w/v) BSA in PBS, pH 7.4 by incubation at 4ºC for overnight. 
The FN matrix was further coated with 3ml of 20μg/ml gplTG as described 
previously (Section 2.2.2.2). Cells detached by trypsinization were then plated 
onto wells at a density of 6×105 cells/well (Section 2.2.3.1). Following cell 
adhesion and spreading, the medium was removed. Wells were washed once with 
ice-cold PBS, pH 7.4 and the adherent cells were lysed by addition of 50μl of 
lysis buffer (1% (v/v) Nonidet, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 1mM benzamidine, 1mM NaF, 1mM Na3VO4, 0.1mM 
phenylmethylsulfonyl fluoride (PMSF) and 1% (v/v) protein inhibitor cocktail). 
The non-adherent cells in the medium were collected and centrifuged at 300×g 
for 5 min at 4ºC and the cell pellets were washed once with ice-cold PBS, pH7.4 
and centrifuged at 300×g for 5 min at 4ºC.  The plate was then incubated on ice 
for 30 min and lysates were collected with a scraper to be mixed with the 
corresponding cell pellet from non-adherent cells. Cell extracts were clarified by 
further centrifugation at 300×g for 5 min at 4ºC. The samples were stored at -
80ºC until use.  
 
2.2.6 Determination of protein concentration by Lowry Method 
 
The protein content of cellular extracts was determined using the commercial kit 
from Bio-Rad based on the Lowry method (Lowry et al., 1951). The 
determinations were made following the manufacturers instruction using BSA as 
the standard. Briefly, 5μl of BSA solution ranging from 0.1-1.5mg/ml, and 1μl of 
cell extract dissolved in 4μl of dH2O, were added to wells of a microtitre plate in 
triplicate. The wells were then incubated with 25μl of Reagent A, followed by 
200μl of Reagent B for 15 minutes at room temperature. The absorbance values 
were recorded at 750nm using a SpectraFluor plate reader to produce the 
calibration graph.      
 
2.2.7 Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
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After protein concentration assay (Section 2.2.6), the protein extracts containing 
certain amounts of total protein were dissolved using 1:1 ratio in 2× strength 
reducing-Laemmli buffer (125mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% 
(v/v) SDS, 10% (v/v) 2-β-mercaptoethanol and 0.004% bromophenol blue) 
(Laemmli et.al. 1970), denatured at 95ºC for 5 min, and then stored at -70ºC until 
use or resolved by the SDS-PAGE method, which was a modification of that 
described by Laemmli et al. (1970) by using the Atto-minigel system. Some of 
the supernatants were and then stored at until required for electrophoresis; rest of 
the cell lysates were stored at -70ºC for protein content estimation. The gels 
consisted of a 3% (w/v) polyacrylamide stacking gel and a 10% (w/v) resolving 
gel. The stacking gel was made using 0.2M Tris 0.2% (w/v) SDS stock solution, 
pH 6.8 and resolving gel contained 0.75M Tris 0.2% (w/v) SDS stock solution, 
pH 8.8. The polymerisation reaction was initiated by the addition of the indicated 
volumes of freshly prepared 5, 8 or 12% ammonium persulphate and N,N,N’,N’-
Tetramethylethylenediamine (TEMED). The stacking and resolving 
polyacrylamide gels were prepared according to the table below. Resolving gels 
(80×60×0.75) were cast using the Atto-mini gel system and water-saturated 
butan-2-ol was poured on the top of the gel to an approximante depth of 5mm to 
provide the gel with a flat upper surface. The gel was then allowed to polymerise 
for 1 hour at room temperature. 
 
The upper surface of the polymerised resolving gels was washed three times with 
distilled water, and the edge of the gel was gently blotted dry using filter paper. 
Stacking gels were prepared by combing 0.65ml of 30% (w/v) acrylamide 
stocksolution, 1.25ml of Tris-SDS stock pH 6.8 and 3.05ml of distilled water. 
Polymerisation was initiated by the addition of 25μl of 10% (w/v) ammonium 
persulphate and 10μl of TEMED. The gel was quickly pipetted between the glass 
plates and the 10-well comb that forms the sample wells was inserted. After 
polymerisation the sample well comb was gently removed from stacking gels and 
the wells then washed and filled with Tris-glycine electrode running buffer pH 
8.5 (25mM Tris, 192mM glycine, and 0.1% (w/v) SDS). A maximum of 50μg of 
protein was loaded into each well. Electrophoresis was performed at 90V through 
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the stacking gel, and then at 120V until the Bromophenol Blue tracking dye 
reached the bottom of the resolving gel. 
 
Table 2.2 The recipe for the polyacrylamide gels 
 
 
Stock solution 
 
Final % (w/v) acrylamide 
 
5% 
 
8% 
 
12% 
30% (w/v) acrylamide/0.8% 
(w/v) bis-acylamide (ml) 
2.5 4.0 6.0 
Tris-SDS pH 8.8 (ml) 3.75 3.75 3.75 
Distilled H2O (ml) 6.25   
10% (w/v) ammonium 
persulphate (μl) 
50 50 50 
TEMED (μl) 10 10 10 
 
2.2.8 Western blotting of proteins from polyacrylamide gels 
 
Proteins resolved by SDS-PAGE were electrophoretically transferred onto 
nitrocellulose membranes (Gelman Biosceiences, UK) using a Bio-Rad wet blot 
system following the protocol of Towbin et al. (1979). The fibre pads, 
electroblotting papers and nitrocellulose sheets were soaked in ice-cold transfer 
buffer, pH 9.2, (48.8mM Tris, 39mM glycine, 0.0375% (w/v) SDS, and 20% 
(v/v) methanol). The protein gel was carefully removed from the cast and 
equilibrated in the transfer buffer for 10 min. The coloured gel holder cassette 
was opened and the pre-soaked filter pad was placed on the black side of the 
cassette. Next, two layers of wetted electrode paper were laid on the filter pad 
and bubbles were removed with a glass roller. The gel was then carefully 
flattened upon the paper and the soaked nitrocellulose was laid onto the gel. 
Another two layers of wetted electrode paper were placed on the top of the 
nitrocellulose membrane followed by the second pre-soaked filter pad, again 
removing any trapped air bubbles. The blotting cassette was then assembled and 
inserted into the blotting apparatus so that the membrane side of the assembly 
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faced the anode electrode. The electroblotting apparatus was filled with 1 l of ice 
cold transfer and frozen ice container was place inside the tank to prevent the 
overheating of the system. The electrotransfer of the proteins was then performed 
at 200mA for 2 h. The transfer of proteins was verified by the transfer of high 
weight molecular markers on the nitocellulose membrane. The membrane was 
washed once with TBS-Tween, pH 7.4, and incubated in the blocking solution, 
5% (w/v) Marvel in TBS-Tween, pH 7.4, with gentle agitation for 1 h at room 
temperature to prevent the non-specific binding of antibodies.   
 
2.2.9 Immuno-development of Western blots 
 
Following blocking, the membranes were incubated with the appropriate 
antibody diluted in a blocking buffer with gentle agitation at 4ºC overnight. The 
blots were then washed four times for 15 min in the blocking buffer with 
agitation. Incubation with the suitable secondary antibody (conjugated to 
horseradish peroxidase) with certain dilutions in the blocking buffer, was 
performed for 2 h at room temperature on a shaker. After incubation with the 
secondary antibody, another set of washes were performed in TBS-Tween, pH 
7.4. Finally membranes were rinsed with PBS, pH 7.4. 
 
The immunodetection of blots were completed using the Amersham enhanced 
Chemiluminescence (ECL) system kit following the manufacturer’s instructions. 
Briefly, the two reagents A and B were mixed in equal quantities (1ml of each 
per blot) prior to addition to the nitrocellulose membranes for 1 min. The 
developing solution was the discarded and the membranes wrapped in a cling 
film before placing in an autoradiography cassette. Exposure was carried out in 
dark room with Kodak X-Omat films exposed to the nitrocellulose sheet for 
varying lengths of time depending on the intensity of the signal. The film was 
developed and fixed using GBX developer and fixer (Sigma) followed by 
extensive washing with water before air-drying. 
 
To ensure equal protein loadings, primary and secondary antibodies were 
removed from membranes with stripping buffer (100mM 2-mercaptoethanol, 2% 
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(w/v) SDS, 65mM Tris-HCl, pH 6.7). The membrane was submerged in stripping 
buffer and incubated at 50ºC for 30 min with occasional agitation. After four sets 
of 15 min washes in TBS-0.5% Tween (v/v), pH 7.4, the membrane was blocked 
in the blocking buffer for 1 h at room temperature. The immunodetection was 
then performed as described above using a control mouse monoclonal anti-α-
tubulin antibody, diluted 1:1000 in the blocking buffer, followed by peroxidase 
conjugate rabbit anti-mouse polyclonal secondary antibody (diluted 1:2000 in the 
blocking buffer). 
 
2.2.10 Co-immunoprecipitation 
 
RGD-treated cells were seeded onto TG-FN matrix where the FN was blocked 
with heparin as described in Section 2.2.2.3. Cells were lysed in cell lysis buffer 
containing 0.25% (w/v) sodium deoxycholate, 150mM NaCl, 0.1mM PMSF, 1% 
(v/v) protein inhibitor cocktail, 500μM specific transglutaminase inhibitor R283, 
and 50mM Tri-HCl, pH 7.4 and put on ice for 30 min with occasional mixing. 
200μg of cell extract was then pre-cleared for 1 h at 4ºC with non-specific rabbit 
or mouse IgG, following by 90 min incubation with 50μl of protein A or G-
Sepharose bead slurries on a rocking platform. Precleared cell lysates were then 
incubated with 0.5μg of appropriate antibody for 90 min at 4ºC. Immune 
complexes were precipitated with 50μl of protein A or G-Sepharose bead slurries 
for 2 h at 4ºC, washed with lysis buffer and extracted in Laemmli sample buffer. 
Samples were resolved by SDS gel electrophoresis, transferred to nitrocellulose 
membrane and immunoprobed with target antibodies (Sections 2.2.7- 2.2.9).  
 
2.2.11 Analysis of protein kinase C α translocation to membrane 
  
The 60mm Petri dishes were sequentially coated with 5μg/ml of FN (in 50mM 
Tris-HCl, pH 7.4) and with 20μg/ml of gplTG (in 2mM EDTA in PBS, pH 7.4) 
as described before (Section 2.2.2). The fibroblast cells were grown to 70% 
confluency and serum starved for 16 h before the experiment. RAD/RGD-treated 
cell suspensions were prepared as before (Section 2.2.3.1), and the cells were 
allowed to attach for 30 min. In some cases, cells were treated with 50nM of 
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PMA (dissolved in DMSO) for 10 min, as a positive control treatment for PKCα 
activation. The supernatants of non-adherent cells were washed once with PBS, 
pH 7.4, collected by gentle scraping into 50μl of ice-cold homogenisation buffer 
(10nM EDTA, 1mM NaF, 1mM Na3VO4, 50nM okadaic acid, 0.1mM PMSF, 
1% (v/v) protein inhibitor cocktail, and 50mM Tris-HCl, pH 7.4) and mixed with 
the corresponding cell pellet from non-adherent cells. Cells were lysed by 
sonication three times for 15 sec and centrifuged to pellet the nuclei and 
unbroken cells at 300×g for 10 min. Protein concentrations were detected as 
described in Section 2.2.7. Equal amounts of supernatants were collected and 
further centrifuged at 100,000×g for 60 min to separate cytosolic and membrane 
fractions. The resulting supernatants were considered to be the cytosolic fraction. 
The pellet was resuspended in 30μl of the homogenisation buffer and was 
considered to be the membrane fraction. The cytosolic and membrane fractions 
were diluted in Laemmli loading buffer and separated by SDS gel electrophoresis 
and electrophoretically transferred to a nitrocellulose membrane, which is 
sequentially probed with mouse monoclonal anti-PKCα (Santa-Cruz, UK) and 
peroxidase conjugated monoclonal anti-mouse IgG (Dako, Denmark) as 
mentioned in Sections 2.2.8-2.2.10.   
 
2.2.12 Detection of intracellular and matrix TG2 via confocal microscopy 
 
Cells were seeded in 8-well glass chamber slides (2×104 cells/well) and allowed 
to grow for 72 h. For the intracellular TG2 staining, cells were fixed and 
permeablized as described previously (Section 2.2.3.2), blocked in 3% heat-
inactivated BSA in PBS, pH 7.4 for 30 min, and then incubated with mouse anti-
human TG2 antibody Cub7402 in blocking buffer (1: 100 dilution) at 37ºC for 2 
h. For the matrix TG2 staining, the cells were incubated with Cub7402 in 
complete medium (1:300 dilution) at 37ºC for 2.5 h and then after washing 3 
times in PBS, pH 7.4, fixed, permeablized and blocked as described above. The 
wells were washed 3 times with PBS, pH 7.4 and then incubated with anti-mouse 
FITC-conjugated secondary antibody in blocking buffer at 37ºC for 2 h. After 3-
time washing in PBS, pH 7.4, coverslips were mounted with Vectashield 
mounting medium and using constant PMT and section depth settings 9 random 
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fields/sample were captured by using Zeiss LSM510 laser confocal microscopy 
and the images were analysed by using Zeiss LSM Image Browser. 
 
2.2.13 Detection of the cell surface TG2 activity via biotin-cadaverine 
incorporation into fibronectin 
 
The transglutaminase activity of cell surface TGs were measure via biotin-
cadaverine incorporation into FN as introduced previously (Heath et al., 2002). 
50µl of 5µg/ml FN in 50mM Tris-HCl, pH7.4 was used to pre-coated 96-well 
plate at 4ºC for 16 h. After washing 3 times with 50mM Tris-HCl, pH7.4, the 
wells were blocked with 3% BSA in PBS, pH7.4 (blocking buffer) for 1 h at 
room temperature. Following trypsinizing and counting, 2× 104 cells in 100µl of 
serum free medium were seeded into each well and incubated for 2 h at 37ºC in 
the presence of 0.132nM biotin-X-cadaverine. 100ng/well of gplTG in serum 
medium containing 10mM DTT and 0.132nM biotin-X-cadaverine with 10mM 
CaCl2 (a positive control) or 10mM EDTA (a negative control)  was used as the 
control samples. After incubation, the reaction was terminated by the addition of 
100µl of 2mM EDTA in PBS, pH7.4 into each well and the cells were removed 
by 100µl of 0.1% (w/v) deoxycholate in 2mM EDTA in PBS, pH7.4 for 10 min 
at room temperature with gentle agitation. After washing 3 times with 50mM 
Tris-HCl, pH7.4, the wells were blocked with blocking buffer for 30 min at 37ºC. 
Biotin-cadaverine incorporation into FN was incubated with an extravidin 
peroxidise conjugate in blocking buffer (1:1000 dilution) at 37ºC for 1 h. After 
washing 3 times with 50mM Tris-HCl, pH7.4, development of the reaction was 
performed by addition of developing buffer containing the substrate 7.5% (w/v) 
3,3’,5,5’-Tetramethyl benzidine in DMSO (TMB). The colour development was 
terminated by addition of 50μl of 2.5M H2SO4 and the absorbance read at 450nm 
using a Spectrafluor plate reader. Results were expressed as absorbance at 
450nm. 
 
2.2.14 Detection of cell surface proteins via biotinylation 
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Biotinylation of cell surface protein with EZ-link Sulfo-NHS-Biotin was 
performed according to manufacturer’s protocol. 1×106 cells were seeded into 
60mm Petri dishes. After washed once with ice cold PBS, pH 8.0, the cells were 
incubated with 0.8µM EZ-link Sulfo-NHS-Biotin dissolved in PBS, pH 8.0 at 
4ºC for 20 min. After the removal of biotin solution, the cells were washed 3 
times with 50mM Tris-HCl, pH 8.0 and lysed in 1% SDS in PBS, pH 8.0 with    
Benzonase. Following the incubation on ice for 30 min, protein concentrations 
were determined as introduced in Section 2.2.6. Cell lysates containing 600µg 
total protein were centrifuged at 13,000×g for 20 min to pellet the non-broken 
cells and then incubated with 50µl resin beads at 4ºC on rotating platform for 
overnight. Following washing three times with PBS, pH 8.0, the biotin-labelled 
cell surface proteins bound to the resin beads were extracted by boiling in 30µl 
Laemmli sample buffer at 95ºC for 5 min. 
 
2.2.15 Detection of FN deposition  
 
2.2.15.1 Biotinylation of FN  
 
Human plasma fibronectin in PBS, pH 7.4 was incubated with EZ-link Sulfo-
NHS-Biotin (Piece) at room temperature for 30 min. The unbound biotin was 
dialysed in 1 l of dialysis buffer PBS, pH 7.4 at 4ºC for at least 24 h. The dialysis 
buffer was changed at least 3 times. After the protein concentration assay 
(Section 2.2.6). The biotin-labelled FN solution was diluted to the concentration 
of 50µM and then stored at -80ºC until use. 
 
2.2.15.2 Analysis of FN matrix assembly by immunofluorescence 
 
6×104 cells /well of wild type, syndecan-4 null, β1 integrin null and EA5, EA5/ 
α5 cells were seeded onto FN or TG-FN in 8-well glass chamber slides. In some 
experiments, the cells were pre- treated with RAD or RGD peptide. The cells 
were incubated for 1 h in serum-free medium and following washing the 
adherent cells with serum-free medium, the cells were incubated with 50nM 
exogenous biotinylated FN (prepared according to manufacturer’s protocol) in 
 
Chapter 2 Materials and Methods 
 
90 
 
serum-free medium. After 1 h, 3 h, 6 h and 16 h incubation, fixed cells were 
blocked with 3% bovine serum albumin (BSA) in PBS, pH7.4 and the cell 
matrices stained with 1μg/ml Cy5-streptavidin. Slides were mounted with 
Vectashield mountant and examined via confocal microscopy. 
 
2.2.16 Statistical analysis 
 
The differences between data sets in cell adhesion assays were analysed by the 
Student’s t test (two-tailed distribution with equal variance). Statistical 
significant difference between data sets was defined in the text by a p<0.05 (two 
sides).  
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Chapter 3: Importance of the syndecan-4/2 and β1 integrin co-
signalling pathway in RGD-independent cell adhesion mediated 
by the TG-FN matrix 
 
3.1 Introduction 
 
The extracellular matrix (ECM) serves as a crucial survival signal for many 
anchorage dependent cells by providing those cells with a suitable environment 
to proliferate, differentiate, migrate and transduce signals thus enabling them to 
exert their biological functions (Hynes, et al., 1999). As one of the major ECM 
components, fibronectin (FN) can interact with different kinds of cell surface 
receptors, such as integrins and syndecans and activate their signalling pathways.  
 
The amino acid sequence Arg-Gly-Asp binding site is a widely occurring cell 
adhesive motif originally discovered in fibronectin (Pierschbacher and Ruoslahti, 
1984), and located in III10. The RGD motif in fibronectin is one the most 
important recognition sites for about half of all known integrins, such as α3β1, 
α5β1, αVβ1, and αVβ3 integrin. When treated with synthetic RGD peptides, the 
cells can not adhere completely on FN (Pierschbacher and Ruoslahti, 1984), 
suggesting the importance of this interaction between cells and matrix mediated 
by integrin receptors. A  recent study discovered that, even when seeded on the 
cell binding domain of FN, the cells could still not accomplish a well-organized 
actin cytoskeleton, which led to  the discovery of another important family of cell 
surface receptors— heparan sulfate proteoglycans (HSPGs) (Bloom, et al., 
1999). Only when the heparan sulfate chains interact with heparin-binding sites 
in FN, can the cell organize mature focal contacts (Woods, et al. 1986). The 
major group of HSPGs is the syndecan family. The syndecans are a four-member 
family (syndecan1-4) of transmembrane cell surface proteoglycans (PGs) that 
bear heparan sulfate glycosaminoglycan (GAG) chains (Bernfield, et al., 1999). 
The syndecans are expressed on virtually all cell types throughout development 
and adulthood, and their expression can be altered under certain 
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pathophysiological conditions, including the processes of tumour onset, 
progression and metastasis (Sanderson, et al., 2004). 
 
Several studies on TG2, FN structure and the integrin signalling pathway have 
demonstrated a novel role for TG2 in the cell adhesion process. The structural 
study for FN showed that the TG2 binding site (the 42kD gelatin-binding 
domain) (Radek, et al., 1993) and the integrin binding site (the RGD cell-binding 
site) are located in different parts of the FN molecule, which provides the 
possibility that TG2 and integrin collaborate rather than compete in the cell 
adhesion process. Moreover, the binding of TG2 with FN was shown to activate 
FAK and increase the GTP loading of the small GTPase RhoA, leading to 
intracellular signalling and induction of   cell adhesion (Janiak, et al., 2006).  
 
The studies of Belkin et al. (2000 and 2001) and Gaudry et al. (1999) indicated 
that TG2 associates with integrin receptors in a number of different cell types via 
binding to the extracellular domains of the β1, β3 and β5 integrin subunits. 
Unlike FN, integrins do not appear to serve as enzymatic substrates of TG2 or 
other transglutaminases and the formation of stable non-covalent integrin-TG2 
complexes is independent of the transamidating activity of TG2 (Akimov et al., 
2000a). Although the binding sites within integrins for TG2 are still unknown, it 
has been demonstrated that integrin-TG2 complexes have a 1:1 stoichiometry 
and all the TG2 on the cell surface is bound to integrin receptors in a FN-
independent manner (Akimov et al., 2000a). Besides the structural evidence for 
interactions, a series of studies led by Mehta and colleagues on tumour cells 
demonstrated the connection between TG2 and the integrin-relevant downstream 
signalling molecule-FAK. The culture of TG2-positive breast cancer cells and 
TG2-transfected fibroblasts on fibronectin-coated surfaces led to the activation of 
FAK, the downstream signalling molecule of integrins (Mehta, et al., 2006). 
Conversely, down-regulation of TG2 by small interfering RNA attenuated FN-
mediated cell attachment (Herman, et al., 2006) and cell survival and FAK 
phosphorylation (Verma, et al., 2006). A recent study showed that GTP-bound 
TG2, present in the ECM, can induce hypertrophic differentiation of 
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chondrocytes through an α5β1 integrin-dependent and FAK-associated cell 
adhesion process (Tanaka, et al., 2007). 
 
As introduced above, TG2 also exists in the ECM as a kind of structural protein 
(Verderio, et al., 1998). The importance of TG2, as an ECM protein, in RGD-
independent cell adhesion was first introduced by Verderio et al. (2003). The 
TG2 bound FN matrix compensated the apoptosis (anoikis) induced by an RGD 
synthetic peptide. This process was PKCα and FAK-dependent. Treating the 
cells with heparinase to digest the cell surface heparan sulfate chains abolished 
the compensatory effect of the TG-FN complex, which indicated the potential 
involvement of HEPG receptors.  
 
The aim of the work contained in this chapter is to identify the potential 
involvement of other cell surface receptor(s), including syndecan-4, syndecan-2, 
β1 integrin, α5 integrin, β3 integrin and α4β1 integrin, and characterise their 
roles in mediating the RGD-independent cell adhesion and actin cytoskeleton 
formation on TG-FN. Given the range of cell surface receptors present in 
fibroblasts, and the availability of receptor mutant cells, mouse embryo 
fibroblasts (MEF), in which syndecan-4, β1 integrin, α5 integrin, or β3 integrin 
has been knocked out, were utilized as the major cell model (Gronthos, et al. 
1997; Bass and Humphries 2002; Verderio, et al., 2003).  
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3.2 Methods 
 
3.2.1 RGD-independent Cell adhesion assay 
 
Cells (2.5 × 104 cell/well) pre-treated with RGD or RAD synthetic peptide were 
seeded on the microtiter plates pre-coated with FN (5μg/ml) or FN with 
immobilized with gplTG (20μg/ml) and allowed to adhere for 20-40 min (Section 
2.2.3.1). Following cell adhesion and spreading, the cells were fixed and stained 
as mentioned before (Section 2.2.3). The differences between data sets were 
performed using Student’s t test (two-tailed distribution with equal variance).  
 
3.2.2 Immunofluorescence staining  
 
To investigate the formation of the actin cytoskeleton in fibroblast with different 
mutations or with silenced cell surface receptors, FITC-labelled phalloidin 
(20µg/ml) was used to detect the actin skeleton formation after the RGD-
independent cell adhesion on FN or TG-FN matrices in 8-well chambers. The 
signals were detected by a Zeiss LSM510 laser confocal microscope (Section 
2.2.4).  
 
3.2.3 siRNA transfection 
 
Syndecan-2 specific targeting siRNA was used to inhibit the expression of 
syndecan-2 in MEF cells by using the HiPerfect Transfection method (Qiagen). 4 
different siRNA sequences targetting mouse syndecan-2 were obtained from 
Qiagen. The sequences are listed below. 
 
Mm_Sdc2_1 SI01412250 TGGAATTTAATTTGTAGAATA 
Mm_Sdc2_2 SI01412264 CAAAGGCAAATTAATGTGTAA 
 
1nM of lyophilized siRNA was dissolved in 100µl of sterile, RNase-free water to 
obtain a 10µM solution and then stored at -20ºC. The transfection was performed 
according to the manusfacture’s protocol. Before transfection, 3×105 cells were 
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seeded into each well of a 6-well plate for 24 h to reach 50-80% confluency. 
Prior to transfection, cells were washed with PBS, pH 7.4 and the medium was 
replaced with 2.3ml pre-warmed fresh complete growth medium. 150ng of 
siRNAs were diluted in DMEM serum free medium siRNAs to reach the final 
volume of 100µl of siRNA working solution at the final concentration of 5nM. 
After pre-incubation with 12µl of HiPerfect Transfection Reagent (Qiagen) at 
room temperature for 5-10 min, the transfection complex was added drop-wise 
onto the cells with gentle swirling the plate to ensure the uniform distribution of 
the transfection complex. The following experiments were performed after 30 h 
siRNA transfection.  
 
3.2.4 Detection of the siRNA transfection efficiency 
 
After 30 h incubation of the syndecan-2 targetting siRNA or the negative control 
siRNA with the MEF cells, cell lysates were collected into 30µl of cell lysis 
buffer and the protein concentration was detected as introduced in Section 2.2.7. 
Western blotting was performed to detect the presence of syndecan-2 by using 
rabbit anti-syndecan-2 polyclonal antibody (1:1000 dilution) and swine anti-
rabbit secondary antibody (1:1000 dilution) (Section 2.2.8- 2.2.9). Signals were 
detected by using enhanced Chemiluminescence (ECL) system kit.  
 
3.2.5 The synthesis and detection of the scrambled siRNA against the 
syndecan-2 specific targeting siRNAs 
 
According to the results from the Western blotting assay for the syndecan-2 
siRNAs-treated MEF cells, the scrambled siRNA were designed with the aid of 
Dr Russell Collighan (Aston University) and synthesized by Sigma-Aldrich. The 
sequences of the scrambled siRNAs were listed below and the effect of these 
siRNAs was detected via Western blotting for syndecan-2 antigen as described in 
Section 4.2.4.   
Scrambled siRNA1:  GTAAATTATGTAAGTTAGTAT 
Scrambled siRNA2:  GATAATCAAAGCGAAATGTAT 
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3.3 Results 
 
3.3.1 Cell surface TG2 is not sufficient to support RGD-independent cell 
adhesion.  
 
3.3.1.1 Susceptibility of MEF cells to Zeocin 
 
For the establishment of the stable TG2 transfected MEF cell line, a range of 
zeocin concentrations (0.1-1.2mg/ml) was used to treat wild type MEF cells to 
identify the lowest possible concentration that would induce about 80% cell 
death within 48-72 h as introduced in Section 2.2.1.7.1. The resulting kill curve 
suggested that at the concentration of 800µg/ml zeocin was the optimal 
concentration for clone selection (Figure 3.3.1).  
 
3.3.1.2 Establishment of tg2-MEF cell line with stable-transfected TG2  
 
Previous data suggested that cell surface TG2 is a co-receptor in mediating 
integrin-dependent cell adhesion on FN. In order to distinguish the effects of cell 
surface TG2 and matrix TG2, MEF cells were stable-transfected with human 
TG2 as introduced in Section 2.2.1.7 and grown in cell medium supplemented 
with 800μg/ml zeocin to select the transfected cells. Selection of transformants 
was undertaken with 400μg/ml of zeocin in the cell culture medium. The effect 
of transfection was studied via detecting the level of TG2 antigen in both whole 
cell lysates and biotinylated cell surface protein via Western blotting (Section 
2.2.8). As shown in Figure 3.3.2, in wild type MEF cells TG2 was found neither 
in cell lysate nor on the cell surface, while after transfection, high levels of TG2 
antigen was detected on the cell surface. These results prove the successful 
establishment of a tg2-MEF cell line, which provides an ideal model to 
investigate the role of cell surface TG2 in the RGD-independent cell adhesion 
process, since the potential influence of exogenous TG2 is ruled out in the wild 
type MEF cell. 
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Figure 3.3.1 The effect of zeocin on MEF cell proliferation via XTT assay.  
 
MEF cells were treated with different concentrations of zeocin (0, 100, 200, 400, 
600, 800, 1000, 1200μg/ml, prepectively). After 48 and 72 h incubation with the 
antibiotic, XTT assay was performed and the absorbance was read at 490nm and 
750nm using a Spectrafluor plate reader (as introduced in Section 2.2.1.7.1). 
 
 
 
 
 
 
 
 
 
Figure 3.3.1 
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Figure 3.3.2 Detection of TG2 in wild type and tg2-MEF cells.  
 
The establishment of tg2-MEF cell line was accomplished as introduced in 
Section 2.2.1.7. The presence of TG2 antigen in wild type and tg2-MEF cells 
was detected in both whole cell lysates and biotinylated-cell surface proteins (As 
described in Section 2.2.14) via Western blotting (As introduced in Section  
2.2.8).  Lane 1, gplTG marker; Lane 2 wild type MEF cells; Lane3 tg2-MEF 
cells.  
 
 
 
 
 
 
 
 
 
Figure 3.3.2 
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The distribution of the TG2 antigen within the whole population of wild type and 
tg2-MEF cells, immunofluorescence staining of the intracellular TG2 was 
applied by using a specific monoclonal antibody Cub7402 against TG2 and the 
fluorescence signals were detected via confocal microscopy as introduced in 
Section 2.2.12. No fluorescence signalling was detected in wild type MEF cells, 
and an equal distribution of TG2 antigen was obtained in tg2-MEF cells, 
indicating the success of the establishment of tg2-MEF cell line (Figure 3.3.3).   
   
In order to confirm the results from the Western blotting of the presence of the 
TG2 antigen within the wild type and tg2-MEF cells, cell surface in situ TG 
activity was measured via a biotin-X-cadaverine incorporation assay as described 
in Section 2.2.13. As shown in Figure 3.3.4, cell surface TG activity was only 
detected in the tg2-MEF cells, but not in wild type MEF cells, which further 
confirmed the presence of TG2 on tg2-MEF cell surface.   
 
To further confirm the presence of TG2 antigen and its ability to be deposited 
into the ECM, the established tg2-MEF cell line was seeded into 8 well chambers 
and after a 72 h incubation, the matrix TG2 antigen was detected via immuno-
fluorescence staining. As shown in figure 3.3.5, in tg2-MEF matrix TG2 could be 
detected, while no signal was found in the wild type MEF cells, further 
confirming the very negligible levels of TG2 in the wild type cells and the 
increased TG2 antigen deposited into the ECM of TG2 transfected cells. 
 
3.3.1.3 Cell surface TG2 could not compensate adhesion to FN in the 
presence of RGD peptides  
 
The effect of cell surface TG2 (that which is likely to be associated with integrins 
following its immediate secretion (Akimov et al., 2000b) on RGD-independent 
cell adhesion was investigated by using wild type and tg2-MEF cells, while wild 
type MEF cells seeded on FN matrix were used as the control group. As shown 
in Figure 3.3.6a and b, no significant difference was found between RAD-treated 
tg2-MEF cells and wild type cells, suggesting that no toxicity was found by over-
expression of TG2. Interestingly, over-expression of cell surface TG2 did not  
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Figure 3.3.3 Detection of intracellular TG2 in wild type and tg2-MEF cells.  
 
The establishment of tg2-MEF cell line was accomplished as introduced in 
Section 2.2.1.7. The presence of intracellular TG2 antigen in wild type (wt MEF) 
and tg2-MEF cells was detected via immunofluorescence staining by using anti-
TG2 antibody Cub7402 and  the fluorescence signals were detected via confocal 
microscopy, while the nuclei were staining by using propidium iodide (PI) (As 
described in Section  2.2.12).   
 
 
 
 
 
 
 
 
 
 
 
                                                                             Figure 3.3.3 
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Figure 3.3.5 Detection of the cell surface TG activity in wild type and tg2-
MEF cells.  
 
The establishment of tg2-MEF cell line was accomplished as introduced in 
Section 2.2.1.7. The activity of the cell surface TG2 in wild type (wt MEF) and 
tg2-MEF cells were measured via biotin-cadaverine incorporation into 
fibronectin (Section 2.2.13).   
 
 
 
 
 
 
 
 
 
                                                                             Figure 3.3.4 
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Figure 3.3.4 Detection of matrix deposited TG2 antigen in wild type and tg2-
MEF cells.  
 
The establishment of tg2-MEF cell line was accomplished as introduced in 
Section 2.2.1.7. The presence of matrix TG2 antigen in wild type and tg2-MEF 
cells were detected via immunofluorescence staining as introduced in Section 
2.2.12.   
 
 
 
 
 
 
 
 
 
 
 
                                                                             Figure 3.3.5 
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improve the cell attachment and spreading process on FN, since no significant 
differences were observed between wild type and tg2-MEF. RGD peptide 
treatment led to a 50% reduction of both cell attachment and cell spreading in 
tg2-MEF, and no significant difference was found when compared to RGD-
treated wild type MEF. Only when both sets of cells were seeded on the TG-FN 
complex were the cells able recover their adhesion capacity (92% in adhesion 
and 95% in spreading) in the presence of RGD peptide. These results indicated 
that cell surface TG2 is not sufficient to compensate the effect of the RGD 
peptides on the cell adhesion and that only when it is deposited into a FN matrix, 
can TG2 facilitate cell adhesion in the presence of RGD peptides.  
 
3.3.2 TG2 is the functional component within the TG-FN complex that 
exerts the compensatory effect in cell adhesion in the presence of RGD 
peptides 
 
3.3.2.1 Immobilisation and detection of TG2 on a heparin-treated FN matrix 
 
Although it has been reported that the TG-FN complex can compensate the effect 
of RGD peptides in inhibiting cell attachment and spreading, the relative 
contribution of these two proteins in the heterocomplex still remains unknown. In 
order to distinguish the roles of FN and TG2, soluble heparin, which is natural 
ligand for FN, was used to block the binding sites for heparan sulphates on FN 
prior to TG2 immobilisation (Itano et al., 1993). Before performing the cell 
adhesion assay, a modified ELISA method (Verderio et al., 1999) was utilized to 
investigate whether heparin-treatment affected the formation of the TG-FN 
complex. To block the heparin-binding sites completely, a 60-fold excess 
concentration of heparin (300μg/ml) to FN (5μg/ml) was used. In this 
experiment, two different concentrations of TG2, 20μg/ml and 30μg/ml, was 
immobilised on FN following heparin incubation. Previous work has been 
demonstrated that 20μg/ml of gplTG is the concentration that can saturate 5μg/ml 
FN coated plastic surface. The relevant levels of TG2 were detected with the 
mouse monoclonal anti-TG2 antibody Cub7402. The result show that the binding 
between heparin and FN did not affect interaction between FN and TG2  
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Figure 3.3.6 The role of cell surface TG2 in cell adhesion process on FN-TG2 
matrix.  
  
The cell adhesion assay were carried on and the attachment and spreading of 
wild type (wt) MEF and tg2-MEF cells were analysed as explained in Section 
2.2.3. a, the cell adhesion of wild type and tg2-MEF cells. The percentage of 
attached cell (cell attachment) or the percentage of spreading cells (cell 
spreading) ± S.D. shown is the mean values from three separate experiments 
performed in triplicate. The mean cell attachment and spreading values were 
expressed as the percentage of control values of non-treated (control) cell seeded 
on FN (which represents 100%) ± S.D. The mean number of cell attachment ± 
S.D. of control taken from 3 experiments was 150 ± 5. The mean percentage 
spreading value ± S.D on FN was 68±0in the 3 experiments, and normalised to 
100%. The * symbol represents significant difference (p<0.05) between FN and 
TG-FN matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. b, visualization of wild type and 
tg2-MEF cells on FN and TG-FN matrix in the presence of RGD peptide.   
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Figure 3.3.7 Detection of the relative levels of TG2 bound to heparin blocked 
FN by ELISA. 
  
The relative levels of TG2 bound to heparin blocked FN immoblized on TCP at 
different concentrations of TG2 were measured via ELISA. 300μg/ml heparin in 
50mM Tris-HCl, pH7.4 was used to block the heparin-binding sites within FN 
molecule before the immobilization of gplTG onto FN matrix. The presence of 
gplTG antigen immobilized on FN matrix was detected by using monoclonal 
antibody Cub7402. Each data point presents the mean absorbance (450nm) 
values ± S.D of three separate experiments undertaken in quadruplicate. The 
final values were acquired by substrating the background values obtained from 
the wells incubated with FN and heparin solution.  
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compared to the control groups and there was no significant difference between 
the two concentrations of TG2. Therefore this method was used in the following 
cell adhesion experiments (Figure 3.3.7).  
 
3.3.2.2 TG2 can compensate the loss of cell adhesion in the presence of RGD 
peptides even after blocking the heparin binding sites on FN  
 
Cell adhesion was performed on heparin-treated matrices and control matrices to 
investigate the ability of TG-FN in RGD-independent cell adhesion by using 
mouse embryonic fibroblasts. As might be expected, the heparin-blocked FN 
matrix led to a significant 30% decrease in cell attachment and over 20% 
decrease in cell spreading (Figure 3.3.8a and b), compared to that of the FN 
control. Cell attachment on TG-FN was 106% of the control cell attachment on 
FN in the non-blocked wells. TG-FN matrix compensated the loss of cell 
adhesion caused by blocking the heparin-binding sites within FN molecules. 
Similar results were obtained when cells were seeded on FN and TG-FN matrix 
with or without heparin blocking in the presence of RGD peptide. Once treated 
with 100μg/ml of RGD peptide, cell attachment was reduced to 50% of the value 
evaluated for the control on FN, while cell spreading dropped to 18% (Figure 
3.3.8a and b) of the control value. The defective cell attachment and spreading 
due to heparin blocking and the presence of RGD peptide was restored back to 
79% and 64%, respectively, when cells were seeded on the TG-FN matrix, This 
suggests that the RGD-independent cell adhesion mediated by the TG-FN 
complex is independent of the interaction between cell surface HSPGs and the 
heparin -binding sites within FN.  
 
3.3.3 Cell adhesion in response to the TG-FN matrix is dependent on the 
interaction between TG and the extracellular heparan sulfate chains. 
 
3.3.3.1 Heparan sulfate chains are required for TG-FN to exert its 
compensatory effect on the RGD peptide-induced loss of cell adhesion 
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Figure 3.3.8 The importance of the heparin binding sites within FN in cell 
adhesion process on FN or FN-TG2 matrix.  
  
Heparin-treated matrix was prepared as described under Methods (Section 2.2.2) 
The cell adhesion assay was carried out and the attachment and spreading of 
Swiss 3T3 fibroblasts were analysed as explained in Section 2.2.3. The 
percentage of attached cell (cell attachment) or the percentage of spread cells 
(cell spreading) ± S.D. shown are the mean values from three separate 
experiments performed in triplicate. The mean cell attachment and spreading 
values were expressed as the percentage of control values of non-treated 
(control) cell seeded on FN (which represents 100%) ± S.D. The mean number 
for cell attachment ± S.D of control taken from 3 experiments was 172 ± 6, 
156±11, and 159±4. The mean percentage spreading value ± S.D on FN was 
80±1, 90±2, and 87±2 in the 3 experiments, and normalised to 100%. The * 
symbol represents significant difference (p<0.05) between FN and TG-FN 
matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN.  
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Figure 3.3.9 The importance of cell surface heparan sulphate chains in cell 
adhesion process on FN or TG-FN matrix.  
  
The cell adhesion assay was carried out and the attachment and spreading of wild 
type (wt) and heparan sulphate-mutant (hs-m) CHO cells were analysed as 
explained in Section 2.2.3. a, The percentage of attached cell (cell attachment) or 
the percentage of spreading cells (cell spreading) ± S.D shown are the mean 
values from three separate experiments performed in triplicate. The mean cell 
attachment and spreading values were expressed as the percentage of control 
values of non-treated (control) cell seeded on FN (which represents 100%) ± S.D 
The mean number of cell attachment ± S.D. of control taken from 3 experiments 
was 176 ± 5, 181±2, and 144±16. The mean percentage spreading value ± S.D on 
FN was 83±1, 83±6, and 69±1 in the 3 experiments, and normalised to 100%. 
The * symbol represents significant difference (p<0.05) between FN and TG-FN 
matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups. b, visualization of wt 
and hs-m CHO cells on heparin-treated FN and TG-FN matrix in the presence of 
RGD peptide.  
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The experiments above indicated that the compensation effect of TG-FN on the 
RGD-induced loss of cell attachment and spreading was independent of the 
interaction between the cell surface heparan sulfate chains and the heparin-
binding sites within FN suggesting TG2 to be the functional component in this 
process. To further investigate whether extracellular heparan sulfate chains are 
involved in the TG-FN mediated cell adhesion, heparan sulfate deficient Chinese 
hamster ovary cells (CHO) were used to determine the cell adhesion in the 
presence of RGD peptide, while wild type CHO cells were used as control cells.   
In this experiment, CHO cells incubated with a concentration of 100μg/ml of the 
RGD peptide considerably decreased cell attachment on FN to approximately 
50%, and cell spreading to about 30% (Figure 3.3.9). As expected, cell 
attachment did not show a reduction when treated with the RAD peptide, which 
indicated that addition of the exogenous peptides at 100μg/ml did not cause 
toxicity to the cells. In agreement with the previous experiments, the TG-FN 
complex restored the cell attachment and spreading back to around 80% of the 
value of the RGD peptide-treated wild type CHO cells. Although there was only 
a 10% reduction in cell attachment on FN when heparan sulphate-deficient cells 
were compared to wild type CHO cells, the cell spreading on FN was 
dramatically decreased in the  heparan sulfate deficient CHO cells to only around 
10% of the control values when  compared with the non-treated wild type CHO 
cells (Figure 3.3.9). No spread cells were observed in the heparan sulphate-
mutant CHO cells in the presence of the RGD peptides. In contrast to the wild 
type CHO cells, TG-FN lost its compensatory effect on the cell adhesion caused 
by the RGD peptides in heparan sulphate-deficient CHO cells. These 
experiments confirm the importance of the extracellular heparan sulfate chains in 
the RGD-independent cell adhesion process mediated by the TG-FN complex. 
 
3.3.3.2 Heparin treatment of TG2 blocked the RGD-independent cell 
adhesion mediated by TG-FN.  
 
The high affinity of TG2 for heparin has been reported (Gambetti et al., 2005). 
Previous work has also demonstrated TG-FN loses its compensatory effect on 
heparinase-treated cells (Verderio et al., 2003). Heparin was therefore used to  
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Figure 3.3.10 The importance of the heparan sulfate binding site(s) of TG2 
in RGD-in dependent cell adhesion on TG-FN.  
  
Cell adhesion was performed on a heparin treated TG-FN matrix after 
immobilization of gplTG on the FN and the attachment and spreading of MEF 
cells was then analysed as explained in Section 2.2.3. The percentage of attached 
cell (cell attachment) or the percentage of spreading cells (cell spreading) ± S.D 
shown are the mean values from three separate experiments performed in 
triplicate. The mean cell attachment and spreading values were expressed as the 
percentage of control values of non-treated (control) cell seeded on FN (which 
represents 100%) ± S.D The mean number of cell attachment ± S.D of control 
taken from 3 experiments was 156 ± 5. The mean percentage spreading value ± 
S.D on FN was 74 ± 0 in the 3 experiments, which was normalised to 100%. The 
* symbol represents significant difference (p<0.05) between FN and TG-FN 
matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups.  
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Figure 3.3.11 Detection of syndecan-4 and β1 integrins in wild type, 
syndecan-4 knock, syndecan-4 vector control and syndecan-4 addback MEF 
cells.  
Western blotting was performed to confirm the presence of syndecan-4 and β1 
integrins in syndecan-4-relevant MEF cells (Section 2.2.9-2.2.10). The 
membranes were stripped and re-probed with anti-α-tubulin antibody to ensure 
the equal loading. Lane 1, wt MEF; Lane 2, syndecan-4 ko MEF; Lane 3, 
syndecan-4 vec MEF; Lane 4, syndecan-4 ab MEF.  
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treat the TG-FN complex after the immobilization of gplTG onto FN and the cell 
adhesion assay was then performed on this heparin-blocked TG-FN matrix. As 
shown in Figure 3.3.10a and b, in the non-treated and RAD-treated cells, only 
70% of cell attachment and 30% of cell spreading was observed on the FN 
matrix, which could not be compensated by the heparin-treated TG-FN matrix. 
The RGD peptide treatment reduced the cell attachment to 40% and the 
spreading to around 12% on both the heparin-blocked FN and TG-FN matrices, 
compared to 48% of cell attachment on FN matrix and 90% on TG-FN matrix 
and 35% of cell spreading on FN and 94% on TG-FN, respectively (Figure 
3.3.10). This result suggests the importance of the heparin-binding ability of TG2 
in mediating the RGD-independent cell adhesion process.  
 
3.3.4 Syndecan-4 plays an important role in RGD-independent cell adhesion 
in response to the TG-FN matrix. 
 
3.3.4.1 Detection of the presence of syndecan-4 antigen in syndecan-4 
relevant MEF cells. 
 
In order to confirm the presence or absence of the syndecan-4 antigen, the wild 
type, syndecan-4 knockout, add-back (ab, syndecan-4 knockout cells transfected 
with human syndecan-4 cDNA) and empty vector control (vec syndecan-4 
knockout cells transfected with vector cDNA) MEF cells were analysed by 
Western blotting. This was performed by using rabbit polyclonal anti-syndecan-4 
antibody (which recognizes both mouse and human syndecan-4), while the 
expression of another major cell adhesion-related receptor β1 integrins was also 
detected. The membrane was stripped and re-probed with mouse anti-α-tubulin 
antibody to ensure the equal loading of the samples. As shown in the top panel of 
Figure 3.3.11, no syndecan-4 was detected in syndecan-4 knockout and vector-
control MEF cells, while the antigen was detected in the wild type and addback 
MEF cells (Figure 3.3.11 middle panel). The loss of syndecan-4 did not affect the 
expression of β1 integrins in all of the above cells.  
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Figure 3.3.12 The importance of cell surface syndecan-4 in the RGD-
independent cell adhesion process on FN and TG-FN matrices. 
a, the RGD-independent cell adhesion assay was carried out and the attachment 
and spreading of syndecan-4 wild type (wt MEF), knock out (SDC4 ko), vector 
control (SDC4 vet) and add-back (SDC4 ab) MEF cells were analysed as 
explained in Section 2.2.3. The percentage of attached cell (cell attachment) or 
the percentage of spreading cells (cell spreading) ± S.D shown are the mean 
values from three separate experiments performed in triplicate. The mean cell 
attachment and spreading values were expressed as the percentage of control 
values of non-treated (control) cell seeded on FN (which represents 100%) ± S.D 
The mean number of cell attachment ± S.D of control taken from 3 experiments 
was 181 ± 11, 172±4, and 142±9. The mean percentage spreading value ± S.D. 
on FN was 68±3, 64±5, and 74±2 in the 3 experiments, and normalised to 100%. 
The * symbol represents significant difference (p<0.05) between FN and TG-FN 
matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups. b, visualization of 
RGD peptide-treated syndecan-4 relevant MEF cells seeded on FN or TG-FN 
matrices.  
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3.3.4.2 TG-FN lost its compensatory effect on RGD-independent cell 
adhesion in syndecan-4 knock out MEF cells 
 
Previous studies suggested the involvement of cell surface heparan sulfate chains 
in the RGD-independent cell adhesion process mediated by the TG-FN complex 
(Verderio, et al., 2003). As the most widely-expressed member of the heparan 
sulfate proteoglycan (HSPG) family, the potential involvement of syndecan-4 
was investigated in the cell adhesion experiments by using syndecan-4 wild type 
(wt), knockout (ko), add-back (ab, syndecan-4 knockout cells transfected with 
human syndecan-4 cDNA) and empty vector control (vct syndecan-4 knockout 
cells transfected with vector cDNA) MEF cells. The cells were seeded on FN and 
TG-FN matrices following the blocking of the interaction between the integrins 
and FN via the RGD peptides. The cells were then allowed to attach at 37ºC in a 
5% CO2 atmosphere for 30 min. 
 
These results showed that the attachment of these cells on FN was considerably 
reduced (about 70%), in the presence of 100μg/ml of RGD peptide. Since it has 
been shown in previous experiments that addition of exogenous peptides at 
100μg/ml do not cause cell toxicity in MEF cells (Section 3.3.1.2), this part of 
the experiment was performed by using this concentration of the RGD peptides. 
As shown in Figure 3.3.12, the TG-FN complex compensated for the inhibitory 
effect of RGD peptides on the wild type MEF cells (back to 80% in cell 
attachment, and 75% in cell spreading, respectively) and in the add-back MEF 
cells (back to 111% and 82% respectively). In contrast, the cell attachment and 
spreading on the TG2 immobilised FN matrix was not restored in the RGD-
treated knockout and vector control MEF (Figures 3.3.12a and b). In these two 
cells on both the FN and the TG-FN matrices with the absence of syndecan-4, the 
levels of cell attachment and spreading remained at around 30% and 10%, 
respectively, while no significant difference (p>0.05) was observed between 
these two matrices. These results indicated that syndecan-4 plays an important 
role as the cell receptor in the RGD-independent cell adhesion on the TG-FN 
matrix. 
 
Chapter 3: Importance of the syndecan-4/2 and β1 integrin co-signalling pathway in 
RGD-independent cell adhesion mediated by the TG-FN matrix 
 
124 
 
 
 
 
 
Figure 3.3.13 The importance of cell surface syndecan-4 in actin stress fibre 
formation on FN-TG2 matrix.  
The cell adhesion assay was carried out and the attachment and spreading of wild 
type (wt), knock out (SDC4 ko), and add-back (SDC4 ab) MEF cells was 
analysed as described in Section 2.2.3. After 20-40 min incubation, the cells were 
fixed with 3.7% paraformaldehyde in PBS, pH7.4, and the actin stress fibre 
formation was detected by using FITC-labelled phalloidin (20μg/ml) as 
introduced in Section 2.2.4. Bar, 20 μm.  
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3.3.4.3 TG-FN failed to restore actin stress fibre formation in syndecan-4 
null MEF cells 
 
The importance of syndecan-4 in supporting actin stress fibre formation has been 
very widely reported (Woods, et al. 1986; Longley, et al. 1999; Woods, et al. 
2000). To confirm the importance of syndecan-4 in the TG-FN mediated cell 
adhesion process in the presence of the RGD peptides, actin cytoskeleton 
staining was performed by using FITC-labelled phalloidin (Section 2.2.4) in the 
RAD or RGD peptides treated MEF cells. As shown in Figure 3.3.13, well-
organized actin stress fibres were detected in wild type MEF cells seeded on both 
the FN matrix, while syndecan-4 null MEF cells exhibited a reduction in 
longitudinal stress fibres and formed stress fibre bundles that were more 
restricted to the cell periphery compared to the wild type MEF cells. The 
observed diffused actin cytoskeletal architecture induced by the RGD peptides 
treatment was only rescued in the wild type MEF seeded on the TG-FN matrix, 
not on the FN-only matrix, whereas syndecan-4 knockout cells failed to respond 
to the TG-FN complex. Once the human syndecan-4 molecule was re-introduced 
into the syndecan-4 knockout cells (in the syndecan-4 addback MEF cells), TG-
FN re-obtained its compensatory effect on supporting actin stress fibre formation 
in the RGD-treated cells. These results indicated the importance of syndecan-4 in 
regulating actin stress fibre formation on the TG-FN matrix.  
 
3.3.4.4 TG2 within the TG-FN complex directly interacts with syndecan-4   
 
To investigate whether there is a direct interaction between matrix TG2 and cell 
surface syndecan-4, the co-immunoprecipitation assay was performed in the wild 
type, syndecan-4 knockout and syndecan-4 addback MEF cells. In order to block 
the cell binding domains within the FN molecules, the cells were seeded on the 
heparin-treated TG-FN matrix in the presence of the RGD peptides. Thereby 
only TG2 was left to mediate the potential interaction between the cells and the 
TG-FN complex. The immunoprecipitation of syndecan-4 by using syndecan-4 
antibody followed by immunoblotting for TG2 revealed the presence of TG2 
antigen in syndecan-4 wild type and add-back MEF cells, but not in syndecan-4  
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Figure 3.3.14 Direct interaction between cell surface heparan sulfate and 
matrix TG2 within TG-FN complex. 
The RGD-independent cell adhesion assay was carried out by using syndecan-4 
knockout MEF cells (Sdc4 ko), syndecan-4 add-back (Sdc4 ab) and wild type 
MEF cells (wt MEF). Cells were seeded on heparin-treated FN-TG2 matrix as 
explained in Section 2.2.2.3. After incubating the cells for 20-40 min, the cells 
were lysed in cell lysis buffer and co-immunoprecipitation assay was performed 
as described in Section 2.2.11 by using syndecan-4 antibody which detects the 
intracellular domain of syndecan-4 molecule. Western blotting assay was applied 
to detect TG2 antigen by using TG2 specific antibody Cub7402.  Guinea pig 
liver TG was used as a marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.14 
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Figure 3.3.15 The direct interaction between cell surface heparan sulfates of 
syndecan-4 and matrix TG2 within TG-FN complex. 
The RGD-independent cell adhesion assay was carried out by using heparan 
sulfate mutant CHO cells (hs-m CHO) and CHO wild type cells (wt CHO). Cells 
were seeded on heparin-treated FN-TG2 matrix as explained in Section 2.2.2.3. 
After incubating the cells for 20-40 min, the cells were lysed in cell lysis buffer 
and co-immunoprecipitation assay was performed by using specific anti-
syndecan-4 antibody as introduced in Section 2.2.11. Western blotting assay was 
applied to detect TG2 antigen by using TG2 specific antibody Cub7402. Guinea 
pig liver TG was used as a marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.15 
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null MEF cells on the TG-FN matrix (Figure 3.3.14), further confirming that the 
direct interaction between TG2 within the TG-FN complex and cell surface 
syndecan-4 . 
 
3.3.4.5 The TG-FN matrix mediates RGD-independent cell adhesion by the 
direct interaction between the cell surface heparan sulfate chains of 
syndecan-4 and the matrix TG2 
 
To confirm whether there is a direct interaction between the cell surface heparan 
sulfate chains and the matrix TG2, the co-immunoprecipitation assays were  
performed by using wild type CHO and heparan sulfate mutant CHO cells after 
seeding on a heparin pre-treated TG-FN matrix in the presence of the RGD 
peptides (Section 2.2.11), thus making sure that the heparin binding sites within 
the FN molecule was blocked by heparin and the interaction between the cell 
surface integrins and the FN within TG-FN complex was inhibited by the RGD 
peptides. Anti-syndecan-4 antibody (which detects the intracellular core protein 
of syndecan-4 molecules) was used in the co-immunoprecipitation assays to pull 
down the syndecan-4 immuno-complex. Western Blotting using mouse 
monoclonal anti-TG2 antibody (Cub7402) was applied to detect the presence of 
TG2 antigen in this complex. As shown in Figure 3.3.15, no TG2 was detected in 
the heparan sulphate mutant CHO cells seeded on the TG-FN matrix, unlike 
shown in the wild type CHO cells. These results indicated the importance of the 
heparan sulfate chains in mediating the interaction between the cells and the 
matrix bound TG2.   
 
3.3.5 TG-FN mediated RGD-independent cell adhesion depends on the 
activation of the inside-out signalling pathway of β1 integrins 
 
3.3.5.1 Detection of the presence of β1 integrin antigen in β1 integrin 
relevant MEF cells 
 
To further confirm the presence or absence of β1 integrins in the wild type, β1 
integrins knockout, add-back (ab, β1 integrins knockout cells transfected with  
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Figure 3.3.16 Detection of β1 integrins and syndecan-4 in wild type, β1 
integrins knock, β1 integrins vector control and β1 integrins addback MEF 
cells.  
Western blotting was performed to confirm the presence of β1 integrins and 
syndecan-4 in β1 integrins-relevant MEF cells (Section 2.2.9-2.2.10). The 
membranes were stripped and re-probed with anti-α-tubulin antibody to ensure 
the equal loading.  Lane 1, wt MEF; Lane 2, β1 integrins ko MEF; Lane 3, β1 
integrins vet MEF; Lane 4, β1 integrins ab MEF.  
 
 
 
 
 
 
Figure 3.3.16 
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Figure 3.3.17 The importance of cell surface β1 integrin in the RGD-
independent cell adhesion process on TG-FN matrices. 
a, the RGD-independent cell adhesion assay was carried out and the attachment 
and spreading of wild type (wt MEF), knock out (INT1 ko), vector control (INT1 
vet) and add-back (INT1 ab) MEF cells were analysed as explained in Section 
2.2.3. The percentage of attached cell (cell attachment) or the percentage of 
spread cells (cell spreading) ± S.D shown are the mean values from three 
separate experiments performed in triplicate. The mean cell attachment and 
spreading values were expressed as the percentage of control values of non-
treated (control) cell seeded on FN (which represents 100%) ± S.D 147 ± 12, 
146±7, and 131±3. The mean percentage spreading value ± S.D on FN was 77±1, 
73±1, and 73±1 in the 3 experiments, and normalised to 100%. The * symbol 
represents significant difference (p<0.05) between FN and TG-FN matrices in 
the presence and/ or absence of RAD or RGD peptide when compared to the 
non-treated cells seeded on FN. The # symbol represents significant difference 
(p<0.05) between individual groups. b, visualization of RGD peptide-treated β1 
integrin relevant MEF cells seeded on FN or TG-FN matrices. 
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Figure 3.3.17a 
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Figure 3.3.17b 
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human β1 integrins cDNA) and empty vector control (β1 integrins knockout cells 
transfected with empty vector cDNA) MEF cells, Western blotting was 
performed by using rabbit polyclonal anti-β1 integrins antibody (which 
recognizes both mouse and human β1 integrins). The expression of another major 
cell adhesion-related receptor syndecan-4 integrins was also detected using 
Western blotting. The membrane was stripped and re-probed with mouse anti-α-
tubulin antibody to ensure the equal loading of the samples. As shown in Figure 
3.3.16, no β1 integrins were detected in β1 integrins knockout and vector-control 
MEF cells, while the antigen was detected in the wild type and addback MEF 
cells. The presence of syndecan-4 antigens in all of the cells proved that the loss 
of β1 integrins did not affect the expression of syndecan-4.  
 
3.3.5.2 β1 integrin is crucial for TG-FN to compensate the effect of the RGD 
peptides 
 
The existence of a syndecan-4 and β1 integrin co-signalling pathway has been 
very well-reported (Couchman and Woods, 1999). Previous data indicated the 
role of syndecan-4 in mediating the RGD-independent cell adhesion on a TG-FN 
matrix. In order to investigate the involvement of β1 integrins in this process, the 
wild type, β1 integrin null MEF (β1 knockout), and β1 ko MEFs transfected back 
with the human β1 integrin cDNA (β1 addback MEF) and empty vector (β1 
vector control MEF) were used in the cell adhesion assay in the presence of the 
RGD peptides.    
 
In these cells, no significant difference (p>0.05) was found between the RAD 
peptides-treated and non-treated cells seeded on FN, suggesting that the 
exogenous peptides at 100μg/ml did not cause cell toxicity in these cell lines. 
The β1 knockout and vector control MEF cells displayed a 2-fold reduction in 
cell adhesion on the FN matrix compared to the wild type cells in a short-term 
adhesion assay (30 min). In the wild type MEF cells, the TG-FN complex 
restored the inhibition effect of the RGD peptides (100μg/ml) back to 90% on 
cell attachment, and 66% on cell spreading, respectively. In the β1 integrin add-
back MEF cells, the RGD peptides reduced the cell attachment to 20% and the  
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Figure 3.3.18 No direct interaction between cell surface syndecan-4 and β1 
integrins.  
The RGD-independent cell adhesion assay was carried out by using syndecan-4 
knockout MEF cells (Sdc4 ko, Lane 3), syndecan-4 add-back (Sdc4 ab, Lane 4) 
and wild type MEF cells (wt MEF, Lane 1). Cells were seeded on heparin-treated 
FN-TG2 matrix as explained in Section 2.2.2.3. After incubating the cells for 20-
40 min, the cells were lysed in cell lysis buffer and co-immunoprecipitation 
assay was performed as introduced in Section 2.2.11 by using syndecan-4 
antibody which detects the intracellular domain of the syndecan-4 molecule. 
Western blotting assay was applied to detect β1 integrin antigen by using a 
specific anti-β1 integrin antigen antibody. Cell lysate with β1 integrins (β1 INT) 
was used as the standard (Lane 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.18 
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spreading to 58%, which were compensated by the TG-FN complex back to 51% 
in cell attachment and 92% in cell spreading. In contrast, cell attachment and 
spreading on the TG2 immobilised FN matrix was not compensated in the β1 
integrin ko and vector control MEF cells in the presence of different 
concentrations of the RGD peptide, which was about 5% in cell attachment, and 
0% in cell spreading (Figure 3.3.17). This data strongly suggested that β1 
integrins play a crucial role in the RGD-independent adhesion in the response to 
the TG-FN matrix. 
 
3.3.5.3 No direct interaction between syndecan-4 and β1 integrin was 
detected in the cells seeded on TG-FN 
 
In order to rule out the possible interaction between cell surface syndecan-4 and 
β1 integrin during the cell adhesion process on TG-FN in the presence of the 
RGD peptides, co-immunoprecipitation assays were  carried out by using the 
RGD peptides-treated wt, syndecan-4 knockout and addback MEF cells seeded 
on heparin-blocked TG-FN matrices. An anti-syndecan-4 antibody that detects 
the intracellular domain of the syndecan-4 molecule was used in the 
immunoprecipitation procedure and an anti-β1 integrin antibody was applied to 
detect the presence of β1 integrins within the immuno-complex. As shown in 
Figure 3.3.18, western blotting of the precipitates and probing with β1 integrin 
antibody revealed that no β1 integrins could be detected, suggesting that 
syndecan-4 does not interact directly with β1 integrin.  
 
3.3.6 TG-FN compensates the RGD-induced loss of cell adhesion in an α5 
integrin-dependent manner 
 
It has been reported that among the integrin family, α5 integrins present the 
closest relationship with β1 integrins in FN-mediated cell adhesion. Previous 
results suggested the crucial role of β1 integrin in RGD-independent cell 
adhesion mediated by TG-FN. In order to investigate the role of α5 integrins in 
this process, mouse embryo cell EA5 and its control EA5/α5 (EA5 cells 
transfected with human α5 integrin cDNA) were used in the cell adhesion assay  
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Figure 3.3.19 Detection of α5 integrins in EA5 and EA5/α mouse embryo 
cells.  
Western blotting was performed to confirm the presence of α5 integrins in both 
whole cell lysates (the middle panel) and biotin-labelled cell surface proteins (the 
top panel) (Section 2.2.14) of EA5/α5 and EA5 mouse embryo cells (Section 
2.2.9-2.2.10). The membrane was re-probed with anti-α-Tubulin antibody to 
ensure the equal loading (the bottom panel).   
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Figure 3.3.20 The crucial role of cell surface α5 integrins in RGD-
independent cell adhesion process on TG-FN matrices. 
a, the RGD-independent cell adhesion assay was carried out on the attachment 
and spreading of EA5/α5 and EA5 mouse embryo cells and analysed as 
explained in Section 2.2.3. The percentage of attached cell (cell attachment) or 
the percentage of spreading cells (cell spreading) ± S.D. shown are the mean 
values from three separate experiments performed in triplicate. The mean cell 
attachment number of values were expressed as the percentage of control values 
of non-treated (control) cell seeded on FN (which represents 100%) ± S.D. The 
mean number of cell attachment ± S.D. of control taken from 3 experiments was 
155 ± 3. The mean percentage spreading value ± S.D. on FN was 73±2 in the 3 
experiments, and normalised to 100%. The * symbol represents significant 
difference (p<0.05) between FN and TG-FN matrices in the presence and/ or 
absence of RAD or RGD peptide when compared to the non-treated cells seeded 
on FN. The # symbol represents significant difference (p<0.05) between 
individual groups. b, visualization of RGD peptide-treated α5 integrin relevant 
MEF cells seeded on FN or TG-FN matrices.  
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Figure 3.3.20a 
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Figure 3.3.20b 
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(Huveneers et al., 2008). To confirm the presence or absence of α5 integrins in 
EA5 and EA5/α5 cells, Western blotting was performed by using rabbit anti-α5 
polyclonal antibody to detect the presence of α5 integrins in whole cell lysates or 
on cell surface via biotinylation, while α-tubulin was used as the standard of 
equal loading. As shown in Figure 3.3.19, α5 integrins were only detected in 
EA5/ α5 cells with re-transfected human α5 integrins, while no α5 integrins could 
be found in EA5 cells in both cell lysates and cell surface.  
 
Embryo cells are considered fibroblast-like cells, while unlike the EA5/α5 
control cells, EA5 cells maintained a round morphology on the FN matrix, which 
proved the importance of α5 integrins in focal adhesion assembly and in actin 
stress fibre formation (Huveneers et al., 2008). There is no significant difference 
(p>0.05) observed between non- and RAD-treated (100μg/ml) cells, suggesting 
that the effect of RGD on cell adhesion is not caused by its toxicity. Like in MEF 
fibroblasts, TG-FN compensated the RGD-induced loss of the cell attachment 
and spreading in EA5/α5 cells (53% and 49% on FN matrix, respectively) back 
to normal level (95% and 94%, respectively). Without α5 integrins, EA5 cells 
only achieved 18% of cell attachment and 7% of spreading when seeded on FN, 
compared to EA5/α5 cells. The RGD peptide treatment significantly abolished 
the cell attachment and spreading and decreased their level to 10% and 0% of the 
control group (Figure 3.3.20). TG-FN failed to restore these losses and no 
statistical significance was obtained between the groups of RGD-treated EA5 
cells seeded FN and TG-FN matrices, which suggested the cell adhesion process 
mediated by TG-FN depends on the presence of cell surface α5 integrins. 
 
3.3.7 The compensatory effect of TG-FN in cell adhesion in the presence of 
RGD peptide is blocked by the treatment of the α5β1 integrin inhibiting 
peptide—A5-1 
 
To further confirm the inhibiting effect of the α5β1 integrin inhibitor, a specific 
inhibiting peptide, A5-1, against this receptor was applied in the cell adhesion 
assay. This peptide inhibited the cell adhesion on the FN matrix in a dose-
dependent manner, and as the concentration of the peptide increased, its blocking  
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Figure 3.3.21 The inhibition of cell surface α5β1 integrins by its specific 
targetting peptide abolishes the compensatory effect of TG-FN on RGD-
independent cell adhesion.  
 
A range of different concentrations of a specific α5β1 integrin targetting peptide 
A5-1 was used to block the cell adhesion process mediated by these integrins 
was used in the cell adhesion assay as explained in Section 2.2.3. The RGD and 
RAD peptides were used as the control treatments, while DMSO was used as the 
vehicle control The percentage of attached cell (cell attachment) or the 
percentage of spread cells (cell spreading) ± S.D shown are the mean values from 
three separate experiments performed in triplicate. The mean cell attachment and 
spreading values were expressed as the percentage of control values of non-
treated (control) cell seeded on FN (which represents 100%) ± S.D. The mean 
number of cell attachment ± S.D. of control taken from 3 experiments was 144 ± 
7. The mean percentage spreading value ± S.D on FN was 82 ± 1 in the 3 
experiments, and normalised to 100%. The * symbol represents significant 
difference (p<0.05) between FN and TG-FN matrices in the presence and/ or 
absence of RAD or RGD peptide when compared to the non-treated cells seeded 
on FN. The # symbol represents significant difference (p<0.05) between 
individual groups.  
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Figure 3.3.21 
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effect on TG-FN mediated cell adhesion was significantly increased. As shown 
in Figure 3.3.22, at the concentration of 5μM, A5-1 blocked 60% of both cell 
attachment and spreading on FN, and TG-FN could not restore the loss of cell 
adhesion, suggesting that the compensatory effect of TG-FN was significantly 
inhibited by the peptide treatment. This inhibition effect by the A5-1 peptide 
confirmed the involvement of α5β1 integrin in RGD-independent cell adhesion 
on the TG-FN matrix.   
 
3.3.8 Syndecan-2 is required in the RGD-independent cell adhesion 
mediated by TG-FN 
 
 3.3.8.1 The silencing of syndecan-2 by siRNA treatment inhibited the 
compensatory effect of TG-FN on the RGD-induced loss of cell adhesion  
 
3.3.8.1.1 The inhibition effect of syndecan-2 targetting siRNA on syndecan-2 
expression 
 
Syndecan-2 specific targeting siRNAs was used to inhibit the expression of 
syndecan-2 in MEF cells as introduced in Section 3.2.3. Universal negative 
control siRNA and scrambled siRNAs designed according to the syndecan-2 
specific siRNAs were used as the control treatments. After a 30 h incubation with 
the siRNAs, the cell lysates were collected into cell lysis buffer and Western 
blotting was performed to detect the presence of syndecan-2 antigen in the cell 
lysates (Sections 2.2.6-2.2.10). As shown in Figure 3.3.22, no effect of the 
control siRNAs, including non-silencing siRNA and the scrambled siRNAs was 
found on the expression of syndecan-2. The SDC-2 siRNA1 and 2 significantly 
inhibited the expression of syndecan-2 down to around 50%.  
 
3.3.8.1.2 The knocking down of syndecan-2 expression did not affect the 
expression of syndecan-4 and β1 integrins 
 
Before further investigation of the effect of syndecan-2 in the TG-FN mediated 
cell adhesion, the effect of the SDC-2 siRNAs on the expression of the other two  
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Figure 3.3.22 Detection of the effect of the syndecan-2 siRNAs on syndecan-2 
expression in MEF cells.  
Syndecn-2 siRNAs targetting mouse syndecan-2 were used to inhibit the 
expression of syndecan-2 in MEF cells (Section 4.2.3). After a 30 h incubation, 
the cells were collected into cell lysis buffer and Western blotting was performed 
to detect the presence of the syndecan-2 antigen within the samples by using the 
rabbit polyclonal anti-syndecan-2 antibody. The universal negative siRNA and 
the scrambled siRNAs designed according to the sequences of the syndecan-2 
siRNAs were used as the negative treatments.  Lane 1, non-treated MEFs; Lane 
2, non-silencing siRNA-treated MEFs; Lane 3, SDC-2 siRNA1-treated cells; 
Lane 4, SDC-2 siRNA2-treated cells; Lane5, scrambled siRNA1-treated MEF 
cells; and Lane 6, scrambled siRNA2-treated MEF cells. 
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Figure 3.3.23 Detection of the effect of the syndecan-2 siRNAs on syndecan-4 
and β1 integrin expression in MEF cells.  
Syndecan-2 siRNAs targetting mouse syndecan-2 were used to inhibit the 
expression of syndecan-2 in MEF cells (Section 4.2.3). After a 30 h incubation, 
the cells were collected into cell lysis buffer and Western blotting was performed 
to detect the presence of the syndecan-4 and β1 integrin antigens within the 
samples by using the specific antibodies. The universal negative siRNA and the 
scrambled siRNAs designed according to the sequences of the syndecan-2 
siRNAs were used as the negative treatments.  α-Tubulin expression levels in the 
samples were used as the equal loading standards. Lane 1, non-treated MEFs; 
Lane 2, non-silencing siRNA-treated MEFs; Lane 3, SDC-2 siRNA1-treated 
cells; Lane 4, SDC-2 siRNA2-treated cells; Lane5, scrambled siRNA1-treated 
MEF cells; and Lane 6, scrambled siRNA2-treated MEF cells.   
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crucial cell surface receptors in this process, syndecan-4 and β1 integrins, was 
measured by using Western blotting. As shown in Figure 3.3.23, no difference of 
the expression levels of both syndecan-4 and β1 integrins were detected between 
the non-treated cells, the control siRNA groups and the syndecan-2 targetting 
siRNAs treated cells, which confirms the specificity of these SDC-2 siRNAs and 
provides the possibility for the application of the siRNAs in the cell adhesion 
assay.  
 
3.3.8.1.3 TG-FN compensates RGD-induced loss of cell adhesion in a 
syndecan-2-dependent manner 
 
It has been reported that syndecan-2 is the co-receptor in syndecan-4 signalling 
(Whiteford et al., 2007). In order to investigate the effect of syndecan-2 on the 
RGD-independent cell adhesion on TG-FN, syndecan-2 targetting siRNAs, SDC-
2 siRNA1 and 2, were used to inhibit protein expression and then the cell 
adhesion assay was performed by using the siRNA-treated cells. The universal 
negative control siRNA and the scrambled siRNAs were used as controls. As 
shown in Figure 3.3.24, no significant difference (p>0.05) in the cell attachment 
and spreading was discovered in the negative control siRNAs treated cells in 
both FN groups, compared to the non-treated cells, suggesting non toxicity of the 
siRNA treatment in the MEF cells. No further difference was found in the RAD 
peptide-treated and non-treated cells on FN in the control siRNA-treated cells, 
which showed no specific toxic effect of RAD peptide to the siRNA-treated 
cells. These data made sure that the future difference in the cell attachment and 
spreading will be due the loss of syndecan-2 expression and the RGD peptide-
treatment, but not the toxicity from either the siRNA treatment or the peptides 
TG-FN restored the loss of the cell attachment and spreading caused by the RGD 
peptides back to over 90% in all of the control groups and no significant 
difference (p>0.05) was found between these groups. With the inhibition of 
syndecan-2 expression, the cells lost about 25% in cell attachment and 60% of 
cell spreading on the FN matrix, which could not be compensated by TG-FN. In 
the presence of RGD peptide, further 30% loss of the cell attachment and 20% of 
spreading was observed on both the FN and the TG-FN matrices. These results  
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Figure 3.3.24 The importance of cell surface syndecan-2 in RGD-
independent cell adhesion process on TG-FN matrices. 
a, Syndecn-2 siRNAs targetting mouse syndecan-2 treated MEF cells (30 h 
incubation) (Section 4.2.3)were used in the RGD-independent cell adhesion 
assay (Section2.2.3). The universal negative siRNA and the scrambled siRNAs 
designed according to the sequences of the syndecan-2 siRNAs were used as the 
negative treatments. The mean cell attachment and spreading values were 
expressed as the percentage of control values of non-treated (control) cell seeded 
on FN (which represents 100%) ± S.D. The mean number of cell attachment ± 
S.D. of control taken from 3 experiments was 157 ± 3. The mean percentage 
spreading value ± S.D on FN was 74 ± 5 in the 3 experiments, and normalised to 
100%. The * symbol represents significant difference (p<0.05) between FN and 
TG-FN matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups. b, visualization of 
syndecan-2 siRNAs and the control siRNA-treated MEF cells seeded on FN or 
TG-FN matrices in the presence of RGD peptide. 
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Figure 3.3.24a 
 
 
C
el
l S
pr
ea
di
ng
C
el
l A
tta
ch
m
en
t
#
#
CNTL             NS siRNA          SDC-2 siRNA1/2          Mis-match siRNA1/2
RAD RGD RAD RGD RAD RGD  RAD  RGD RAD RGD RAD  RGD
Chapter 3: Importance of the syndecan-4/2 and β1 integrin co-signalling pathway in 
RGD-independent cell adhesion mediated by the TG-FN matrix 
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.24b 
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Figure 3.3.25 The importance of syndecan-2 in actin cytoskeleton formation 
on TG-FN matrix.  
 The cell adhesion assay were carried on by using syndecan-2 targetting siRNA-
treated MEF cells (Section 4.2.3) as explained in Section 2.2.3, while the 
universal negative control (NC) siRNA was used as the control treatment. After 
20-40 min incubation, the cells were fixed with 3.7% paraformaldehyde in PBS, 
pH7.4, and the actin stress fibre formation was performed by using FITC-
labelled phalloidin (20μg/ml) as described in Section 2.2.4. Bar, 20 μm. 
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suggest the involvement of syndecan-2 in the RGD-independent cell adhesion 
mediated by TG-FN.  
 
3.3.8.2 Syndecan-2 is crucial for TG-FN to exert its function in actin 
cytoskeleton formation   
 
The role of syndecan-2 in actin stress fibre formation has been demonstrated and 
its involvement in TG-FN signalling pathway was suggested by cell adhesion 
experiments (Section 3.3.8.2). In order to further investigate the role of 
syndecan-2 in TG-FN regulated actin cytoskeleton formation, the actin stress 
fibre was detected via immunofluorescence staining in syndecan-2 targetting 
siRNA-treated MEF cells, and the non-treated, universal negative control siRNA 
and the scrambled siRNAs were used as the control groups (Section 3.2.2). As 
shown in Figure 3.3.25, after 1 h incubation, well-organized actin fibres were 
detected in the control groups on both FN and TG-FN matrices in the presence of 
RAD peptide. Once treated with RGD peptide, the cells seeded on FN lose their 
longitudinal stress fibres, which were restored in the cells plated on TG-FN 
matrix. The loss of syndecan-2 induced a diffused actin cytoskeletal architecture 
on FN, and with the reduced expression of syndecan-2, the cells failed to respond 
to the TG-FN matrix in the presence of the RGD peptides. This work indicates 
the importance of syndecan-2 in regulating actin cytoskeleton organization, 
which is crucial for TG-FN to exert its compensation effect on the RGD-induced 
cell adhesion and actin stress fibre formation.        
 
3.3.9 β3 integrins are not required by TG-FN to compensate the effect of 
RGD peptide on cell adhesion 
 
Even though β1 integrins have been proven to be the major cell surface integrins 
that mediate cell adhesion on FN, accumulating research indicates that β3 
integrins are also involved in this process (Switala-Jelen et al., 2004). In order to 
study the potential involvement of β3 integrin in the TG-FN matrix model of this  
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Figure 3.3.26 The β3 integrins are not required by TG-FN to mediate RGD-
independent cell adhesion.  
The RGD-independent cell adhesion assay was carried out and the attachment 
and spreading of β3 wild type and knockout MEF cells was analysed as 
explained in Section 2.2.3. The percentage of attached cell (cell attachment) or 
the percentage of spread cells (cell spreading) ± S.D shown are the mean values 
from three separate experiments performed in triplicate. The mean cell 
attachment and spreading values were expressed as the percentage of control 
values of non-treated (control) cell seeded on FN (which represents 100%) ± 
S.D. The mean number of cell attachment ± S.D. of control taken from 3 
experiments was 158 ± 6. The mean percentage spreading value ± S.D on FN 
was 80 ± 2 in the 3 experiments, and normalised to 100%. The * symbol 
represents significant difference (p<0.05) between FN and TG-FN matrices in 
the presence and/ or absence of RAD or RGD peptide when compared to the 
non-treated cells seeded on FN. 
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Figure 3.3.26 
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project, β3 integrin knockout (ko) mouse embryo fibroblasts and its wild type 
control cells were used in cell adhesion assays. As shown in Figure 3.3.26, in 
wild type MEF cells, RGD treatment led to 50% and 55% loss of the cell 
attachment and spreading respectively, which was restored to 92% and 94% 
respectively by the TG-FN complex. During long-term (above 60 min) tissue 
culture, no significant morphological difference was observed in β3 ko cells 
compared to the wild type MEF cells. In a short-term incubation on the FN 
matrix (30 min), even though no significant difference was found in the cell 
attachment between the wild type and knockout cells, the knockout cells lost 
~20% loss of spreading (p<0.05) compared to the wild type cells, confirming the 
involvement of β3 integrins in cell adhesion on FN. No significant difference 
was observed when both of the cells were seeded onto the TG-FN matrix, when 
compared to the wild type cells on the FN matrix. In the presence of RGD 
peptide, β3 ko cells lost 66% and 74% of the cell attachment and spreading, 
respectively on FN, while TG-FN compensated the effect of the RGD peptides 
back to 94%, in which no significant difference was found compared to the 
RGD-treated wild type cells on TG-FN. This suggests that β3 integrins are not 
required for TG-FN to exert its compensatory effect on the RGD-induced loss of 
cell adhesion.      
 
3.3.10 α4β1 integrins are not involved in the signalling transduction 
mediated by TG-FN 
 
It has been reported that TG2 can be involved in an α4β1 integrin-related cell 
adhesion process where it acts as a cell suface corecepto for FN. Hence in order 
to investigate the role of α4β1 integrin in RGD-independent cell adhesion on TG-
FN, rat anti-mouse α4β1 integrin functional blocking antibody-treated MEF cells 
were used in cell adhesion assays, while its isotype control antibody was used as 
a negative treatment. In Figure 3.3.21, at the concentration of 25µg/ml, the 
isotype control antibody did not affect the cell adhesion process on FN, 
compared to the non-treated cells, suggesting no toxicity of these antibodies to 
the MEF cells at this concentration. In the experimental groups, no significant 
difference was found between the functional blocking antibody treated cells on 
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FN and the isotype control antibody, suggesting that α4β1 integrin is not crucial 
in the cell adhesion process on FN. No enhanced or reduced cell adhesion and 
spreading was found in the cells on TG-FN in the absence or presence of RGD 
peptide, which indicates that α4β1 integrin is not required by TG-FN to exert its 
compensatory effect on RGD-induced loss of  cell adhesion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Importance of the syndecan-4/2 and β1 integrin co-signalling pathway in 
RGD-independent cell adhesion mediated by the TG-FN matrix 
 
156 
 
 
 
 
 
 
 
Figure 3.3.27 TG-FN compensates RGD-independent cell adhesion in α4β1 
integrin-independent manner.   
The RGD-independent cell adhesion assay was carried out by using rat anti-
mouse α4β1 integrin functional blocking antibody (clone 9C10) and its isotype 
control antibody (Isotype Ab)-treated MEF cells as described in Section 2.2.3. 
The percentage of attached cell (cell attachment) or the percentage of spread cells 
(cell spreading) ± S.D. shown are the mean values from three separate 
experiments performed in triplicate. The mean cell attachment and spreading 
values were expressed as the percentage of control values of non-treated 
(control) cell seeded on FN (which represents 100%) ± S.D. The mean number of 
cell attachment ± S.D. of control taken from 3 experiments was 139 ± 3. The 
mean percentage spreading value ± S.D. on FN was 80 ± 1 in the 3 experiments, 
and normalised to 100%. The * symbol represents significant difference (p<0.05) 
between FN and TG-FN matrices in the presence and/ or absence of RAD or 
RGD peptide when compared to the non-treated cells seeded on FN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Illustration removed for copyright restrictions 
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3.4 Discussion 
 
It has been reported that the TG-FN heterocomplex, by acting as a novel cell 
adhesion matrix, can compensate the RGD peptide-induced loss of cell adhesion 
(resulting from the blocking of integrin’ interactions with the cell binding 
domains within the FN molecule) (Verderio, et al., 2002). Previous work also 
demonstrated the involvement of cell surface heparan sulfate chains in this RGD-
independent cell adhesion process mediated by TG-FN matrix (Verderio, et al., 
2003). The initial aim of this project was to find out which type(s) of cell surface 
receptor(s) and intracellular molecule(s) are involved in this process.     
 
By using heparin treatment, the heparin binding sites within FN were blocked 
before TG2 was immobilized on FN, which as shown by ELISA did not affect 
the formation of the TG-FN complex. The undertaking of the RGD-independent 
cell adhesion experiments on this heparin-treated matrix indicated that even 
though FN could not fully mediate cell adhesion through integrins or cell surface 
proteoglycans on this heparin-treated matrix, TG-FN can still compensate the 
effect of the RGD peptides, suggesting that TG2 is likely to be the functional 
component to exert the compensatory effect on the RGD-peptide-induced loss of 
cell adhesion. The following experiments using heparin to block the potential 
heparan sulfate binding site(s) within the TG2 molecule completely abolished 
this function of the TG-FN complex in cell adhesion assays. Also in the heparan 
sulfate mutant CHO cells, no compensation effect of the RGD peptide was 
observed in TG-FN groups, supporting the previous data using heparinase-treated 
cells in which TG-FN lost its compensation (Verderio, et al., 2003). This further 
indicates that the importance of the cell surface heparan sulfate chains in this 
novel cell adhesion process.  
 
Heparan sulfate proteoglycans (HSPGs) are the major source of heparan sulfate 
chains on the cell surface, which are composed of a family of cell adhesion-
relevant surface receptors— syndecans. The syndecan family includes four 
members, syndecan-1-4, among which syndecan-4 is the most widely expressed 
and has been reported to be involved in focal adhesion assembly and in 
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supporting the formation of actin stress fibres during the cell adhesion process. 
The importance of syndecan-4 has been reported in fibroblasts (Woods et al., 
2000). By using syndecan-4 knockout MEF cells, the role of syndecan-4 in the 
RGD-independent cell adhesion on TG-FN was investigated and confirmed. 
Without the presence of cell surface syndecan-4, TG-FN lost its compensatory 
effect on the RGD peptides completely in the cell adhesion process, which was 
due to the loss of the direct interaction between TG2 and syndecan-4, 
demonstrated by co-immunoprecipitation experiments. The important role of 
syndecan-4 was also proven in actin stress fibre formation by using syndecan-4 
wild type, knock-out and add-back MEF cells, revealing that without the support 
of syndecan-4, TG-FN could not promote the organization of actin stress fibres 
in the presence of RGD peptide, while in the wild type and add-back cells, this 
complex accomplished the restoring of the RGD-independent actin cytoskeleton 
formation. Since the core protein of syndecan-4 has also been reported in 
regulating cell adhesion, the heparan sulfate mutant CHO cells were used in co-
immunoprecipitation assays by using an anti-syndecan-4 antibody (which detects 
the intracellular domain of syndecan-4 core protein) to pull the syndecan-4 
immuno-complex. The absence of TG2 antigen in immunocomplex of the mutant 
CHO cells, compared to its presence in the wild type cells, indicated the direct 
link between TG2 and heparan sulfates and ruled out the involvement of the 
syndecan-4 core protein in TG-FN mediated cell adhesion.  
 
The involvement of both syndecan-4 and β1 integrins in cell attachment and 
spreading has been widely demonstrated, suggesting that syndecan-4 is a co-
receptor in the β1 integrin signalling pathway in supporting actin stress fibre 
formation (Bass et al., 2007). Since the involvement of syndecan-4 has been 
proven in RGD-independent cell adhesion mediated by TG-FN, further studies 
were performed to investigate whether β1 integrin also participates in this 
process. In the β1 integrin knockout MEF cells, TG-FN lost its compensatory 
effect completely, providing the first evidence of the crucial role of β1 integrins 
in signal transduction mediated by TG-FN. Meanwhile, the activation of β1 
integrins by its direct interaction with syndecan-4 was ruled out, based on the 
discovery that no interaction was detected between these two receptors via co-
Chapter 3: Importance of the syndecan-4/2 and β1 integrin co-signalling pathway in 
RGD-independent cell adhesion mediated by the TG-FN matrix 
 
160 
 
immunoprecipitation assays. Among the α integrin family, α5 integrin has been 
shown to be most important companion to β1 integrin in regulating FN-mediated 
cell adhesion (Takagi et al., 2003), which led to the hypothesis that α5 integrin 
could be the crucial partner for β1 integrin to regulate the RGD-independent cell 
adhesion on TG-FN. The failure of this complex in compensating RGD-
independent cell adhesion in α5 integrin knockout cells proved this hypothesis. 
By using an inhibiting peptide A1-5 designed to target the α5β1 integrin to block 
its interaction with FN, cell attachment and spreading were inhibited in a dose-
dependent manner in the cells seeded on FN. Unlike its compensatory effect on 
RGD peptide induced loss of cell adhesion, TG-FN failed to rescue the loss of 
cell adhesion when the inhibitor and the inhibiting peptide was present , further 
confirming that α5β1 integrin receptor complex is crucial in the cell adhesion 
process mediated by TG-FN.  
 
Recent work suggested that another member of the syndecan family— syndecan-
2 is also involved in regulating actin cytoskeleton formation during cell adhesion 
(Munesue et al., 2002). Meanwhile it has been reported that syndecan-2 is highly 
expressed in fibroblasts. To investigate the potential role of syndecan-2 in 
fibroblast cell adhesion on TG-FN, syndecan-2 specific targeting siRNAs was 
used to block the expression of syndecan-2 in MEF cells. The success in 
inhibiting syndecan-2 expression significantly reduced the compensatory effect 
of TG-FN on the RGD-independent cell adhesion, which gave the first clue of 
the importance of syndecan-2 in TG-FN mediated signalling transduction. By 
further investigating the actin cytoskeleton formation, in syndecan-2 siRNA-
treated cells it was demonstrated these cells could not organize well-formed actin 
stress fibres, moreover they failed to respond to the TG-FN matrix in the 
presence of the RGD peptides which not only confirms the importance of 
syndecan-2 in actin cytoskeleton formation, but also its involvement in the RGD-
independent cell adhesion mediated by TG-FN.  
 
Even though defined as a vitronectin-relevant cell surface receptor, β3 integrin 
has also been reported to participate in cell adhesion on FN (Switala-Jelen et al., 
2004). In β1 integrin knock-out MEF cells, although present in those cells, β3 
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integrins could not fulfil the role of β1 integrin in RGD-independent cell 
adhesion on TG-FN, suggesting β3 integrins are not required by TG-FN to 
compensate the effect of the RGD peptides. In order to confirm this result, β3 
integrin knock-out MEF cells were used in the RGD-independent cell adhesion 
assay. In short-term incubations, the absence of β3 integrin did not affect the cell 
attachment on FN and only partially inhibited cell spreading (around 20% 
reduction), confirming the involvement of β3 integrin in the FN-mediated cell 
adhesion.  On the contrary, neither cell attachment nor cell adhesion was affected 
when the knockout cells were seeded on TG-FN, ruling out the requirement of β3 
integrins by TG-FN in mediating RGD-independent cell adhesion. 
 
α4β1 integrin is another cell surface receptor that has been reported involved in 
cell adhesion on FN, also this integrin is related to TG2 in mediating cell 
adhesion (Moyano et al., 2003). In α4β1 integrin functional blocking antibody-
treated MEF cells, no significant difference was found compared to the Isotype 
antibody or non-treated cells, suggesting in short-term incubation (30 min), α4β1 
integrin is not required by cells to mediate their adhesion on FN. No further 
reduction or enhancement was discovered in the antibody-treated cells seeded on 
TG-FN, which ruled out the possibility that α4β1 integrin is essential for TG-FN 
to exert its compensatory effect on cell adhesion.              
 
To sum up the above work, it was demonstrated that the TG-FN complex can 
compensate the effect of RGD peptide induced loss of cell adhesion and actin 
cytoskeleton formation through the syndecan-4/2 and α5β1 integrin co-signalling 
pathway, which is independent of β3 and α4β1 integrins. This process could be 
potentially involved in the matrix turnover process important to wound healing 
and tumour progression and may provide a therapeutic target for regulating the 
above processes. There are still remaining questions to be answered: (1) What 
intracellular signalling pathway(s) are involved in this cell adhesion process 
mediated by TG-FN; (2) What is the relationship between these three cell surface 
receptors, syndecan-4, syndecan-2 and α5β1 integrin; (3) What is the functional 
effect of this RGD-independent cell adhesion on physiological or pathological 
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process(es). The next chapters will explore the intracellular signalling pathway 
and matrix deposition processes mediated by the TG-FN matrix.  
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Chapter 4: The characterisation of intracellular signalling 
molecules in the RGD-independent cell adhesion process 
mediated by the TG-FN complex 
 
4.1 Introduction 
 
The importance of the ECM protein FN in cell-ECM interaction has been widely 
investigated and reported (Pankov and Yamada, 2002). There are two major cell 
surface receptor families that are involved in this process, known as integrins and 
syndecans. It has been reported that around half of the members from the integrin 
family can bind to the RGD-cell binding domain of FN, which initiates the cell 
adhesion process. Integrins, which can interact with FN matrix, including α2β1, 
α3β1, α5β1, αVβ1, αVβ3, and αVβ5 integrins (Hersel et al., 2003). When 
integrins bind to the RGD-binding motif of FN, they initiate the cell adhesion 
process on FN. The involvement of the syndecan family in cell spreading was 
first reported on the discovery that the interaction of RGD cell binding sites with 
integrins can only mediate the formation of the nascent focal adhesions and the 
cells fail to form stress fibres and/or a cytoskeletal network (Bloom et al., 1999; 
Woods et al., 1984). Within FN there are at least two heparin binding sites 
mediating the interaction between FN and syndecans. The syndecan family are 
heparan sulfate proteoglycans (HSPGs) and form the major source of cell surface 
heparan sulphates. Syndecan-4 is the most ubiquitous member of the syndecan 
family. Although integrins are the main cell surface receptors responsible for 
cell-ECM interactions, in some cases, integrin engagement is not sufficient for a 
complete adhesion signalling process (Bloom et al., 1999; Huhtala, et al., 1995; 
Izzard, et al., 1986). Syndecan-4 can bind the HepII heparin-binding domain of 
FN with high affinity, which leads to the formation of focal adhesions necessary 
for cell adhesion (Woods et al. 2000). The binding of syndecan-4 to the heparin 
binding domain within FN provides a second signal that is required for formation 
of stress fibres and maturation of focal adhesions in mesenchymal cells (Woods, 
and Couchman, 1998). The heparan sulfate chains of syndecan-4 can interact 
with ECM proteins or growth factors to transduce the outside signals into the 
cells. The effect of both integrins and syndecans on cell adhesion and spreading 
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is defined as the β1 integrin and syndecan-4 co-signalling pathway. There are 
several intracellular signalling molecules that have been reported to be crucial in 
this signal transduction process, including protein kinase C α (PKCα), focal 
adhesion kinase (FAK), Rho and Rho kinase (ROCK) and extracellular signal-
regulated kinase (ERK).  
 
Once activated by the outside signals (via the interaction with ECM proteins or 
the binding with growth factors), the intracellular variable (V) region of 
syndecan-4 core protein binds directly with the catalytic domain of PKCα (Keum 
et al., 2004; Lim et al., 2003) in the presence of phosphatidylinositol 4,5-
bisphosphate (PIP2) (Simons and Horowitz, 2001; Woods and Couchman, 2001), 
which triggers the activation of PKCα and its interaction with β1 integrins (Bass 
and Humphries, 2002). Activation of PKCα facilitates its translocation from the 
cytosol to the membrane and permits its binding with the cytoplasmatic domain 
of β1 integrins, which activates the inside-out signalling mechanism for this 
integrin family (Bass et al., 2007a; Nakashima, 2002). As an important 
downstream molecule in integrin signalling, FAK has been well studied.  The 
interaction of integrins and their relevant ligands can trigger the phosphorylation 
of FAK at different Tyr sites, such as Tyrosine 397, 861, 925 etc., so that the 
FAK signalling complex will be formed. Initiated by the autophosphorylation of 
FAK at Tyr397, FAK binds to the Src family, which in turn promotes the 
phosphorylation of Tyrosine sites 407, 576, 577, 861 and 925, leading to the 
maximal activation of FAK function (Parsons, 2003). Interestingly the 
phosphorylation of Tyr861 suggests the activation of a ligand-independent 
signalling pathway (also known as inside-out signalling) (Shi and Boettiger, 
2003). Once activated FAK can also trigger the cell survival signalling pathway 
mediated by ERK1/2 (Yee et al., 2008). 
 
It has been reported that the Rho small GTPase family, composed of Rho, Rac 
and Cdc42, is involved in cell adhesion and migration, especially Rho and its 
downstream molecule ROCK in syndecan signalling transduction (Whiteford et 
al., 2007). By using syndecan-4 activating antibody, Saoncella and colleagues 
(1999) accomplished the full cell spreading on the cell binding domain of FN 
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(cell adhesion process mediated by β1 integrins), which was blocked by Rho 
inhibitor C3 exotransferase (Saoncella et al., 1999). This discovery demonstrated 
the role of Rho as a downstream signalling molecule in the syndecan-4 pathway. 
Other researchers suggested that Rho and ROCK is also involved in actin 
skeleton formation mediate by syndecan-2 (Whiteford et al., 2007). Even though 
there are still conflicting opinions, the importance of Rho and ROCK in cell 
spreading and actin stress fibre organization has been accepted widely. 
  
TG2 is also regarded as a cell adhesion mediator. Interacting with the gelatin-
binding domain of FN, cell surface TG2 can facilitate integrin-regulated cell 
adhesion (Radek et al., 1993) via its non-covalent interaction with β1 and β3 
integrins (1:1 stoichiometry), which is independent of its transamidating activity 
(Akimov and Belkin, 2001; Akimov et al., 2000). Moreover, the binding of TG2 
with FN activates FAK and increases the GTP loading of the small GTPase 
RhoA, which may trigger the intracellular signalling pathway and induce its 
relevant cell adhesion (Janiak et al., 2006). Mehta and colleagues also 
demonstrated that FAK is the downstream signalling molecule in TG2-related 
tumour cell adhesion and survival (Mehta et al., 2006), which can be attenuated 
by TG2 siRNA treatment (Herman et al., 2006; Verma et al., 2006). The role of 
matrix TG2 in RGD-independent cell adhesion was initially reported by Griffin 
and colleagues. Once deposited into the ECM, TG2 can form a hetero-complex 
with FN, named TG-FN, which can function as a structural protein (Verderio et 
al., 1998). The novel function of TG2, as an ECM protein, in RGD-independent 
cell adhesion was firstly introduced in 2003 (Verderio et al., 2003). Even though 
the function of this matrix complex has been proven, the actual intracellular 
signalling pathway in this RGD-independent cell adhesion process on TG-FN has 
not been completely revealed. In order to pursue earlier work about cell surface 
receptors and investigate the involvement of the intracellular signalling pathway 
that mediates RGD-independent cell adhesion on TG-FN, the intracellular 
signalling molecules, including PKCα, FAK, ERK1/2, ROCK, were studied.  
 
The aim of this chapter is to continue the investigation of the signalling pathway 
in the RGD-independent cell adhesion mediated by TG-FN. Previous work from 
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Chapter 3 suggested the involvement of syndecan-4/2 and α5β1 integrin co-
signalling pathway in the above process. In order to further confirm the 
discoveries and study the intracellular signalling, the downstream signalling 
molecules in this pathway were studied, including PKCα, FAK, ERK1/2 and 
ROCK by using specific inhibitors and the detection of the phosphorylation or 
translocation status of certain kinases.   
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4.2 Methods 
 
4.2.1 Inhibition of the signalling transduction processes by specific 
treatments in the RGD independent cell adhesion  
 
Before detachment by trypsin, Swiss 3T3 or mouse embryonic fibroblast (MEF) 
cells were pre-treated with different treatments to block the activity or function 
of certain signalling molecules or receptors, including PKCα inhibitor Go6976 
(5μM dissolved in DMSO, 30 min), GK21 peptide (8μM dissolved in DMSO, 1 
h), ERK1/2 inhibitor PD98059 (10μM dissolved in DMSO, 1 h), ROCK inhibitor 
Y27632 (10μM dissolved in DMSO, 30 min), or 25μg/ml of β1 integrin 
functional blocking antibody HMβ1-1 or its Isotype control antibody for 1 h. In 
some cases, DMSO (0.1%) was used as the vehicle control to rule out its toxic 
effect on the cells. Following the removal of the treatments, RGD-independent 
cell adhesion was performed as introduced in Section 2.2.3.    
 
4.2.2 Detection of the PKCα translocation from cytosol to membrane 
 
Following PKCα inhibitor treatment (Section 4.2.1), RGD-independent cell 
adhesion was performed in Swiss 3T3 cells. The cells were allowed to adhere for 
around 30 min in the 60mm Petri dishes were previously sequentially coated with 
5μg/ml of FN (in 50mM Tris-HCl, pH 7.4) and with 20μg/ml of gplTG (in 2mM 
EDTA in PBS, pH 7.4) as described before (Section 2.2.2). 50nM of PMA in 
DMSO was used in the positive control treatment. Non-adherent cells were 
collected and washed with ice-cold PBS, pH 7.4 and gently mixed with ice-cold 
homogenisation buffer (Section 2.2.12), while adherent cells were harvested in 
the same buffer and mixed with the corresponding samples. The cells were lysed 
via sonication and the cell membrane and cytosol fractions isolated followed the 
procedures introduced in Section 2.2.12. The presence of PKCα antigen in the 
different cell fractions was detected via Western blotting by using specific anti-
PKCα antibody (Section 2.2.8-10).  
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4.2.3 Detection the interaction between PKCα and syndecan-2 via co-
immunoprecipitation 
 
Co-immunoprecipitation assays were performed to detect interaction between 
syndecan-2 and PKCα by using wild type, syndecan-4 knockout and Y188L 
syndecan-4 mutant MEF cells as introduced in Section 2.2.11. Briefly rabbit anti-
syndecan-2 polyclonal antibody and protein A beads were used to pull down the 
syndecan-2 immunecomplex in the pre-cleared cell lysates samples. Western 
blotting (Section 2.2.9) was used to detect the presence of PKCα antigen in this 
immune-complex by using mouse anti-PKCα monoclonal antibody.   
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4.3 Results 
 
4.3.1 TG-FN compensates the effect of RGD peptide on cell adhesion in a 
PKCα-dependent signalling pathway.  
 
4.3.1.1 PKCα inhibitor Go6976 inhibits the compensatory effect of TG-FN 
on the RGD-independent cell adhesion process 
 
As an important intracellular molecule in the syndecan-4 signalling pathway, the 
role of PKCα was investigated by using its specific inhibitor Go6976 in treated 
Swiss 3T3 fibroblasts. DMSO was used as the vehicle control. As shown in 
Figure 4.3.1, in the presence of RAD peptide, no significant difference of both 
cell attachment and spreading was found compared to non-treated cells, 
suggesting no toxicity of the RAD peptide (100μg/ml). As shown before, TG-FN 
restored the loss of cell attachment and spreading caused by RGD peptide 
treatment back to 93.8% and 94.5% respectively. When treated with PKCα 
inhibitor Go6976, a reduction of 33.2% of cell attachment and 26.7% of 
spreading was obtained on the FN matrix in non-treated cells, while in the RAD 
groups, 31.8% and 24.4% of cell attachment and spreading was blocked by 
Go6979, respectively. RGD peptide-treated cells on FN matrix could only reach 
31.4% of cell attachment and 21.5% of cell spreading, compared to the control 
cells. In the vehicle control group, TG-FN restored the loss of cell attachment 
and spreading induced by the RGD peptide back to normal and accomplished 
around 95% compensation, while in the inhibitor groups, TG-FN failed to 
recover the effect of the inhibitor in RGD treatments. These results suggest the 
involvemen t o f PKCα in  TG-FN signal transduction in Swiss 3T3 fibroblast 
cells.  
 
4.3.1.2 The importance of the interaction of PKCα with the syndecan-4 
intracellular domain. 
  
It has been reported that PKCα is an important downstream molecule of the 
syndecan-4 signalling pathway. To investigate the potential importance of the  
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Figure 4.3.1 The involvement of PKCα in RGD-independent cell adhesion to 
FN and TG-FN matrices.  
The Swiss 3T3 fibroblasts were treated with PKCα inhibitor Go6976 and cell 
adhesion was performed as described previously (Section 4.2.1). The attachment 
and spreading of Swiss 3T3 cells was analysed as introduced in the Methods 
(Section 2.2.3). Each data point represents the mean percentage of attached cell 
(cell attachment) or the mean percentage of spreading cells (cell spreading) ± 
S.D. of three separate experiments performed in triplicate. The ordinates in the 
top graphs represent the mean cell attachment expressed as mean percentage of 
DMSO-treated Swiss 3T3 cells (control) attachment to FN ± S.D., presenting 
100%. The mean number of cell attachment ± S.D. of control taken from 3 
experiments was 139 ± 1. The ordinates in the lower graphs designate the mean 
percentage of spreading cell, expressed as mean percentage of spreading on FN ± 
S.D. The mean percentage of control spreading on FN ± S.D was assessed as 75 
± 4, and normalized to 100%. The * symbol represents significant difference 
(p<0.05) between FN and TG-FN matrices in the presence and/or absence of 
RAD or RGD peptide when compared to the non-treated cells seeded on FN. The 
# symbol represents significant difference (p<0.05) between individual groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Illustration removed for copyright restrictions 
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Figure 4.3.1 
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Figure 4.3.2 The involvement of the interaction between PKCα and 
syndecan-4 in RGD-independent cell adhesion to FN and TG-FN matrices.  
The Y188L mutant MEF cells and wild type MEF cells were used in cell 
adhesion assays performed as described previously (Section 2.2.3). The 
attachment and spreading of MEF cells was analysed as introduced in the 
Methods (Section 2.2.3). Each data point represents the mean percentage of 
attached cells (cell attachment) or the mean percentage of spreading cells (cell 
spreading) ± S.D. of three separate experiments performed in triplicate. The 
ordinates in the top graphs represent the mean cell attachment expressed as mean 
percentage of wild type MEF cells (control) attachment to FN ± S.D., presenting 
100%. The mean attachment value ± S.D. was 126 ± 1. The ordinates in the 
lower graphs designate the mean percentage of spreading cell, expressed as mean 
percentage of spreading on FN ± S.D. The mean percentage of control spreading 
on FN ± S.D was assessed as 82 ± 4, and normalized to 100%. The * symbol 
represents significant difference (p<0.05) between FN and TG-FN matrices in 
the presence and/ or absence of RAD or RGD peptide when compared to the 
non-treated cells seeded on FN. The # symbol represents significant difference 
(p<0.05) between individual groups. 
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Figure 4.3.2 
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interaction between PKCα and syndecan-4, cell adhesion was performed by 
using syndecan-4 mutant MEF cells Y188L (syndecan-4 null MEF cells re-
transfected with human syndecan-4 cDNA with the mutation of the PKCα 
binding site within its cytoplastic domain) (Bass et al., 2007) and wild type MEF 
cells were used as the control group. As shown in Figure 4.3.2, the RAD 
treatment did not affect either the cell attachment or spreading process in wt 
MEF cells and Y188L MEF cells on FN, compared to non-treated cells on FN, 
suggesting at the concentration of 100μg/ml, no toxicity of RAD or RGD peptide 
was found in both cell types. In wt MEF, RGD treatment reduced 45% of cell 
attachment and 40% of spreading on FN, which was restored back to 93% and 
86% by TG-FN, respectively, suggesting the compensatory effect of TG-FN on 
the RGD-induced loss of cell adhesion. While in the Y188L mutant cells, 23% 
and 40% loss of cell attachment and spreading, respectively, were observed on 
the FN matrix only, compared to the wild type control group. The RGD peptide 
further reduced 37% of cell attachment and 29% of cell spreading on the FN 
matrix, which could not be compensated by the TG-FN complex, since similar 
level of cell attachment and spreading were found in both FN and TG-FN 
matrices (p>0.05). The above results confirm the importance of the interaction 
between PKCα and syndecan-4 in cell adhesion on FN. Importantly the 
involvement of this binding is also required in mediating the TG-FN signalling 
transduction process.  
 
4.3.1.3 TG-FN compensates RGD-independent cell adhesion mediated by the 
binding of PKCα with β1 integrins. 
 
It has been reported that the GK21 peptide mimics the intracellular domain of β1 
integrin which mediates its interaction with PKCα (Parsons et al., 2002). As 
such, this peptide can be used to inhibit cell adhesion on FN. To investigate the 
role this interaction in cell adhesion on TG-FN, cell adhesion was performed by 
using GK21 and its scrambled peptide in Swiss 3T3 cells. Cells treated with 
DMSO and RAD peptide seeded on FN were used as one vehicle control group, 
while  the  scrambled  peptide was used as a negative control. As shown in figure  
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Figure 4.3.3 The importance of PKCα and β1 integrin interaction in RGD-
independent cell adhesion to FN and TG-FN matrices.  
The Swiss 3T3 fibroblasts were treated with GK21 peptide (which blocks the 
interaction between the intracellular domain of β1 integrin and PKCα) and its 
scrambled control, while DMSO was used as the vehicle control. The attachment 
and spreading of Swiss 3T3 cell was analysed as introduced in the Methods 
(Section 2.2.3). Each data point represents the mean percentage of attached cells 
(cell attachment) or the mean percentage of spreading cells (cell spreading) ± 
S.D. of three separate experiments performed in triplicate. The ordinates in the 
top graphs represent the mean cell attachment expressed as mean percentage of 
DMSO-treated Swiss 3T3 cells (control) attachment to FN ± S.D., representing 
100% in the presence of RAD peptide. The mean attachment value ± S.D. was 
139 ± 1. The ordinates in the lower graphs designate the mean percentage of 
spreading cells, expressed as mean percentage of spreading on FN ± S.D. The 
mean percentage of control spreading on FN ± S.D was assessed as 75 ± 4, and 
normalized to 100%. The * symbol represents significant difference (p<0.05) 
between FN and TG-FN matrices in the presence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups. 
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Figure 4.3.3 
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Figure 4.3.4 Detection of the translocation of PKCα in the RGD-independent 
cell adhesion in Swiss 3T3 cells.   
RGD-independent cell adhesion assay was performed as introduced before in 
PKCα inhibitor Go6976-pre-treated (5μM, 1 h) Swiss 3T3 cells (Section 2.2.3 
and Section 4.2.1). 50nM PMA was used as a positive control treatment for 
PKCα activation, while DMSO was used the vehicle control treatment. Cell 
lysates were collected into membrane fraction collection buffer. Membrane and 
cytosol fractions were isolated from total 200µg protein/sample as introduced in 
Section 2.2.12. The presence of PKCα antigen was detected by using mouse 
monoclonal anti-PKCα antibody (1:1000 dilution) via Western blotting. The 
densitometric values obtained for the bands are represented in Lane 1, PMA-
treated cells seeded on FN; Lane 2, DMSO-treated cell seeded on FN in the 
presence of RAD; Lane 3, DMSO-treated cells on FN or TG-FN (Lane 4) in the 
presence of RGD; Lane 5, Go6976-treated cells FN in the presence of RAD; 
Lane 6, Go6976-treated cells on FN or FN-TG (Lane 7) in the presence of RGD. 
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Figure 4.3.4 
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4.3.3, nosignificant difference of cell attachment and spreading was found 
between DMSO vehicle control cells and scrambled peptide-treated cells in the 
presence of RAD peptide in both Swiss 3T3 cells, indicating no toxicity of these 
two peptides. RGD peptide led to 37.6% and 43.3% loss of cell attachment and 
spreading, respectively, in Swiss 3T3 cells on FN, which was restored back to 
92.8% and 86.7% by the TG-FN complex, respectively. In the presence of RAD 
peptide, GK21 peptide at the concentration of 8μM led to 21.9% and 25.8% loss 
of cell attachment and spreading in Swiss 3T3 cells seeded on FN, which could 
not be restored by the TG-FN complex. When treated with RGD peptide, only 
41.8% of cell attachment and 32.8% cell spreading were found in these 
fibroblasts on FN, only 43.5% in cell attachment and 34.3% in cell spreading on 
TG-FN, and no significant difference was found between the matrices, 
suggesting TG-FN could not compensate the loss caused by the GK21 peptide. 
The above data indicates that TG-FN mediated cell adhesion in the presence of 
the RGD peptide is dependent on the interaction between PKCα and β1 integrins.   
 
4.3.1.4 TG-FN promotes the translocation of PKCα. 
 
The translocation of PKCα indicates its activation in supporting cell adhesion. To 
investigate whether the translocation of PKCα occurs in cell adhesion on TG-FN, 
the fractions of cell cytosol and membranes were isolated and Western blotting 
was performed to detect the presence of PKCα antigen in both fractions. Serum-
starved Swiss 3T3 cells were pre-treated with 5μM PKCα inhibitor Go6976 or 
DMSO (vehicle control) for 1 h, and then cells were trypsinized and seeded on 
FN or TG-FN matrices in the presence of RAD or RGD peptide. After around 1 h 
incubation, cells were collected in membrane isolation buffer and membrane and 
cytosol fractions were isolated as introduced in Materials and Methods (Section 
2.2.12 and Section 4.2.2). RAD-treated cells on FN were used as control group, 
while cells treated with 50nM PMA were used as positive control in the presence 
of RAD peptide.  Increased PKCα in the membrane fraction was found in PMA 
control groups compared to the non-DMSO treated cells seeded on FN. The 
RGD treatment led to the decrease of PKCα translocation from cytosol to  
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Figure 4.3.5 Detection of the interaction between PKCα and syndecan-2.  
Wild type, syndecan-4 knockout, Y188L syndecan-4 mutant MEF cells were 
used in co-immunoprecipitation experiments as introduced in Section 4.2.3. After 
collection into cell lysis buffer (Section 2.2.11) and pre-cleared by using rabbit 
IgG (0.5μg/sample) and protein A beads, rabbit anti-syndecan-2 polyclonal 
antibody (0.5μg/sample) and protein A beads were used to pull down the 
syndecan-2 immuno-complex and Western blotting was then used to detected the 
presence of PKCα antigen (top image) (1:1000 dilution) within this complex 
from the different cell samples (Section 2.2.9). The IgG bands (bottom image) 
were used to represent equal protein loadings. 
 
 
 
 
 
 
 
 
Figure 4.3.5 
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Figure 4.3.6 Detection of the phosphorylation of FAK Tyr397 in the RGD-
independent cell adhesion in Swiss 3T3 cells.   
The RGD-independent cell adhesion assay was performed as introduced before 
(Section 2.2.3). 50µg/sample of total protein collected in cell lysis buffer was 
used to detect the presence of specific antigens by using specific antibodies, 
including rabbit polyclonal anti-p-Tyr397-FAK (1:1000 dilution) (a, top image) 
and mouse monoclonal anti-FAK (0.6µg/blot) (b, top image). The membranes 
were stripped and re-probed with mouse monoclonal anti-α-tubulin antibody to 
ensure the equal loading (a and b, bottom images). The densitometric values 
obtained for the bands was normalised against the values for the tubulin bands 
and represented as the mean net area value (relative FAK-397, or relative FAK) 
± S.D. from three separate experiments. Each data point was expressed as a 
percentage of the control FN level, which represents 100%. The * symbol 
indicates the statistically different values when compared to the non-treated cells 
seeded on FN. Lane 1, non-treated cells seeded on BSA; Lane 2, non-treated cell 
seeded on FN and TG-FN (Lane 3); Lane 4, RAD-treated cells FN and FN-TG2 
(Lane 5); Lane 6, RGD-treated cells on FN and TG-FN (Lane 7). 
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Figure 4.3.6a 
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Figure 4.3.6b 
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membrane, since 70% decrease of membrane PKCα was found in RGD treated 
cells on FN. The levels of PKCα translocation was 106% in the cells seeded on 
TG-FN compared to control level. Go6976 treatment resulted in a significant 
reduction of PKCα translocation in both RAD and RGD treated cells on FN, 
which could not be restored by the TG-FN complex (Figure 4.3.4). As expected, 
high levels of cytosol PKCα were discovered in the groups with low levels of 
membrane PKCα. 
 
4.3.1.5 PKCα is the potential intracellular signalling link between syndecan-
2 and syndecan-4     
 
It has been suggested that syndecan-2 can act as a downstream signalling 
molecule of syndecan-4 signalling transduction in actin cytoskeleton formation. 
In order to investigate the potential involvement of PKCα in this co-signalling 
pathway, syndecan-4 wild type, knockout, and Y188L syndecan-4 mutant MEF 
cell lysates were collected and the co-imminoprecipitation assay using anti-
syndecan-2 antibody to pull down PKCα was performed to detect the interaction 
between PKCα and syndecan-2. As shown in Figure 4.3.5, without the presence 
of syndecan-4 or the binding site for PKCα within syndecan-4 intracellular 
domain, the interaction between PKCα and syndecan-2 was significantly 
weakened, compared to that in wild type MEF cells, while IgG bands indicated 
that there was an equal amount of protein used in this experiment. These results 
suggest not only the direct interaction between syndecan-2 and PKCα, but also 
the importance of syndecan-4 in mediating this interaction process, particularly it 
suggests the initiative role of the binding of PKCα to syndecan-4 in triggering the 
downstream interaction of PKCα to syndecan-2.  
 
4.3.2 TG-FN signalling activates focal adhesion kinase 
 
4.3.2.1 The importance of p-FAK397 
 
Previous work indicated that FN-TG2 promotes the phosphorylation of FAK at 
Tyr397 in HOB cells even in the presence of RGD peptide, which suggested the 
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involvement of FAK in the signalling transduction on the FN-TG2 complex. To 
study the role of FAK, pre-serum starved Swiss 3T3 cells (16 h) were treated 
with 100μg/ml of RAD or RGD peptide and then seeded on FN or FN-TG2 
matrices. BSA (3%) in PBS, pH7.4 was used as negative control matrix, while 
cells seeded on FN matrix without peptide treatment was used as the control 
group. Cells were allowed to adhere for around 1 h, after washing adherent cells 
with PBS, pH7.4, samples were collected into cell lysis buffer. The levels of total 
and tyrosine phosphorylated forms of FAK in the samples were examined via 
Western blotting as introduced in Materials and Methods. Figure 4.3.6a presents 
the content of p-FAK397, while Figure 4.4.6b shows the levels of total FAK in the 
samples. Tubulin was used as the internal control. The sample from the cells 
seeded on BSA was used as the negative control group, as shown in Figure 4.3.6, 
a reduction of FAK397 phosphorylation can clearly be observed and the amount of 
phosphorylated FAK397 is only 8% of that of the FN control. RAD peptide 
treatment did not affect the level of p-FAK397, even though there was a slight 
increase of the amount of antigen in the samples from cell seeded on TG-FN, 
there is no statistical difference found. The RGD treatment significantly reduced 
the phosphorylation of FAK397 on FN to 10%, compared to control group. 
However TG-FN restored the level of p-FAK397 back to 83 % of the control 
level.  
 
Total levels of FAK were also investigated via Western blotting in the samples. 
The blot shows a similar level of total FAK in each group and no significant 
differenece was found between them. The level of total protein applied in 
Western blotting was normalized by the internal standard tubulin. These results 
indicated the importance of the phosphorylation of FAK397 in RGD-independent 
cell adhesion on TG-FN.    
 
4.3.2.2 The importance of p-FAK861. 
 
As introduced before, the phosphorylation of FAK at tyrosine site 861 indicates 
the activation of the ligand-independent activation of the β1 integrin signalling 
pathway. In order to investigate the involvement of this phosphorylation site,  
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Figure 4.3.7 Detection of the phosphorylation of FAK at Tyr861 in the RGD-
independent cell adhesion in Swiss 3T3 cells.   
The RGD-independent cell adhesion assay was performed as introduced before 
(Section 2.2.3). 50µg/sample of total protein collected in cell lysis buffer was 
used to detect the presence of specific antigens by using specific antibodies, 
including rabbit polyclonal anti-p-Tyr861-FAK (1:1000 dilution) (a, top image) 
and mouse monoclonal anti-FAK (0.6µg/blot) (b, top image). The membranes 
were stripped and re-probed with mouse monoclonal anti-α-tubulin antibody to 
ensure the equal loading (a and b, bottom images). The densitomertric values 
obtained for the bands was normalised against the values for the tubulin bands 
and represented as the mean net area value (relative FAK861, or relative FAK) ± 
S.D. from three separate experiments. Each data point was expressed as a 
percentage of control FN level, which represents 100%. The * symbol indicates 
the statistically different values when compared to the non-treated cells seeded 
on FN (Lane 2). Lane 1, non-treated cells seeded on BSA, Lane 2 non-treated 
cell seeded on FN, and TG-FN (Lane 3), Lane 4, RAD-treated cells FN and FN-
TG2 (Lane 5), Lane 6, RGD-treated cells on FN and TG-FN (Lane 7). 
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Figure 4.3.7a 
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Figure 4.3.7b 
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pre-serum starved Swiss 3T3 fibroblasts were seeded on FN or TG-FN for 
around 1 hour, in the presence of RGD peptide, while RAD peptide was used as 
control peptide. 3% BSA in PBS, pH7.4 acted as the negative control matrix and 
non-treated cells on FN as control group. Western blotting was performed to 
detect the antigen level of p-FAK861 and total FAK as introduced in Material and 
Methods. Figure 4.3.7 shows the level of p-FAK861. As expected in the negative 
control group, the level of p-FAK861 decreased to 13% of that of the control FN 
group, while RAD treatment did not affect the phosphorylation of FAK861 on FN, 
indicating non-toxic effect of 100μg/ml of both RAD and RGD peptide on 
phosphorylation of FAK. The TG-FN complex increased the amount of antigen, 
while no significant difference was found. RGD peptide treatment significantly 
reduced the level of p-FAK861 when the cells were seeded on FN to 8%, 
compared to control level, which was compensated by TG-FN back to 65%. No 
significant difference was observed in the levels of total FAK between each 
group via Western blotting (Figure 4.3.7). The above data suggests the 
involvement of the phosphorylation of FAK861 in the signalling transduction 
process mediated by TG-FN and the importance of the β1 integrin inside-out 
signalling pathway. 
 
4.3.3 ERK1/2 dependent signalling on TG-FN 
 
4.3.3.1 ERK1/2 inhibitor blocks the compensatory effect of TG-FN 
 
It has been reported that ERK1/2 is one the most important downstream 
molecules in the β1 integrin-relevant cell survival pathway (Yee et al., 2008). To 
investigate the potential importance of the interaction between ERK1/2 in RGD-
independent cell adhesion mediated by TG-FN, cell adhesion was performed by 
using a specific ERK1/2 inhibitor, PD98059 in Swiss 3T3 cells. As shown in 
Figure 4.3.8, the RAD treatment did not affect etiher cell attachment or spreading 
in the DMSO vehicle control (0.1% (v/v)), suggesting at the concentration of 
100μg/ml, no toxicity was found in both RAD and RGD-treated cells. In these 
fibroblasts, 35% and 29% of cell attachment and spreading was blocked,  
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Figure 4.3.8 The involvement of phosphorylation of ERK1/2 in RGD-
independent cell adhesion to FN and TG-FN matrices.  
The Swiss 3T3 fibroblasts were treated with ERK1/2 inhibitor PD98059 (10μM, 
1 h) and the cell adhesion assay was performed as described previously (Section 
4.2.1). The attachment and spreading of Swiss 3T3 cell was analysed as 
introduced in Methods (Section 2.2.3). Each data point represents the mean 
percentage of attached cells (cell attachment) or the mean percentage of spread 
cells (cell spreading) ± S.D. of three separate experiments performed in triplicate. 
The ordinates in the top graphs represent the mean cell attachment expressed as 
mean percentage of DMSO-treated Swiss 3T3 cells (control) attachment to FN ± 
S.D., presenting 100%. The mean attachment value ± S.D was 200 ± 5. The 
ordinates in the lower graphs designate the mean percentage of spreading cell, 
expressed as mean percentage of spreading on FN ± S.D. The mean percentage 
of control spreading on FN ± S.D was assessed as 88 ± 1, and normalized to 
100%. The * symbol represents significant difference (p<0.05) between FN and 
TG-FN matrices in the presence and/ or absence of RAD or RGD peptide when 
compared to the non-treated cells seeded on FN. The # symbol represents 
significant difference (p<0.05) between individual groups. 
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Figure 4.3.8 
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Figure 4.3.9 Detection of the phosphorylation of ERK1/2 in the RGD-
independent cell adhesion in Swiss 3T3 cells.   
The RGD-independent cell adhesion assay was performed as introduced before 
(Section 2.2.3). 50µg/sample of total protein collected in cell lysis buffer was 
used to detect the presence of specific antigens by using specific antibodies, 
including rabbit polyclonal anti-p-ERK1/2 (1:1000 dilution) (a, top image) and 
mouse monoclonal anti-ERK1/2 (0.6µg/blot) (b, top image). The membranes 
were stripped and re-probed with mouse monoclonal anti-α-tubulin antibody to 
ensure the equal loading (a and b, bottom images). The densitometric values 
obtained for the bands was normalised against the values for the tubulin bands 
and represented as the mean net area value (relative p-ERK1/2, or relative 
ERK1/2) ± S.D. from three separate experiments. Each data point was expressed 
as a percentage of control FN level, which represents 100%. The * symbol 
indicates the statistically different values when compared to the FN control. Lane 
1, non-treated cells seeded on BSA, Lane 2 non-treated cell seeded on FN, and 
TG-FN (Lane 3), Lane 4, RAD-treated cells FN and FN-TG2 (Lane 5), Lane 6, 
RGD-treated cells on FN and TG-FN (Lane 7). 
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Figure 4.3.9a 
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Figure 4.3.9b 
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respectively in the presence of PD98059, suggesting the involvement of ERK1/2 
in the cell adhesion process. When treated with RGD peptide, a further 38% 
inhibition of cell attachment and 65% of spreading took place on FN. Most 
importantly, the inhibitory effect of PD98059 significantly inhibited the 
compensation of TG-FN, compared to the DMSO-treated cells (p<0.05). As 
shown in Figure 4.3.8, in the presence of RGD peptide, the compensation 
dropped from 87% to 57% in cell attachment and 82% to 22% in cell spreading, 
suggesting that TG-FN is dependent on ERK1/2 signalling to rescue cells from 
RGD-independent cell adhesion.   
 
4.3.3.2 TG-FN compensates the phosphorylation of ERK1/2 in the presence 
of the RGD peptides  
 
The potential influence of RGD on the phosphorylation of ERK1/2 was further 
investigated by detecting the phosphorylation of ERK1/2 in HOB cells seeded on 
FN or TG-FN matrices via Western blotting (as described in Section 2.2.8). 
Figure 4.3.9a represents the p-ERK1/2 levels, while figure 4.3.9b shows the total 
level of ERK1/2 in fibroblast cells on BSA, FN or TG-FN in the presence of 
RAD or RGD peptide. BSA was used as a negative control and led to 80% 
reduction in ERK1 and 50% in ERK2. Confirming the cell adhesion results, no 
effect of RAD peptide in ERK1/2 phosphorylation was obtained compared to 
non-treated control groups. RGD peptide treatment reduced the levels of ERK1 
and ERK2 down to ~40% in both ERK1 and ERK2, compared to control cells on 
FN. Even though no significant difference was discovered between cells on TG-
FN and FN in the presence of RAD peptide, TG-FN restored the level of p-
ERK1/2 back to around 90% in the RGD-treated cells.  
 
Western blotting was also performed in parallel to study the effect of RGD 
inhibition on the total levels of ERK1/2 in the same protein samples. As shown 
in Figure 4.3.9, RGD treatment did not affect the total levels of ERK1/2 
compared to RAD treatment, and no difference was found between the FN and 
the TG-FN samples. The above data suggests that the compensatory effect of 
TG-FN is dependent on the phosphorylation of ERK1/2.  
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3.3.4 β1 integrin inside-out signalling is involved in the signal transduction 
mediated by TG-FN 
 
3.3.4.1 The effect of β1 integrin functional blocking antibody on the 
phosphorylation of FAK 
 
FAK is the downstream signalling molecule in the β1 integrin pathway. The 
phosphorylation of Tyr861 and Tyr397of focal adhesion kinase (FAK) indicates the 
activation of the signal transduction mediated by β1 integrins. It has been proven 
that the phosphorylation of Tyr861 is independent of the need for integrin ligand 
binding, and is a key step in the mediation of the inside-out signalling pathway of 
β1 integrin unlike the phosphorylation of Tyr397which indicates the activation of 
FAK in the cells adherent to their cell binding sites within the ECM (Shi and 
Boettiger, 2003). To investigate the potential function of β1 integrin functional 
blocking antibody— HMβ1-1 (Noto, et al., 1995), p-Tyr861 and p-Tyr397 were 
used as two parameters to study which signalling pathway of β1 integrin is 
affected by this antibody. In HMβ1-1 treated Swiss 3T3 cells, the antibody 
inhibited the phosphorylation at Tyr397 compared to isotype antibody treated cells 
on FN matrix, while the phosphorylation of Tyr861 was not affected (Figure 
4.3.10). This suggests that the effect of HMβ1-1 is to block the outside-in 
signalling pathway, but not the inside-out signal transduction of β1 integrin, as 
such it inhibits cell adhesion on FN. 
 
3.3.4.2 TG-FN compensates the RGD-independent cell adhesion through β1 
integrin inside-out signalling pathway  
 
After confirming the function of HMβ1-1 in blocking the outside-in signalling 
pathway of β1 integrin, cell adhesion assay was performed on FN and TG-FN 
matrices. At the concentration of 25μg/ml, HMβ1-1 treatment led to a 46% 
decrease in cell attachment and blocked 56% of cell spreading on FN compared 
to  non-treated  cells  seeded  on  FN, while  its  isotype  control  antibody did not  
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Figure 4.3.10 Detection of the phosphorylation of FAK at Tyr397 and Tyr861 
in the RGD-independent cell adhesion of HMβ1-1-treated Swiss 3T3 cells.   
The RGD-independent cell adhesion assay was performed as introduced before 
(Section 2.2.3) by using β1 integrin functional blocking antibody 25μg/ml 
HMβ1-1 pre-treated-Swiss 3T3 cells (1 h). 50µg/sample of total protein collected 
in cell lysis buffer was used to detect the presence of specific antigens by using 
specific antibodies, including rabbit polyclonal anti-p-Tyr397-FAK (1:1000), 
rabbit polyclonal anti-p-Tyr861-FAK (1:1000 dilution), and mouse monoclonal 
anti-FAK (0.6µg/blot). The membranes were stripped and re-probed with mouse 
monoclonal anti-α-tubulin antibody to ensure the equal loading. Lane 1, non-
treated cells seeded on BSA, Lane 2 Isotype negative control antibody-treated 
cell seeded on FN, and TG-FN (Lane 3), Lane 4, HMβ1-1-treated cells FN and 
TG-FN (Lane 5). 
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Figure 4.3.11 The involvement of inside-out signalling of β1 in RGD-
independent cell adhesion to FN and TG-FN matrices. 
The Swiss 3T3 fibroblasts were treated with 25μg/ml of β1 integrin functional 
blocking antibody HMβ1-1 for 1 h and cell adhesion assay was performed as 
described previously (Section 2.2.3). The isotype control antibody was used as a 
negative control treatment. The attachment and spreading of Swiss 3T3 cell was 
analysed as introduced in the Methods (Section 2.2.3.4). Each data point 
represents the mean percentage of attached cells (cell attachment) or the mean 
percentage of spread cells (cell spreading) ± S.D. of three separate experiments 
performed in triplicate. The ordinates in the top graphs represent the mean cell 
attachment expressed as mean percentage of non-treated Swiss 3T3 cells 
(control) attachment to FN ± S.D., presenting 100%. The mean attachment value 
± S.D. was 135 ± 5. The ordinates in the lower graphs designate the mean 
percentage of spreading cell, expressed as mean percentage of spreading on FN ± 
S.D. The mean percentage of control spreading on FN ± S.D was assessed as 80 
± 2, and normalized to 100%. The * symbol represents significant difference 
(p<0.05) between FN and TG-FN matrices in the presence and/ or absence of the 
antibodies when compared to the non-treated cells seeded on FN. The # symbol 
represents significant difference (p<0.05) between individual groups. 
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show any effect on either cell attachment or spreading. This confirms the effect 
of HMβ1-1 on cell adhesion is not due to its toxicity.  In contrast cells seeded on 
TG-FN matrix restored the loss of cell attachment and spreading back to ~90% 
(Figure 4.3.11).  It has been suggested that HMβ1-1 exerts its blocking effect by 
inhibiting the signalling transduction of the β1 integrin outside-in pathway (Noto, 
et al., 1995), which has been confirmed (see above) by Western blotting of the 
phosphorylation of p-FAK397 and p-FAK861. Hence the compensatory effect of 
TG-FN in the presence of this antibody was understood to be dependent on the 
inside-out signalling of β1 integrins in an outside-in pathway-independent 
manner.  
 
4.3.5 ROCK is a downstream molecule in the TG-FN signalling pathway 
 
Previous data indicated that syndecan-2 is important for TG-FN to mediate 
RGD-independent cell adhesion. To further investigate this signalling pathway, 
ROCK, one of the important intracellular molecules in syndecan-2 signal 
transduction, was studied by using its specific inhibitor—Y27632 in the RGD-
independent cell adhesion assay. Fibroblasts cells were pre-treated with 10µM 
Y27632 for 30 min and then cell adhesion in the presence of RGD or RAD 
peptide was performed as introduced in Section 2.2.3. DMSO was used as the 
vehicle control, while non-treated cells on FN were used as the control group. As 
shown in Figure 4.3.12, at the concentration of 0.1% (v/v), on FN no significant 
difference in cell adhesion and spreading was observed between the DMSO 
group and control group in Swiss 3T3 cells, suggesting no toxicity of DMSO on 
both cell lines, meanwhile RAD treatment did not show toxic effects on both cell 
lines, as shown in previous results.  Y27632 treatment led to 37% and 80% loss 
of cell attachment and spreading, respectively, on FN in these fibroblasts, 
suggesting inhibition of ROCK affected cell spreading more than cell attachment 
on FN. In the presence of RGD peptide, Swiss 3T3 cells lost a further 40% in cell 
attachment and non-spreading cells were found in this group. Unlike the 
significant compensatory effect of this matrix complex in the non-treated and 
DMSO-treated cells, TG-FN could not compensate the loss of either cell 
attachment or spreading in Swiss 3T3 cells in the presence of ROCK inhibitor 
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Y27632, since no significant difference was found between the cells seeded on 
FN and TG-FN matrices (p>0.05). This data suggests that the TG-FN complex 
depends on the intracellular signalling molecule ROCK to exert its compensatory 
effect on RGD-independent cell adhesion. 
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Figure 4.3.12 The involvement of ROCK in RGD-independent cell adhesion 
to FN and TG-FN matrices.  
The Swiss 3T3 fibroblasts were treated with ROCK inhibitor Y27632 and cell 
adhesion was performed as described previously (Section 4.2.1). The attachment 
and spreading of Swiss 3T3 cell were analysed as introduced in Methods 
(Section 2.2.3). Each data point represents the mean percentage of attached cells 
(cell attachment) or the mean percentage of spread cells (cell spreading) ± S.D. 
of three separate experiments performed in triplicate. The ordinates in the top 
graphs represent the mean cell attachment expressed as mean percentage of 
DMSO-treated Swiss 3T3 cells (control) attachment to FN ± S.D., presenting 
100%. The mean attachment value ± S.D. was 140 ± 2. The ordinates in the 
lower graphs designate the mean percentage of spreading cell, expressed as mean 
percentage of spreading on FN ± S.D. The mean percentage of control spreading 
on FN ± S.D was assessed as 83 ± 3, and normalized to 100%. The * symbol 
represents significant difference (p<0.05) between FN and TG-FN matrices in 
the presence and/ or absence of RAD or RGD peptide when compared to the 
non-treated cells seeded on FN. The # symbol represents significant difference 
(p<0.05) between individual groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Illustration removed for copyright restrictions 
Chapter 4: The characterisation of intracellular signalling molecules in the RGD-
independent cell adhesion process mediated by TG-FN complex 
 
204 
 
 
 
 
 
 
 
 
 
Figure 4.3.12 
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 4.4 Discussion 
 
The previous chapter demonstrated that cell surface receptors β1 integrin and 
syndecan-4/2 are crucial for the TG-FN complex to rescue the cells from RGD-
dependent loss of cell adhesion. This chapter aimed to further investigate which 
intracellular signalling molecule or molecules are involved in this signal 
transduction process.  
 
As one of the most important intracellular signalling molecules in syndecan-4 
and β1 integrin co-signalling, the potential role of protein kinase C α (PKCα) was 
first investigated by using PKCα inhibitor Go6976 in cell adhesion assays. This 
inhibitor not only significantly blocked the cell adhesion process on FN, but also 
inhibited the compensatory effect of TG-FN in RGD-independent cell adhesion 
and spreading. This was the first indication that PKCα could be the intracellular 
signalling molecule in TG-FN mediated cell adhesion. This part of work was 
further explored by using special syndecan-4 mutant MEF cells, in which the 
syndecan-4 knockout cells were transfected with a syndecan-4 cDNA with the 
PKCα binding site mutated within the syndecan-4 intracellular domain (Bass et 
al., 2007b). As expected, without the support for the intracellular interaction 
between PKCα and syndecan-4, TG-FN lost its compensatory effect completely 
on RGD peptide-treated Y188L MEF cells, further confirming that PKCα 
participates in the signal transduction in cell adhesion on TG-FN. As a crucial 
link between syndecan-4 and β1 integrins, PKCα can bind to the cytoplasmatic 
domain of β1 integrins once it is activated and translocated from the cytosol to 
membrane. In order to prove that PKCα can directly interact with β1 integrins, 
which plays an important role in mediating RGD-independent cell adhesion on 
TG-FN, a specially designed GK21 peptide that mimics the PKCα binding site 
within β1 integrin cytoplasmatic domain (Parsons et al., 2002), was used in cell 
adhesion assays. In the peptide-treated cells, TG-FN failed to compensate the 
loss of cell attachment and spreading induced by GK21, suggesting not only the 
importance of PKCα, but also the interaction between PKCα and β1 integrins for 
TG-FN to exert its compensatory effect on RGD peptide induced loss of cell 
adhesion. As an indication of its activation, PKCα translocates from the cytosol 
Chapter 4: The characterisation of intracellular signalling molecules in the RGD-
independent cell adhesion process mediated by TG-FN complex 
 
206 
 
to membrane, where it binds to β1 integrins. In Western blotting by using PKCα 
specific antibody, PKCα antigen could be detected in both cytosol and membrane 
fractions, while in non-treated cells seeded on TG-FN, more signal was detected 
in membrane fractions compared to the cells on FN, suggesting that TG-FN 
activates PKCα signalling pathway and in turn promotes its translocation. This 
effect of TG-FN was inhibited by the treatment of PKCα inhibitor Go6976, 
which further confirmed the cell adhesion results and provided solid proof of the 
crucial role of PKCα. Even though it has been suggested that syndecan-2 is the 
downstream cell surface receptor for syndecan-4, there is no proof for this 
hypothesis yet. By using syndecan-4 knock out and Y188L mutant cells in co-
immunoprecipitation assays, the decreased interaction between PKCα and 
syndecan-2 was detected in these two cells compared to wild type MEF cells, 
which for the first time demonstrates that syndecan-4 regulates the interaction 
between PKCα and syndecan-2 and suggested that PKCα is also a crucial link 
between syndecan-4 and syndecan-2 signalling.  
 
Focal adhesion kinase (FAK) is an important kinase in β1 integrin signalling in 
regulating focal adhesion and actin cytoskeleton formation. Once activated by β1 
integrin signal, FAK can be autophosphorylated at Tyr397, which will leads to the 
further phosphorylation at Tyr861, Tyr925, etc. RGD peptide treatment led to 
significant loss of p-Tyr397 in cells seeded on FN compared to non- or RAD-
treated cells, which could be restored in the cells on TG-FN matrix, suggesting 
this complex compensates RGD-independent cell adhesion in a FAK-dependent 
manner. The compensated phosphorylation of Tyr861 can also be detected in 
RGD-treated cells on the TG-FN matrix. The interesting discovery of RGD-
independent p-Tyr861 in TG-FN matrix offered more information, considering 
that p-Tyr861 indicates the activation of the ligand-independent cell adhesion 
process mediated by β1 integrins (Shi and Boettiger, 2003), suggesting the 
activation of β1 inside-out signalling pathway by TG-FN mediated cell adhesion.  
 
The improvement of cell adhesion and spreading mediated by TG-FN in an 
RGD-independent manner suggests the possibility that this matrix can protect the 
cell from cell adhesion- related apoptosis (named anoikis). In order to investigate 
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the cell survival pathway mediated by β1 integrins, the role of its downstream 
signalling molecule ERK1/2 was studied by using its specific inhibitor PD98059. 
As expected, PD98059 significantly inhibited the compensatory effect of TG-FN 
in RGD-treated fibroblasts, which offered the first indication of the involvement 
of ERK1/2 in the TG-FN signalling pathway. The importance of ERK1/2 was 
further proven by detecting the phosphorylation of ERK1/2 in RGD-treated and 
control cells on FN or TG-FN matrices via Western blotting. The p-ERK1/2 
signal was significantly decreased in RGD-treated cells on FN, which was 
restored by the TG-FN complex, indication that ERK1/2 regulates RGD-
independent cell survival pathway mediated by the TG-FN matrix complex.  
 
The role of p-FAK861, as an indicator of the activation of the inside-out signalling 
in β1 integrin signalling pathway, has been introduced above. The compensation 
of p-FAK861 by TG-FN suggested that this complex could exert its function in 
mediating cell adhesion through the inside-out signal transduction of β1 integrins 
activated by syndecan-4. In order to further confirm this hypothesis, a β1 integrin 
functional blocking antibody-HMβ1-1, which has been suggested to block the β1 
integrin outside-in signalling (Noto et al., 1995), was used in cell adhesion assays 
on FN and TG-FN matrices. In order to confirm the effect of HMβ1-1 on the β1 
integrin signalling, the phosphorylation of Tyr861 and Tyr397 were investigated 
via Western blotting. This functional blocking antibody inhibited p-Tyr397, while 
the p-Tyr861 was not significantly affected, which further confirmed that HMβ1-1 
blocked cell adhesion via inhibiting the β1 integrin outside-in signalling, but not 
the inside-out one. Unlike the cells on FN, the cell adhesion and spreading 
process on TG-FN was not affected by the HMβ1-1 treatment, suggesting that 
TG-FN compensates RGD-independent cell adhesion via activating β1 integrin 
inside-out signalling triggered by its interaction with syndecan-4.  
 
As a well-known downstream signalling molecule in syndecan-2 signal 
transduction, the potential involvement of ROCK was investigated by using its 
specific inhibitor Y27632 in the RGD-independent cell adhesion assay. Y27632 
completely blocked the compensation of TG-FN in RGD-treated fibroblasts, 
suggesting ROCK is involved in cell adhesion on TG-FN. Interestingly, this 
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inhibitor affected cell spreading process more significantly than cell adhesion on 
both FN and TG-FN, further confirming the importance of syndecan-2 in 
regulating cell spreading and actin cytoskeleton formation.  
 
To sum up the above observation, this chapter’s work demonstrates that the 
intracellular signalling molecules PKCα, FAK, ERK1/2, and ROCK are crucial 
for TG-FN to exert its compensatory effect on RGD-induced loss of cell 
adhesion. Importantly PKCα is likely to be the essential link between syndecan-4 
and syndecan-2 in activating β1 integrin inside-out signalling pathway mediated 
by TG-FN.    
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Chapter 5: Fibronectin deposition mediated by TG-FN matrix 
 
5.1 Introduction 
 
The importance of FN matrix for the survival and functioning of adhesion-
dependent cells, including cell adhesion, growth, development, differentiation 
and migration, has been very well documented (Kaspar et al., 2006).  Cells 
adherent to FN matrix can in turn moderate the structure and deposition of FN 
molecules, also known as FN fibril assembly. This is initiated by the interaction 
between cell surface receptors integrins and matrix FN. Cell surface integrin-
bound FN is deposited into matrix with the association of actin skeleton 
formation. It has been reported that the above process of FN deposition depends 
on the involvement of different cell surface receptors and intracellular signalling 
molecules. α5β1 integrin is one of major cell surface receptors that has been 
proven to  participate in FN assembly. Interacting with soluble or secreted FN on 
the cell surface, clustered α5β1 integrin can promote formation of short FN 
fibrils and link FN to the actin skeleton network through its intracellular domain. 
Other cell surface receptors (e.g. syndecan-2) are also suggested to be involved 
in FN deposition via association with α5β1 integrin, meanwhile intracellular 
molecules, PKC (Lin et al., 2002) and RhoA (Zhong, et al., 1998) also 
participate in this process.    
 
The involvement of cell surface TG2 in fibronectin fibril formation and 
deposition has been previously documented (Akimov, et al, 2001), where it was 
shown that the enzyme cooperates with but cannot substitute for α5β1 integrin in 
fibronectin assembly. Transamidating activity was not thought to be involved in 
this mechanism. In contrast in other reports the crosslinking activity of TG2 was 
reported to be important in FN assembly and deposition (Verderio et al., 1999; 
Yuan et al., 2007). Previous work demonstrated the importance of TG-FN in 
restoring RGD-independent cell adhesion, while the long-term effect of TG-FN 
in rescuing RGD-induced anoikis has not been demonstrated yet. In this chapter 
the potential role of TG-FN in regulating FN fibril assembly process is 
investigated.  
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The aim of this chapter is to further study the influence of TG-FN matrix in 
regulating the matrix turnover process, such as FN fibril formation in the 
presence of RGD peptides. By using fluorescence staining of biotin-labelled 
exogenous FN, confocal microscopy was used to detect the deposited FN matrix 
by the cells seed on FN or TG-FN matrix. Certain type of cell surface knockout 
MEF cells, binding site mutant cells and the siRNA treatment were used in the 
experiments to investigate the involvement of these receptors in the FN 
deposition by the cells seeded on FN-TG matrix.    
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5.2 Methods 
 
5.2.1 Vinculin staining 
 
Sub-confluent cells were serum-starved for 16 h and harvested. After 20 min 
treatment with RAD or RGD peptide, cells were seeded in 8-well glass chamber 
slides (8×104 cells/well) previously coated with FN or TG-FN and allowed to 
attach and spread for 1 h. Cells were fixed and permeablized as described 
previously (Section 2.2.3.2). For staining of vinculin, cells were blocked in PBS 
buffer supplemented with 3% (w/v) heat-inactivated BSA and then incubated 
with mouse anti-vinculin antibody (Sigma-Aldrich) in blocking buffer for 2 h, 
followed by 2 h incubation with FITC-conjugated anti-mouse secondary 
antibody (Dako). Coverslips were mounted with Vectashield mounting medium 
and using constant PMT and section depth settings 9 random fields/ samples 
were captured by a Zeiss LSM510 laser confocal microscopy using the Zeiss 
LSM Image Browser.  
 
5.2.2 Biotin-labelled FN 
 
Biotinylated FN prepared according to manufacturer’s protocol. 1 mg/ml of 
human plasma fibronectin (2.2μM (Merck, UK)) was incubated with 22μM 
Sulfo-NHS-LC-Biotin (Peirce, UK) (ratio 1:10) at room temperature for 30 min. 
Biotin-FN solution was removed by dialysis in dialysis buffer (PBS, pH7.4) at 
4ºC for 24 h. The concentration of biotinylated FN solution was determined by 
the Lowry Method (Section 2.2.7). Meanwhile the labelling effect was studied 
via Western blotting by using Extr-avidin conjugated antibody and anti-FN 
antibody to detect biotinylated FN and FN protein, respectively. Untreated 
human plasma FN was used as the internal standard (Section 2.2.8-2.2.10).   
 
5.2.3 FN staining 
 
A monolayer of cells on FN or TG-FN with RAD or RGD treatment was 
prepared as introduced in Section 2.2.3.1. Following a 1 h incubation, 50nM 
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exogenous biotinylated-FN was added into fresh serum free medium. After 
different time courses of incubation, fixed cells (Section 2.2.3.2) were blocked 
with 3% (w/v) heat-inactivated BSA in PBS pH7.4 and then incubated with 
1μg/ml Cy5-streptavidin (Jackson Immno Research) for 2 h at 37ºC. After 
washing 5 times in PBS, pH7.4, the slides were mounted with Vectashield 
mountant (Vector Laboratories) and examined by confocal fluorescence 
microscopy (Zeiss).  
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5.3 Results 
 
5.3.1 TG-FN promotes the loss of cell adhesion formation caused by the 
RGD peptides  
 
It has been well documented that vinculin is one of the major proteins in focal 
adhesion. In order to investigate the role of TG-FN in focal adhesion formation, 
immunofluorescence staining of vinculin was performed by using wild type MEF 
cells. After RAD or RGD treatment, MEF cells were seeded onto FN or TG-FN 
matrices for 1 h. After blocking with 3% (w/v) BSA in PBS, pH7.4 for 30 min, 
the cells were incubated with anti-vinculin antibody and then FITC-conjugated 
secondary antibody. Immunofluorescence signals were detected using the 
confocal microscope, as described in Section 2.2.4. As shown in Figure 5.1, more 
vinculin is present at focal contacts detected in the cells on TG-FN complex 
compared to the FN matrix in the presence of RAD peptide. On the FN matrix, 
RGD peptide reduced the presence of vinculin in focal adhesions and the cells 
remained roundish morphologically. TG-FN restored the formation of focal 
adhesions inhibited by the RGD peptide treatment. This data indicates TG-FN 
can compensate the loss of focal adhesions induced by RGD peptides.  
 
5.3.2 Detection of biotinylated-FN  
 
After biotinylation and dialysis, Western blotting was performed to detect biotin-
labelled FN protein by using both anti-human FN and Extra-avidin conjugated 
antibody. The Western blots displayed in Figure 5.3.2 shows an SDS-PAGE (3% 
(w/v) polyacrylamide stacking gel and a 5% (w/v) resolving gel) separation. 
Human plasma FN was used as standard marker. Biotinylated FN was detected 
by using Extr-avidin conjugated antibody at molecular weight of 220kDa, 
meanwhile FN protein was detected by using anti-human FN antibody, no 
difference was observed between biotin-labelled FN and standard FN molecule, 
suggesting that biotinylation does not affect the molecular weight of FN 
molecules.  
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Figure 5.3.1 TG-FN compensates the loss of focal adhesion formation caused 
by RGD peptide.  
The focal adhesion was stained as described in Section 5.2.1. 4×104 cells/ well of 
wild type MEF cells were seeded onto FN or TG-FN matrices for 1 h in the 
presence of RAD or RGD peptide. After fixation and blocking, the cells were 
incubated with anti-vinculin antibody (1:200 dilution) for 2 h and FITC-
conjugated anti-mouse secondary antibody (1:200 dilution) for 2 h at 37ºC. The 
slides were mounted with Vectashield mounting medium and using constant 
PMT and section depth settings 9 random fields/sample were captured by Zeiss 
LSM510 laser confocal microscopy using Zeiss LSM Image Browser.  
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Figure 5.3.2 Detection of biotinylated FN molecule via Western blotting  
Biotinylated FN solution was prepared as described in Section. Briefly, 2.2μMof 
FN solution in PBS was incubated with 22μM Sulfo-NHS-LC-Biotin for 30 min 
at room temperature. The solution was dialysed in PBS, pH7.4 for 24 h and 
protein concentration was determined via Lowry Method. Western blotting was 
performed to detect biotinlylated FN and FN antigens. In figure 5.3.2, the upper 
blot shows biotinylated FN (by using Extr-evidin conjugated antibody, 1:2000 
dilution), while the bottom blot represents the FN protein antigen by using anti-
FN antibody (1:2000 dilution and secondary antibody 1:2000 dilution). Lane 1, 
biotinylated FN and Lane 2, human plasma FN standard.  
 
 
 
 
 
 
 
 
 
 
Figure 5.3.2 
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5.3.3 TG-FN restores the loss of FN deposition induced by the RGD peptide 
treatment 
 
To study the potential involvement of TG-FN in FN matrix deposition, biotin-
labelled FN was used for incubation with MEF cells treated with RAD or RGD 
peptide on FN or TG-FN matrices, while different time courses were applied to 
detect the time-dependent (1-6 h) effect of TG-FN on FN assembly as introduced 
in Section 5.2.3. In Figure 5.3.3, the biotin-labelled FN was detected. In RAD 
peptide-treated cells, TG-FN started to promote FN deposition within 1 h 
incubation, which increased the FN fibril formation in a time-dependent manner, 
compared to FN alone. With increasing time, more well-organized FN fibrils 
around and over the cells were observed in the TG-FN groups. Unlike the control 
cells with RAD treatment, RGD peptide inhibited the formation of FN fibrils and 
biotin-labelled FN which remained scattered around the cell surface. In longer-
term incubations, even though there was FN deposition, the FN matrix was 
randomly deposited with short and non-organized fibrils. Unlike on the FN 
matrix, cells seeded on TG-FN complex restored the FN fibril assembly in the 
presence of RGD peptide, and the FN deposition increased in a time-dependent 
manner, which agrees with the results obtained from cells treated with RAD 
peptide. And well-formed FN fibril network was observed in these groups on 
TG-FN at 6 h incubation with the cells, suggesting the importance of TG-FN in 
regulating FN deposition in an RGD-independent manner.   
 
5.3.4 The crucial role of PKCα in FN deposition mediated by TG-FN 
 
Previous work suggested that PKC is involved in the FN deposition process (Lin 
et al., 2002). In order to investigate the potential involvement of PKCα in FN 
deposition mediated by TG-FN, GK21 peptide (which blocks the interaction 
between PKCα and the intracellular domain of β1 integrins) and the syndecan-4 
Y188L mutant MEF cells (the PKCα binding site mutant in syndecan-4 
intracellular domain) were used in the FN fibril formation assay on FN or TG-FN 
matrices. After 1 h incubation on FN or TG-FN, the GK21 peptide pre-treated 
wild type MEF,  
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Figure 5.3.3 TG-FN restores the loss of FN deposition induced by RGD 
peptide. 
6×104 cells/ well wild type MEF cells were seeded into FN or TG-FN coated 
chamber slides in the presence of RAD or RGD peptide. After 1 h incubation, the 
monolayer of cells were washed once with serum free medium and then 
incubated with 50nM biotinylated FN for 1 h, 3 h, and 6 h, respectively. At the 
end of each incubation and fixation of the cells with 3.7% paraformaldehyde  in 
PBS, pH 7.4, following 30 min blocking in 3% BSA in PBS, pH 7.4, biotinylated 
FN was stained with 1μg/ml Cy5-streptavidin in 3% heat-inactivated BSA in 
PBS, pH 7.4. Slides were mounted with Vectashield mountant (Vector 
Laboratories) and examined by confocal fluorescence microscopy (Leica 
Lasertechnik). 
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1 
h
3 
h
6 
h
RAD RGD
FN                         TG-FN FN                        TG-FN
 
Chapter 5: Fibronectin deposition mediated by TG-FN matrix 
 
219 
 
 
 
 
 
 
Figure 5.3.4 TG-FN mediates FN deposition via PKCα- dependent signalling 
pathway.  
Wild type MEF cells were pre-treated with 8μM GK21 peptide for 1 h to block 
the interaction of PKCα and the β1 integrin intracellular domains. Wild type 
MEF, Y188L (PKCα-binding domain mutant syndecan-4 MEF cells) and GK21 
peptide-treated wild type MEF cells were seeded onto FN or TG-FN matrices at 
the density of 6×104 cells/ well and allowed to adhere for 1 h. 50nM biotinylated 
FN was added to monolayer of cells in serum free medium and incubated for 6 h. 
Following washing, fixation, and blocking procedures, deposited FN was stained 
by using Cy5-streptavidin (1μg/ml) for 1 h and the mounted slides with 
Vectashield mountant were visualized by confocal microscopy.  
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Y188L MEF and wild type MEF cells were incubated with 50nM exogenous 
biotinylated-FN for 6 h and then FN deposition was detected via fluorescence 
staining. As shown in Figure 5.3.4, wild type MEF cells on FN matrix started to 
organize the FN matrix after 6 h incubation, while more well-organized FN 
fibrils were observed in the group of cells seeded on the TG-FN complex. Unlike 
the wild type cells, GK21 peptide treatment and Y188L mutant cells could not 
deposit a FN matrix and biotin-labelled FN was in the main deposited around the 
cell surface, suggesting the importance of PKCα in the FN deposition process. 
Most importantly, TG-FN could not compensate the FN fibril formation in the 
GK21-treated or the Y188L syndecan-4 mutant cells. The above data suggests 
that PKCα is the crucial link in FN deposition process. The loss of increased FN 
deposition in cells seeded on TG-FN suggested that the TG-FN complex 
promotes FN deposition process through a PKCα-dependent pathway. 
Meanwhile the potential involvement of β1 integrins and syndecan-4 was 
suggested since it has been proved in previous work that PKCα links the 
signalling pathway of these two cell surface receptors—β1 integrin and 
syndecan-4.  
 
5.3.5 The importance of α5β1 integrin in FN deposition regulated by TG-FN 
 
By using GK21 peptide-treated MEF cells, it is suggested that TG-FN promotes 
FN deposition via a PKCα signalling pathway mediated by interaction between 
PKCα and β1 integrin. To investigate the roles of α5 and β1 integrins, the FN 
deposition assay was performed by using α5 and β1 integrin null MEF cells. 
Monolayers of cells on FN or TG-FN matrices were prepared following a 1 h 
incubation of above cells on these matrices. 50nM exogenous biotinylated FN 
was then added into each group and incubated with the cells for 16 h, 
immunofluorescence was detected by confocal microscopy. Figure 5.3.5 shows 
that in wild type cells, well-organized FN fibrils were deposited by the cells 
seeded on both FN and TG-FN matrices. Without the presence of α5 or β1 
integrins, even after long-term incubation (16 h), the cells still could not deposit 
well-organized  FN  fibrils,  compared  to  the  wild  type  cells,  only  randomly  
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Figure 5.3.5 α5 and β1 integrins are crucial for TG-FN to compensate RGD-
independent FN deposition.  
Wild type, β1 integrin null MEF and α5 null EA5 fibroblasts were seeded onto 
FN or TG-FN matrices at the density of 6×104 cells/ well for 1 h to obtain the 
monolayer of above cells. 50nM biotin-labelled FN in serum free medium was 
incubated with cells for 16 h. The slides were prepared as introduced in Section 
5.2.3 and visualized by confocal microscopy.  
 
 
 
 
 
 
 
Figure 5.3.5 
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Figure 5.3.6 The importance of syndecan-4 in FN deposition mediated by 
TG-FN complex.  
Monolayers of wild type and syndecan-4 null MEF cells were prepared as 
introduced before (Section 5.2.3). 50nM biotinylated FN was used to incubate 
with the cells on FN or TG-FN matrices. After 6 h incubation, the deposited 
biotin-labelled FN was staining by using Cy5-streptavidin (1μg/ml) and 
visualized by confocal microscopy as introduced in Section 5.2.3. 
 
 
 
Figure 5.3.6 
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deposited FN matrices was observed in those groups, while in EA5 α5 null MEF 
cells, biotin-labelled FN was discovered only around the periphery of cells . No 
difference was observed between the null cells seeded on FN and TG-FN 
matrices, indicating TG-FN could not compensate the loss of FN deposition 
caused by the absence of cell surface receptors α5 and β1 integrins. These results 
suggest that the FN deposition process mediated by TG-FN is dependent on cell 
surface receptor α5β1 integrin.    
 
5.3.6 TG-FN mediates FN deposition in a syndecan-4-dependent manner 
 
Previous data suggested that PKCα, as a downstream signalling molecule in 
syndecan-4 pathway, is important for TG-FN to restore the RGD-independent 
cell adhesion and FN deposition process. To investigate the potential role of 
syndecan-4 in the above process, syndecan-4 null MEF cells were incubated with 
biotinylated FN and after 6 h incubation, FN deposited in ECM was visualized 
via immunofluorescence staining. As shown in Figure 5.3.6, after a 6 h 
incubation, wild type MEF cells deposited well-organized FN fibrils on the FN 
matrix, but cells on TG-FN produced more FN. Unlike in the wild type cells, no 
well-organized FN fibrils were found in syndecan-4 null MEF cells, randomly 
deposited FN was found and the majority of biotin-labelled FN still found around 
the periphery of cells. This result indicates the involvement of syndecan-4 in 
mediating cell-related FN fibril formation on TG-FN matrix.  
 
5.3.7 Cell surface syndecan-2 is required by TG-FN in regulating FN 
deposition  
 
The role of syndecan-2 in FN deposition has been demonstrated. Previous work 
also suggested that the inhibition of syndecan-2 expression significantly reduced 
the compensatory effect of TG-FN on the RGD-independent cell adhesion. In 
order to investigate the role of syndecan-2 in the FN fibril formation in the 
fibroblasts seeded on TG-FN, syndecan-2 specific targeting siRNA was used to 
silence syndecan-2 in MEF cells, while the universal negative control siRNA was  
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Figure 5.3.7 Syndecan-2 is required by TG-FN to regulate FN fibril 
formation by fibroblasts.  
Monolayers of wild type and syndecan-2 siRNA or universal negative control 
siRNA-treated MEF cells were prepared as introduced before (Section 5.2.3). 
50nM biotinylated FN was used to incubate with the cells on FN or TG-FN 
matrices. After 6 h incubation, the deposited biotin-labelled FN was staining by 
using Cy5-streptavidin (1μg/ml) and visualized by confocal microscopy as 
introduced in Section 5.2.3.  
 
 
 
 
 
Figure 5.3.7 
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Figure 5.3.8 The involvement of TG2 activity in mediating FN fibril 
assembly.  
Monolayers of wild type MEF cells were prepared as introduced before 
(Section5.2.3). 50nM biotinylated FN was used to incubate with the cells in the 
presence of 500μM TG2 inhibitor R283 on FN or TG-FN matrices. After 6 h and 
16 h incubation, the deposited biotin-labelled FN was staining by using Cy5-
streptavidin (1μg/ml) and visualized by confocal microscopy (Section 5.2.3).  
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used as the negative control treatment. The 50nM biotinlyated FN was incubated 
with these cells for 6 h and the FN deposited in ECM was detected via confocal 
microscopy. As shown in Figure 5.3.7, well-organized FN fibrils were observed 
in the matrix laid down by the RAD-treated wild type MEF cells, while only 
randomly deposited FN was deposited by syndecan-2 siRNA treated-MEF cells. 
No difference of the biotinylated FN was discovered between the non-treated or 
the universal negative control siRNA-treated cells, ruling out the toxicity of the 
siRNA treatments with the RAD peptides. Unlike the wild type MEF cells, TG-
FN could not enhance the FN fibril formation with the reduced expression of 
syndecan-2. In the presence of RGD peptide, when seeded on the TG-FN matrix, 
wild type or the control siRNA-treated MEF cells restored the FN fibril 
formation induced by RGD peptide, while the abolishment of the cell surface 
syndecan-2 resulted in the loss of the compensatory effect of TG-FN. The above 
data suggest that syndecan-2 is important in regulating FN fibril formation and 
crucial for TG-FN to compensate the RGD-induced loss of matrix FN deposition 
by fibroblasts.  
  
5.3.8 The effect of TG-FN on FN deposition is independent of the 
transamidating activity of TG2.  
 
Previous work suggested that cell surface TG2, as an enzyme with the 
transamidating activity, can mediate FN deposition. To investigate whether the 
effect of matrix TG2 on FN fibril formation is dependent on its transglutaminase 
activity, TG2 inhibitor R283 (Balklava et al., 2002; Freund et al., 1994) was 
incubated with wild type MEF cells and the biotin-labelled FN was monitored 
after a 6 h and 16 h incubation. Meanwhile as shown in previous result, there is 
no detectable cell surface TG2 present in MEF cells, which provides an ideal 
model to investigate the matrix TG2 activity in regulating FN deposition. Figure 
5.3.8 presents the matrix biotinylated FN staining. After 6 h incubation, cells 
started to lay down matrix FN fibrils, and a well-organized FN matrix was found 
after 16 h incubation. Most importantly, the TG2 inhibitor R283 at the 
concentration of 500μM, which has been published to completely inhibit TG2 
activity, did not affect the FN deposition process compared to the non-treated 
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cells. These results suggest that matrix TG2 within the TG-FN complex mediates 
the FN deposition process in a transamidating activity-independent manner. 
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5.4 Discussion 
 
The involvement of TG2 in fibronectin fibril formation and deposition has been 
previously documented (Akimov and Belkin, 2001) where it was shown that the 
enzyme cooperates with but cannot substitute for α5β1 integrin in fibronectin 
assembly. Transamidating activity was not thought to be involved in this 
mechanism. In contrast in other reports the crosslinking activity of TG2 was 
reported to be important in FN assembly and deposition (Verderio et al., 1999; 
Yuan et al., 2007). In order to investigate whether the FN bound TG2 via its 
interaction with syndecan-4 is also involved in FN fibril assembly, FN matrix 
deposition was studied by using biotin-labelled FN in mouse embryo fibroblasts. 
Importantly cell surface TG2 was not detectable in the MEF cells used in these 
experiments, thus providing an ideal model to answer the above question, since 
the potential interference of cell surface TG2 is ruled out. The TG-FN complex 
increased the rate of fibril formation by wild type MEF cells when compared to 
cells plated on FN alone in the early time periods (1-6 h) which appeared to 
equalise in both sets of cells after 16 h when saturation of the system had 
probably occurred. Importantly even in the presence of RGD peptide the 
deposition of FN was still maintained in the presence of TG2. However as 
expected (Mao and Schwarzbauer, 2005), RGD peptide treatment of cells seeded 
on FN alone led to rounded cells with lack of focal adhesion assembly  and  a 
marked  inhibition of  FN matrix deposition with  most exogenous biotin-labelled 
FN shown to accumulate on the cell surface. This fits with previous observations 
in that focal adhesion point assembly, actin cytoskeleton formation and 
intracellular signalling via RhoA is required for FN fibril formation to occur 
(Fernandez-Sauze et al., 2009; Zhong et al., 1998). Of particular interest is the 
observation that even in the presence of RGD peptide which may be expected to 
block a large proportion of α5β1 integrin sites fibril formation still occurs at an 
effective level. However this is not surprising when considering that the TG-FN 
matrix when bound to syndecan-4 even in the presence of RGD peptides still 
leads to focal adhesion assembly, resulting in a signalling cascade leading to 
activation of syndecan-2, ROCK, Rho and formation of a rigid actin 
cytoskeleton. Previous studies have suggested cell surface heparan sulfate chains 
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particularly those of syndecan-2 in FN assembly (Klass et al., 2000; Mao and 
Schwarzbauer, 2005), a process mediated by activation of PKCα and RhoA 
(Xian et al., 2009). The importance of syndecan-4 in supporting cell spreading, a 
crucial process in cell-mediated FN fibril assembly, is well demonstrated (Okina 
et al., 2009). However in long-term incubations (20 h), no difference in FN fibril 
formation has been observed in syndecan-4 siRNA treated and control cells 
(Huveneers et al., 2008). Given the potential importance of syndecan-4 in the 
TG-FN mediated fibronectin deposition at earlier time periods we similarly 
investigated the importance of syndecan 4 using the early time stages (6 h) in FN 
fibril formation. In syndecan-4 null and syndecan-4 mutant Y188L (a mutant for 
PKCα binding) (Bass et al., 2007) MEF cells, and cells where the GK21 peptide 
was used to block the interaction between PKCα and β1 integrin obvious 
differences in FN fibril formation, when compared to wild type control cells, 
were discernible. In syndecan-4 null, Y188L mutant and GK21 peptide-treated 
cells, biotin-labelled FN was located mainly on the cell surface and when present 
the biotin labelled FN was distributed randomly in the cell attached area. This 
suggests for the first time, the importance of syndecan-4 in the initiating stages of 
FN fibril formation in a PKCα and β1 integrin-dependent manner. However it 
should be noted that in previous findings using longer time periods  and where 
syndecan-4 was silenced using siRNA-treatment (Huveneers et al., 2008; Mao 
and Schwarzbauer, 2005) the loss of syndecan-4 in FN deposition could be 
compensated by other cell surface receptors e.g. syndecan-2 or α5β1 integrin 
(Huveneers et al., 2008; Klass et al., 2000). Unlike in the RGD-treated wt MEF 
cells, TG-FN could not restore the loss of FN fibril assembly in cells lacking 
syndecan 4, α5 or β1 integrin (Huveneers et al., 2008), indicating the dependence 
of TG-FN on these cell receptors in mediating FN fibril formation. Use of the 
TG2 inhibitor R283 (Balklava et al., 2002; Freund et al., 1994) ruled out any 
involvement of transamidating activity in fibril formation in this process.  
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Chapter 6: Discussion 
 
The interaction between cells and the ECM plays a crucial role in regulating cell 
adhesion, migration, proliferation, differentiation and the relevant signalling 
transduction process (Raines, 2000). Initiated by the interaction between cell 
surface receptors and its substratum, cell adhesion is regulated by different 
matrix proteins, receptors and intracellular signalling molecules. According to 
the type of the matrix protein(s), receptors and signalling molecules involved, a 
cells destiny is determined.  Among the matrix proteins, fibronectin is one of the 
most important matrix proteins in mediating fibroblast cell adhesion (Pankov and 
Yamada, 2002). As a high-molecular-mass glycoprotein, FN can exist in a 
soluble form synthesized by hepatocytes and secreted into the in blood or as an 
insoluble fibril extracellular or basement membrane protein produced by 
fibroblasts or other cells (Mosher, 1984). 
 
The molecular structure of FN molecule has been well investigated and reported, 
especially the domains that are related to cell adhesion, which is one of its 
essential functions as an ECM proteins. Located at the III9-10 domain of FN, the 
presence of the Arg-Gly-Asp (RGD) motif was first reported by Rierschbacher 
and Ruoslahti (1984), which was identified as the major integrin binding site in 
charge of the interaction of FN with about half of the integrin family members, 
such as α5β1, α8β1, αvβ1, αvβ3, αvβ5 and αvβ6 integrins etc. (Ruoslahti, 1996).  
It has been wildly accepted that β1 integrins are the major cell surface receptors 
that mediate cell adhesion on FN (Takagi, et al., 2003). Once bound to the RGD 
cell-binding domain, integrins can activate their intracellular signalling molecule 
focal adhesion kinase (FAK) and trigger the autophosphorylation of FAK at 
Tyr397, which can in turn promote the phosphorylation of other Tyrosine sites 
including Try925 and Try576. This activation of β1 integrins has been known as the 
outside-in signalling pathway, since the direct interaction between integrins and 
its matrix ligand are required (Luo et al., 2007). As one of the essential 
components of focal adhesion (FA), the activation of FAK is crucial for both the 
 
Chapter 6 Discussion 
 
232 
 
actin skeleton and the focal adhesion formation. Apart from its role in regulating 
cell adhesion and spreading, integrins are also important in the cell survival 
pathway mediated by ERK1/2 to prevent the cells from undergoing apoptosis and 
to promote their survival, with activation of FAK acting as an upstream 
signalling molecule of the cell survival pathway (van Nimwegen and van de 
Water, 2007). Other members of the integrin family, such as β3 integrins, are 
also involved in cell adhesion on FN via their interaction with the RGD cell-
binding domain (Switala-Jelen et al., 2004). It has been reported that increased 
cell surface β3 integrin expression can enhance cell adhesion on FN (Timar et al., 
1998), while the importance of these integrins as a major component of FA has 
also been widely reported and studied to investigate the effect of FA on cell 
behaviour (Wehrle-Haller and Imhof, 2002).   
 
The involvement of another cell surface receptor—syndecan-4 and its interaction 
with FN in cell adhesion was revealed by the finding that even in the presence of 
the RGD-cell binding domain, the cells still could not fully accomplish cell 
spreading, until the presence of the heparin binding domains was provided to the 
cells (Bloom et al., 1999; Woods et al., 1984). By binding to the heparin-binding 
sites within FN (present at the domains III12-14 within FN), syndecan-4 can 
further support cell adhesion by activating its intracellular signalling molecule 
protein kinase C α (PKCα) to support the FA formation (Woods et al., 2000). 
Further studies by different groups were devoted to pursuing the role of PKCα in 
regulating syndecan-4 signalling transduction. As a crucial step of PKCα 
activation, the translocation of the kinase from the cytosol to the membrane is 
required by the downstream signal transduction (Nakashima, 2002), where it 
interacts with the cytoplasmatic domain of β1 integrins to activate these receptors 
intracellularly (Parsons et al., 2002). The β1 integrin and syndecan-4 signalling 
pathways are linked by PKCα, known as the β1 integrin and syndecan-4 co-
signalling pathway which is crucial in regulating FN-mediated cell adhesion. 
Most recent evidence demonstrated that syndecan-4 can also function as a co-
receptor for β3 integrins in regulating RGD-dependent astrocytes cell adhesion 
via promoting FA and actin stress fibre formation in the cells through RhoA and 
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PKCα signalling (Avalos et al., 2009).The third cell surface receptor binding site 
is the CS-1 sites residing in repeats III4-5 of FN, also known as the HepIII 
domain. CS-1 interacts in the main with two members of integrin family, α4β1 
and α4β7 integrins (Moyano et al., 1997). It has been reported that α4β1 integrins 
can mediate cell adhesion through the association of chondroitin sulfate 
proteoglycans (CSPGs) (Moyano et al., 1999). Other studies suggest that the 
effect of α4β1 integrins on FA organization and actin skeleton formation is 
influenced through inhibiting the activation of RhoA (Moyano et al., 2003).   
 
Tissue transglutaminase is a multi-functional protein with transamidating, 
GTPase, protein disulphide isomerase (PDI) activities, while recent research also 
suggested TG2 may function as a serine threonine protein kinase. Even though 
TG2 lacks the characteristic features for externalization, the enzyme can be 
secreted through the non-classical Golgi/ER pathway onto cell surface and is 
then deposited into ECM (Balklava et al., 2002).  Due to the different locations 
of this enzyme, TG2 can regulate cell behaviour through various mechanisms. 
Intracellularly, the functions of TG2 are probably more relevant to cell survival 
and differentiation. For example, the cytoplasmatic TG2 acts as a pro-apoptotic 
protein in the HEK293 cells (Milakovic et al., 2004), as well as regulating the 
differentiation of neutrophil granulocytes (Balajthy et al., 2006).  On the cell 
surface, TG2 has been identified as a co-receptor for β integrins to enhance cell 
adhesion on FN (Akimov and Belkin, 2001b; Akimov et al., 2000) by promoting 
integrin clustering (Janiak et al., 2006) and further to support FN fibril formation 
(Akimov and Belkin, 2000, 2001a). It has also been reported that TG2 at the 
leading edge of the migrating cells can mediate EGF-related cell migration 
(Antonyak et al., 2009). It has been reported that the crosslinking of matrix 
protein by TG2, e.g. FN and collagen, can protect them from degradation by cell 
surface enzymes including MMPs, which can be beneficial to cell adhesion and 
proliferation (Chau et al., 2005; Collighan and Griffin, 2009). Previous work by 
Griffin and colleagues (2003) suggested that in both osteoblast and fibroblast cell 
models the TG-FN complex, in which TG2 acts as a matrix protein without the 
transamidating activity, can compensate the RGD-independent cell adhesion in a  
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Figure 6.1 Schematic showing the effect of stress and tissue damage on cell 
adhesion and matrix remodelling. 
During stress or tissue injury, cells increase the expression of TG2, which leads 
to its secretion and deposition into the ECM, leading to the formation of a TG2 
and FN hetero-complex— TG-FN. MMPs can digest the matrix proteins and 
result in the release of the RGD motif containing matrix fragments, which can 
inhibit the interaction of the cell with the ECM, leading to masking the cell 
surface integrin receptors, ultimately Anoikis. The TG-FN complex can rescue 
the cells from the RGD peptide induced loss of cell adhesion, thus maintaining 
cell survival.  
 
 
Figure 6.1 
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cell surface heparan sulphate-dependent manner (Verderio et al., 2003). It has 
been shown that the release of the RGD peptides in a stress-induced process e.g. 
during wound healing following tissue trauma, due to proteolytic digestion by 
matrix metalloproteinases (MMPs), can compete for integrin binding sites and 
block the integrin-mediated cell-ECM interaction and in turn induce the loss of 
cell adhesion and the induction of anoikis (Buckley et al., 1999). Regarding the 
fact that increased expression and matrix deposition of TG2 has been found in 
the cells under stress conditions (Kawai et al., 2008; Upchurch et al., 1991). It 
was therefore felt essential to investigate the mechanism of the formed TG-FN 
complex in regulating RGD-independent cell adhesion, which may provide a 
further role for TG2 in the wound healing process, but in addition may also 
provide a promising application of this TG-FN complex in the tissue engineering 
field (Figure 6.1).  
 
The aim of this project was to study the mechanism and physiological 
importance of the TG-FN-mediated cell adhesion process which can occur in the 
presence of integrin blocking RGD peptides  
 
In order to distinguish the roles played by cell surface TG2 ,where it acts as an 
integrin coreceptor ,and matrix bound TG2 in RGD-independent cell adhesion, 
tg2-MEF cells with stable over-expression of human TG2and their wt controls 
were used. Since there is no detectable TG2 antigen in whole cell lysates, at the  
cell surface and in the matrix in the wild type MEF cells, these cells provide an 
ideal model to investigate the role of matrix TG2 in RGD-independent cell 
adhesion without the interference from the exogenous TG2. In the transfected 
tg2-MEF cells, the wild type TG2 can be detected in cell lysates, on the cell 
surface and in the ECM, suggesting the successful transfection of this cell line. In 
the cell adhesion assay, even with the increased expression of cell surface TG2, 
no enhanced increase in cell adhesion was obtained in these cells in the presence 
of the RGD peptides, only when seeded onto the TG-FN matrix was cell 
attachment and spreading restored in both the wild type and the tg2-MEF cells 
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thus  ruling out the involvement of cell surface TG2 in the RGD-independent cell 
adhesion and further confirming that, only when deposited into ECM and bound 
to FN, can TG-FN mediate RGD-independent cell adhesion.   
 
In order to specify which component of this TG-FN complex is the functional 
part in mediating RGD-independent cell adhesion on TG-FN, heparin, the natural 
binding partner with high affinity for both TG2 and FN (Bennett et al., 1997; 
Gambetti et al., 2005), was used to block the binding sites within these two 
molecules. ELISA studies (Verderio et al., 1999) indicated that pre-treatment of 
FN with heparin did not influence the immobilization of TG2 on FN. Blocking 
the heparin-binding sites within FN did not affect the compensatory effect of TG-
FN in RGD-treated cells, however when heparin treatment was applied after the 
formation of TG-FN matrix, thus blocking the heparin-binding ability of TG2, 
this TG-FN complex lost its compensatory effect on the RGD-independent cell 
adhesion completely. This suggested that TG2 is the functional component 
within the TG-FN heterocomplex that mediates the RGD-independent cell 
adhesion. Previous use of  heparinase to digest the cell surface heparan sulfates 
demonstrated the importance of heparan sulfate chains for TG-FN to regulate  
RGD-independent cell adhesion (Verderio et al., 2003). In order to further 
confirm this result, heparan sulfate mutant CHO cells was used in the cell 
adhesion assay on the FN and TG-FN matrices. The significant inhibition of cell 
spreading in the mutant CHO cells on FN, confirmed the role of heparan sulfate 
chains in regulating cell adhesion on TG-FN. Unlike the wild type cells, TG-FN 
failed to restore the cell attachment and spreading in the RGD peptide-treated 
cells, further supporting the direct involvement of heparan sulfates in mediating 
the cell adhesion on TG-FN.       
 
Among the heparan sulfate proteoglycan family, syndecan-4 is the most widely 
expressed member (Oh and Couchman, 2004) and has been reported to be crucial 
in associating in the β1 integrin-related actin cytoskeleton formation (Beauvais 
and Rapraeger, 2004). Since it is also the major resource of heparan sulfate 
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chains in fibroblasts, syndecan-4 was first investigated as the target receptor in 
this RGD-independent cell adhesion on TG-FN. In syndecan-4 knockout MEF 
cells (Bass et al., 2007), the cell adhesion assay revealed that these cells failed to 
response to the TG-FN matrix in the presence of RGD peptide, however once 
this receptor was introduced back into the knockout cells, MEF cells with stably 
transfected human syndecan-4 cDNA re-gained their response to TG-FN even in 
the presence of the RGD peptides. This offered the first hint of the involvement 
of syndecan-4 in regulating RGD-independent cell adhesion on TG-FN. To 
investigate the role of syndecan-4 in the organization of the actin skeleton 
(Woods et al., 2000), actin stress fibre formation was visualized by using 
fluorescence staining. In the wild type and syndecan-4 addback cells a well-
organized actin skeleton was observed in the cells on FN or TG-FN matrices, 
however once treated with the RGD peptide, the cells lost their actin cytoskeletal 
architecture, which could be restored by the TG-FN complex. Unlike the wild 
type and addback cells, syndecan-4 null MEF cells presented a reduction in 
longitudinal stress fibres and only stress fibre bundles were found at the cell 
periphery. Most importantly, this disruption of the actin architecture could not be 
compensated by the TG-FN complex, further confirming the essential role of 
syndecan-4 in mediating the RGD-independent cell adhesion on TG-FN. The 
direct interaction between matrix TG2 and cell surface syndecan-4 was detected 
via co-immunoprecipitaion by using a specific anti-syndecan-4 antibody against 
the intracellular domain of the syndecan-4 molecule to pull down the immuno-
complex, while the syndecan-4 knockout MEF cells were used as the negative 
control cell line. By using the RGD peptide treated MEF cells seeded on the 
heparin pre-treated TG-FN matrix, the heparin binding domain on TG2 was 
blocked and cell adhesion by FN-TG matrix  was completely inhibited indicating  
TG2 to be the matrix protein that cells to bind to in the heterocomplex. Since 
TG2 antigen, either in the cell lysate or at the cell surface was not detected in 
syndecan-4 null MEF cells, which was comparable to the observation in 
syndecan-4 wild type and add-back cells, this further supports that syndecan-4 
and the exogenous matrix TG2 undergo a direct interaction. Previous work 
demonstrated that the core proteins of syndecan-4 can also mediate cell adhesion 
process (Echtermeyer et al., 1999). Thereby, in order to distinguish which part(s) 
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of syndecan-4 molecule, i.e. the heparan sulfate chains or the core proteins, are 
involved in the interaction between TG2 and syndecan-4, heparan sulfate mutant 
CHO cells and its wild type control cells were used in the co-
immunoprecipitation assay using the syndecan-4 targeting antibody. This 
revealed that without the presence of heparan sulfate chains, there was no 
detectable interaction between TG2 and syndecan-4 demonstrating that the 
heparan sulfate chains are essential in mediating the binding of syndecan-4 to 
matrix bound TG2.  
 
The presence of syndecan-4 and β1 integrin co-signalling pathway has been well 
reported (Humphries et al., 2005). Even though the previous work from Griffin 
and colleagues demonstrated that the β1 integrin functional blocking antibody 
did not affect the compensatory effect of TG-FN in the RGD-independent cell 
adhesion (Verderio et al., 2003), this  did not rule out the involvement of the 
inside-out signalling of β1 integrins. Based on the discovery that, in β1 integrin 
knockout MEF cells (Retta et al., 1998), the TG-FN matrix lost its compensation 
effect when cells were treated with RGD peptides (which could be restored by 
introducing human β1 integrin cDNA into the knockout cells), the crucial role of 
β1 integrins in RGD-independent cell adhesion was suggested. By using 
syndecan-4 wild type, knockout and addback MEF cells seeded on the heparin-
treated TG-FN matrix in co-immunoprecipitation assays, the possibility of the 
direct interaction between syndecan-4 and β1 integrins was ruled out (Xian et al., 
2010). This suggested that the intracellular link between syndecan-4 and β1 
integrins is not as by a direct interaction when involved in mediating the RGD-
independent cell adhesion on TG-FN.  As one of the major partner of β1 
integrins in regulating cell adhesion on FN, the potential role of α5 integrins 
(Cukierman et al., 2001; Johansson et al., 1997) in the cell adhesion process was 
also studied by using α5 integrin knockout mouse embryo cells and the control 
cells transfected with human α5 integrin cDNA (Huveneers et al., 2008). The 
failure of the TG-FN complex in restoring the cell attachment and spreading in 
the presence of RGD peptides, suggesting that the α5β1 integrin complex is 
crucial for TG-FN to exert its compensatory effect on the RGD peptides, This 
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was further confirmed by the cell adhesion assay by using a specific α5β1 
integrin targeting peptide A5-1 (Kim et al., 2008) and another α5β1 integrin 
targeting inhibitor c34 (Heckmann et al., 2008), which have been reported to 
block the cell adhesion process mediated by the α5β1 integrins.  
 
Since the involvement of another two cell surface receptors— α4β1(Isobe et al., 
1999; Takahashi et al., 2000) integrins and β3 integrins (Akimov et al., 2000) has 
been reported in TG2-related cell adhesion , the potential roles of these two 
integrins were investigated by using a specific blocking antibody and a knockout 
MEF cell line, respectively. No effect of the α4β1 integrin blocking antibody on 
FN or TG-FN-mediated cell adhesion was discovered in the presence of the RGD 
peptides in short-term cell adhesion assays (around 40 min), suggesting that α4β1 
integrins are not required by this TG-FN complex in short-term RGD-
independent cell adhesion. This supports the previous report in that, unlike the 
α5β1 integrin, although α4β1 integrin is involved in actin skeleton organization 
in certain cell types, the involvement of syndecan-4 signalling pathway is not 
required (Peterson et al., 2005). Even though slight inhibition in cell spreading 
on FN was observed in the β3 integrin knockout MEF cells, which confirmed the 
role of β3 integrins  in regulating FA formation (Switala-Jelen et al., 2004), it did 
not influence the compensation of TG-FN in RGD peptide-treated MEF cells, 
suggesting that TG-FN mediates the RGD-independent cell adhesion in a β3 
integrin-independent manner.  
 
Recent work demonstrated that syndecan-2, another member of the syndecan 
family can be involved in actin cytoskeleton formation, as a downstream 
signalling molecule of syndecan-4 signalling pathway, although the link between 
these two Syndecans has not been fully elucidated (Oh and Couchman, 2004; 
Whiteford et al., 2007). It is also suggested that syndecan-2 can be involved in 
the α5β1 integrin-regulated actin stress fibre formation (Kusano et al., 2000). A 
subsequent report from the same group demonstrated the relevant independent 
role of this receptor in actin cytoskeleton organization with the regard to the fact 
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that in the cells with a comparable expression of α5β1 of overexpression of 
syndecan-2 could enhance actin stress fibre formation (Munesue et al., 2002). 
Considering the presence of syndecan-2 in fibroblasts (Whiteford et al., 2008), 
the hypothesis of the involvement of syndecan-2 in regulating cell adhesion by 
TG-FN was investigated by using syndecan-2 targeting siRNAs to silence the 
syndecan-2 in MEF cells. Unlike the non-treated or the negative control siRNAs 
treated cells, the syndecan-2 siRNA treatment abolished the compensatory effect 
of TG-FN cell adhesion completely in the presence of the RGD peptides, 
indicating that syndecan-2 is also required by TG-FN to exert its compensatory 
effect on the RGD peptides. This was further confirmed by actin stress fibre 
staining which showed that the reduction of the syndecan-2 expression resulted 
in a poorly organized actin cytoskeleton even in the presence of the TG-FN 
complex. Most interesting, was the finding that no direct interaction between 
syndecan-2 and matrix TG2 could be detected via co-immunoprecipitation, 
suggesting the indirect involvement of syndecan-2, probably as a downstream 
effector, in the RGD-independent cell adhesion on TG-FN.    
 
The above work demonstrated that at the cell surface receptor level, TG-FN 
requires the presence of syndecan-4, syndecan-2 and α5β1 integrins to exert its 
compensatory effect on RGD-independent cell adhesion. These three receptors 
could work as a network linked by their intracellular signalling molecules.  
 
As introduced above, PKCα has been reported as the crucial link for the 
syndecan-4 and β1 integrin signalling pathway (Humphries et al., 2005). The 
involvement of these two receptors in TG-FN mediated RGD-independent cell 
adhesion was confirmed by previous results. Thereby, PKCα was the first 
intracellular signalling molecule to be investigated in our model. First of all, 
PKCα activation was blocked by a specific PKCα inhibitor Go6976 (Jensen et 
al., 2009), which abolished the compensatory effect of TG-FN on the RGD-
independent cell adhesion, suggesting the potential dependence on PKCα by TG-
FN to exert its compensatory effect. The activation of PKCα by syndecan-4 is 
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triggered by the binding of PKCα with the cytoplasmatic domain of syndecan -4 
(Woods et al., 2000). Since the PKCα binding domain within syndecan-4 
intracellular core protein is known it provides the possibility of the development 
of the syndecan-4 mutant Y188L, which is unable to bind PKC alpha and which 
can be transfected into Syndecan 4 null MEF cells (Bass et al., 2007). The loss of 
compensation of TG-FN in the RGD-induced cell adhesion assay when using the 
Y188L MEF cells suggested the importance of the interaction between PKCα 
and syndecan-4 in regulating the RGD-independent cell adhesion by TG-FN. The 
translocation of PKCα from cytosol to membrane is a crucial step during its 
activation (Nakashima, 2002). By detecting the presence of PKCα antigens 
within the cytosol and membrane fractions in the RGD peptide-treated fibroblast 
in the presence or absence of the PKCα inhibitor Go6976, it was demonstrated 
that both the RGD peptides and Go6976 inhibited the PKCα translocation. 
Importantly, TG-FN can promote PKCα translocation in the RGD peptide-treated 
fibroblasts, but not in the Go6976-treated cells, suggesting that TG-FN requires 
PKCα activation to exert its function in mediating cell adhesion in the RGD-
independent manner. On the inner membrane surface, PKCα binds to the 
cytoplasmatic domain of β1 integrins and in turn triggers the inside-out 
signalling of β1 integrins. A specific cell-penetrating peptide GK21 (which 
mimics the PKCα binding domain within β1 integrins) was used to block the 
binding between PKCα and β1 integrins (Parsons et al., 2002). The loss of 
interaction between PKCα and β1 integrins completely abolished the 
compensatory effect of TG-FN, which not only confirmed the importance of 
PKCα as a downstream signalling molecule for syndecan-4 in TG-FN signalling 
pathway, but also indicated the involvement of the inside-out signalling of β1 
integrins in the RGD-independent cell adhesion mediated by this matrix 
complex. Even though accumulating research suggests that syndecan-2 can 
associate with syndecan-4 during cell spreading and actin cytoskeleton 
formation, the actual mechanism of this co-signalling pathway has not been 
reported (Whiteford et al., 2007). Considering the importance of PKCα in the 
crosstalk between syndecan-4 and β1 integrins (Humphries et al., 2005), the 
hypothesis that PKCα could also be involved in the signal transduction between 
syndecan-4 and syndecan-2 was tested in syndecan-4 null and Y188L mutant 
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cells and  in co-immunoprecipitation assays by using syndecan-2 specific 
antibody to pull down the syndecan-2 binding proteins. The reduced PKCα 
signals in the knockout and mutant cells for the first time demonstrated that 
PKCα could be the essential link between syndecan-4 and syndecan-2. To sum 
up, the above findings, PKCα is the important regulator in syndecan-4/2 and β1 
integrin co-signalling pathway, which is crucial for TG-FN to exert its 
compensatory effect on the RGD-independent cell adhesion.  
 
The next step was to investigate whether the inside-out signalling pathway of β1 
integrins which could be activated by PKCα and is required by TG-FN to 
mediate the cell adhesion process. A functional blocking antibody against mouse 
β1 integrins, HMβ1-1 (Noto et al., 1995), was used in the cell adhesion on the 
FN and TG-FN matrices, meanwhile the phosphorylation of Tyr397 and Tyr861 in 
FAK was detected in the antibody-treated cells to investigate the function of this 
antibody. Previous reports suggested that the phosphorylation on Tyr861 in FAK 
is independent of the ligand binding of β1 integrins and is the indicator of the 
activation of the β1 integrin inside-out signalling pathway (Shi and Boettiger, 
2003). The cell adhesion and the Western blotting results revealed that the loss of 
cell adhesion induced by HMβ1-1 was due to its blocking effect of the β1 
outside-in signalling (showing by the reduced signal in p-Tyr397) but not its 
inside-out signalling (since the p-Tyr861 signals were not significantly affected by 
this antibody). The restored cell attachment and spreading by TG-FN in the 
antibody-treated cells suggested that this complex mediates the cell adhesion 
process through the inside-out signalling pathway in an outside-in signal 
transduction-independent manner. By further detecting the phosphorylation of p-
FAK at Tyr397 and Tyr861 in RGD-treated cells on the FN or TG-FN matrices, it 
was showed that the RGD peptides blocked the phosphorylation at both sites of 
FAK, which can be compensated in the cells seeded on the TG-FN matrix, 
indicating that FAK is the downstream molecule in TG-FN signalling pathway 
through its activation at Tyr397 and Tyr861.  
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Figure 6.2 Schematic showing the α5β1 integrin and syndecan-4/2 co-
signalling pathway in the mediation of the RGD-independent cell adhesion 
on TG-FN.  
Via its direct interaction with the cell surface heparan sulphate proteoglycan 
syndecan-4, TG2 within  the TG-FN heterocomplex activates  syndecan-4 
mediated signalling via  PKCα which  in turn triggers the inside-out signal 
transduction of α5β1 integrins and  actin cytoskeleton formation by syndecan-2, 
thus maintaining cell adhesion and homeostasis. 
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The importance of another molecule in β1 integrin signalling—ERK1/2 (Saleem 
et al., 2009) was investigated firstly by using its specific inhibitor PD98059 
(Fujita et al., 2007). The inhibitor treatment significantly inhibited the 
compensatory effect of TG-FN in the presence of the RGD peptides, indicating 
the involvement of ERK1/2. The phosphorylation of ERK1/2 (p-ERK1/2) 
indicates the activation of these kinases, which was significantly inhibited by the 
RGD peptide treatment in the cells seeded on FN matrix, while the p-ERK1/2 
was restored by the TG-FN complex, suggesting that this matrix compensates the 
effect of RGD peptide to protect cells from anoikis through the ERK1/2 
signalling.  The importance of syndecan-2 in mediating the RGD-independent 
cell adhesion by TG-FN was confirmed by using a specific inhibitor of Rho 
kinase (ROCK) Y27632, the proposed downstream signalling molecule in 
syndecan-2 pathway (Whiteford et al., 2007). The Y27632-treated cells failed to 
response to the TG-FN complex, which suggests that ROCK is involved in the 
RGD-independent cell adhesion and further supports the importance of 
syndecan-2 in the process.  
 
To conclude, by using specific inhibitors and detecting the phosphorylation of 
the various kinases, the requirement by TG-FN for the involvement of 
intracellular signalling molecules, including PKCα (the crucial link between 
syndecan-4/2 and β1 integrin co-signalling pathway), FAK, ERK1/2 and ROCK, 
was demonstrated in the RGD-independent cell adhesion. In addition the 
activation of the inside-out signalling of β1 integrin is essential for the TG-FN 
complex to exert its function (Figure 6.2).   
 
Fibronectin (FN) mediates the cell adhesion process by interacting with cell 
surface receptors through its different cell binding sites. It is essential to 
embryogenesis and found associated with the ECM in large quantities during 
wound healing and angiogenesis. Cell surface TG2 involvement in fibronectin 
deposition in an integrin dependent but transamidating independent manner has 
been reported previously (Akimov and Belkin, 2001a). In contrast in other 
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reports the crosslinking activity of TG2 was also reported to be required in FN 
assembly and deposition (Verderio et al., 1999; Yuan et al., 2007). As a stress 
response protein, the deposition and binding of matrix TG2 with FN can rescue 
the cells from the loss of cell adhesion induced by the blocking of the interaction 
between integrins and the FN cell binding domains by RGD containing peptides 
(Verderio et al., 2003). By monitoring FN fibril formation through addition of 
soluble biotinylated FN, the involvement of TG2 transamidating activity was 
ruled out in this event by addition of a site directed TG irreversible inhibitor 
R283 (Balklava et al., 2002; Beck et al., 2006). We show that the TG-FN 
complex can increase the rate of fibril formation by wild type MEF cells when 
compared to equal numbers of cells adhered on FN alone in the early stages of 
FN deposition (1-6 h). Importantly in keeping with the role of this stress induced 
heterocomplex in wound healing and matrix turnover it was demonstrated that 
even in the presence of the RGD containing peptides FN fibril formation was still 
maintained. This was in direct contrast to cells seeded on FN alone where RGD 
peptide treatment led to rounded cells with lack of focal adhesion assembly and a 
marked inhibition of FN fibril assembly. This fits with previous observations in 
that focal adhesion point assembly, actin cytoskeleton formation and intracellular 
signalling via RhoA is required for FN fibril formation to occur all of which are 
present in cells seeded on TG-FN in the presence of RGD peptides (Mao and 
Schwarzbauer, 2005; Zhong et al., 1998).  
 
Interestingly it has been reported in longer-term incubations (20 h) that no 
difference in FN fibril formation was observed between syndecan-4 siRNA-
treated cells and control cells (Huveneers et al., 2008). Given our observation 
that syndecan-4 may be important in the early stages of fibril formation 
following cell spreading, a further investigation of fibril formation was 
performed in syndecan-4 knockout cells, the syndecan-4 Y188L mutant (which is 
unable to bind PKCα) (Bass and Humphries, 2002) and GK21 peptide (Parsons 
et al., 2002) treated (which blocks binding of PKC alpha to syndecan-4) cells.  
The results of these experiments clearly indicated that syndecan-4 and its 
downstream signalling molecule PKCα is crucial for FN bound TG2 to mediate  
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Figure 6.3 Schematic summarizing the TG-FN-mediated cell adhesion and 
FN fibril formation pathway.  
As a response to stress induction/ tissue injury, the increased expression of TG2 
leads to its externalization and deposition into ECM and formation of TG-FN 
complex, meanwhile the upregualtion and secretion of proteases, such as the 
MMPs, start to degrade the matrix protein during matrix turnover, leading to 
release of the RGD motif containing fragments which block integrin mediated 
cell adhesion inducing the loss of cell adhesion and cell death. The direct 
interaction between matrix FN bound TG2 and the heparan sulfate chains of 
syndecan-4 lead to activation of the inside-out signalling of β1 integrins by the 
binding between PKCα and the intracellular domain of β1 integrins, promoting 
α5β1 integrin-related cell adhesion and focal adhesion formation. As a 
downstream molecule of syndecan-4, syndecan-2 is activated by intracellular 
PKCα, without the direct interaction with the matrix TG2, this mediates 
cytoskeletal formation and cell contraction via activation of ROCK, while its 
extracellular domain together with any α5β1 integrins not blocked by RGD 
peptides capture the soluble FN molecules and mediate the FN fibril deposition 
process.                         
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FN fibril formation. The poorly formed FN fibrils by β1 or α5 integrin knockout 
fibroblasts also confirmed that these two receptors are crucial for TG-FN to 
enhance the FN fibril formation by fibroblasts seeded on it. Previous reports have 
demonstrated a role for RGD-independent mechanisms involving heparan 
sulphate proteoglycans in FN polymerisation and syndecan-2 has been 
implicated has having a regulatory role in this mechanism (Klass et al., 2000). 
The observation that siRNA silencing of syndecan-2 considerably reduced FN 
fibril formation when cells were bound to FN–TG in the presence of RGD 
peptides strongly suggested the importance of this syndecan-2 in TG-FN 
mediated cell adhesion, cell contractility and FN fibril formation.  
 
To conclude the above findings, the stress induced secretion and deposition of 
TG2 and its binding with matrix FN can rescue the RGD-induced loss of cell 
adhesion through syndecan-4/2 and β1 integrin co-signalling pathway mediated 
by their intracellular signalling molecules PKCα, FAK, ERK1/2 and ROCK. The 
role of this TG-FN complex and its relevant signalling pathway in the RGD-
independent cell adhesion/survival is also crucial in regulating  FN fibril 
formation, which is crucial to both wound healing and angiogenesis (Mao and 
Schwarzbauer, 2005), while it could also be pathological during situations of 
tissue fibrosis where the presence of large amounts of both TG2 and fibronectin 
are found (Verderio et al., 2005) (Figure 6.3).  
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Appendix 1: List of Abbreviations 
  
Aβ Amyloid β- protein 
ADP Adenosine-5’-diphosphate 
ANT1 Adenine nucleotide translocator 1 
APC Antigen presenting cells 
AR α1B- adrenoceptor 
ATCC American Type Culture Collection 
ATP Adenosine-5’-triphosphate 
BSA Bovine serum albumin 
Ca2+ Free calcium ion 
CBD Cell binding domain 
CCl4 Carbon tetrachloride 
CD Celiac disease 
cDNA Complementary deoxyribonucleic acid 
CE Cornified envelope 
CHO Chinese hamster ovary cells 
CNS Central nervous system 
DFMO Difluoromethylornithine 
DH Dermatitis herpetiformis 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dinethyl sulphoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
FAK Focal adhesion kinase 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylene diamine tetraacetic acid 
ELISA Enzyme linked immunoabsorbant assay 
ERK Extracellular signal-regulated kinase 
FITC Fluorescein isothiocyanate 
FXIII Factor XIII 
FXIII A Factor XIII A subunit 
FXIII B Factor XIII B subunit 
FN Fibronectin 
γ-IFN γ-interferon 
GA Gluten ataxia 
GAG Glycosaminoglycan 
GDP Guanosine-5’-diphosphate 
gplTG Guinea pig liver transglutaminase 
GTP Guanosine-5’-triphosphate 
GRGDTP  H-Gly-Arg-Gly-Asp-Thr-Pro-OH 
GTPase Gunoaine-5’-triphosphatase 
HCV Hepatitis C virus 
HSPGs Heparan sulfate proteoglycans 
HRP Horseraish peroxidise 
HS Heparan sulfate 
IFN- γ Intereferon- γ 
IgG Immunoglobulin 
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IGFBP-3 Insulin-like growth factor-binding protein-3 
IRS-2 Insulin receptor substrate 2 
JMD Juxtamembrane domain 
kDa Kilodaltons 
LTPB-1 Latent TGF-β1 binding protein-1 
M Molar 
MAPK Mitogen-activated protein kinase 
MEF Mouse embryo fibroblast 
MEK MAPK kinase 1 
ml Milliliters 
Mm Millimolar 
μ Micro 
μl Microlitres 
Μm Micromolar 
Mrna Messsenger ribonucleic acid 
MT1-MMP Membrane type 1- metalloproteinase 
Nm Nanomolar 
NF-κB Buclear factor kappa-light-chain-enhancer of activated B 
cells 
NO Nitric oxide 
OA Osteoarthritis 
PAGE Polyacrylamide gel electrophorsis 
PBS Phophate buffered saline 
PCR Polymerase chain reaction 
PDI Protein disulphide isomerise 
PGs Proteoglycans 
pH Negative log of hydrogen ion concentration 
PHSRN Pro-His-Ser-Arg-Asn 
PI Propidium iodide 
PI3K Phosphoinositide 3-kinases 
PKC α Protein kinase C α 
PKC δ Protein kinase C δ 
PLC Phospholipase C 
PLCδ Phospholipase C δ 
PMSF Phenylmethylsulfonyl fluoride  
RA Retinoic acid 
RBC Red blood cell 
RREs Retinoid-responsive elements 
SDS Sodiumdodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate- polyacrylamide gel 
electrophoresis 
siRNA Small interfering RNA 
ROCK  Rho kinase 
SPRs Small proline-rich proteins 
TEMED N,N,N’,N’-tetramethylene diamine 
TG Transglutaminase 
TGFβ Transforming growthe factor β 1 
THG Thapsgargin 
TIG3 Tazarotene-induced gent 3 
TG2 Tissue transglutaminase 
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TGF-β1 Transforming growth factor β 1  
TMB 3,3’,5,5’-tetramethylbenzidine 
TNF Tumour necrosis factor 
Tris Tris (Hydroxymethyl)-aminoethane 
Triton X-100 t-Ocylphenoxypolyethoxyethanol 
VEGFR Vascular endothelial growth factor receptor 
XTT Sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis 
(4-methoxy-6-nitor) benzeme sulfonic acid hydrate 
 
